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Abstract 
Drug discovery and development is a long process: it takes usually 12 to 15 years before a 
drug candidate reaches the market. The pharmacokinetics of the drug is an important aspect 
of drug discovery and development, because the drug must reach its target site and exert the 
therapeutic response. The pharmacokinetic parameters of new compounds should be 
investigated early in drug discovery. Pharmacokinetic predictions can be made with 
Quantitative Structure-Property Relationships (QSPR) which are computational models that 
correlate chemical features with pharmacokinetic properties. The correlations are based on 
in vivo or in vitro pharmacokinetic data and molecular descriptors. QSPR models can be 
used to predict the pharmacokinetic parameters even before any actual drug synthesis and 
can be exploited to guide drug discovery. Pharmacokinetic models can also simulate 
concentration profiles of drugs during the drug discovery and development process. 
It was decided to develop QSPR models of pharmacokinetic parameters of drugs to be 
delivered by the systemic or ocular routes. A combination of Principal Component Analysis 
and Partial Least Square multivariate statistical methods was used to obtain QSPR equations 
for volume of drug distribution and fraction of unbound drug in plasma. Parallel modelling 
of these parameters resulted in acceptable R2 (0.58 - 0.77) and Q2 values (0.55 - 0.58). These 
models are based on a large set of structurally unrelated compounds, they are open and they 
have a defined applicability domain. Charge and lipophilicity related descriptors were the 
relevant ones which influenced the volume of distribution and free fraction of drug in 
plasma.  
Pharmacokinetics is an important factor in the development of ocular medications, 
because the ocular drug targets are difficult to reach, particularly in the posterior tissues 
such as retina and choroid. Therefore, drugs need to be injected intravitreally in the 
treatment of retina and choroid diseases (e.g. in exudative age-related macular degeneration) 
and thus prediction of intravitreal pharmacokinetics would be especially advantageous in 
ocular drug discovery and development. The first comprehensive collection of intravitreal 
volume of distribution and clearance values of compounds was collated based on extensive 
rabbit eye data from the literature. Moreover, predictive QSPR models for intravitreal 
clearance and half-life were created which had R2 and Q2 values of 0.62 – 0.84 for clearance 
and 0.61 - 0.80 for half-life. LogD7.4 and hydrogen bonding capacity defined the intravitreal 
clearance and half-life of compounds with a molecular weight below 1500 Da. The 
intravitreal volumes of drug distribution lay within a narrow range (80% within 1.18 - 2.28 
ml). The QSPR models for intravitreal clearance and the typical values for intravitreal 
volumes of distribution were implemented in pharmacokinetic simulation models; the 
simulated profiles based on the real and predicted pharmacokinetic parameter values were 
similar. Thus, a combination of QSPR and pharmacokinetic models can be used in drug 
discovery and development to aid in the design of drugs and drug delivery systems. 
A comprehensive comparison of intravitreal pharmacokinetic data between rabbit and 
human was carried out to clarify the translational value of the rabbit model. The analysis 
revealed that the rabbit can be considered as a clinically predictive animal model for 
intravitreal pharmacokinetics of small molecules (18 Da - 1500 Da) and macromolecules 
(7.1 kDa - 149 kDa). There was a correlation between the intravitreal clearance values in 
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human patients and healthy rabbits; they showed similar, but not identical, absolute values. 
The intravitreal pharmacokinetics of small molecules is mainly governed by permeability-
limited clearance across blood-ocular barriers and occurs via the posterior route, whereas 
large molecules are cleared mostly via the anterior route. Although the literature contains 
some claims about the significance of the viscosity of the vitreous, it seems that this is not 
a major factor in drug elimination from the eye.  
In conclusion, new in silico tools were generated for systemic and ocular 
pharmacokinetics and drug delivery. These models can be exploited in industrial drug 
discovery and will hopefully speed up the development of new medications. 
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1 Introduction 
The absorption, distribution, metabolism and excretion (ADME) of drugs are important 
pharmacokinetic processes that exert an influence on drug efficacy, safety, dosing and 
patient compliance. These factors need to be investigated at various stages during drug 
discovery and development since any new drug must possess pharmacokinetic properties 
that are compatible with successful drug treatment. Pharmacokinetic problems have been 
identified as an important reason for drug attrition during the clinical stages of drug 
development (van de Waterbeemd and Gifford, 2003). Currently the vast majority, as many 
as 90%, of the compounds in the clinical phase, will fail due to many reasons not only lack 
of efficacy or unacceptable toxicity but also because of pharmacokinetics issues (Kola, 
2008). Furthermore, delivery of sufficient amounts of active drug to certain target sites (e.g. 
brain, retina) is sometimes difficult. Thus, new methods and innovative approaches are 
needed in pharmacokinetic evaluation and drug delivery to facilitate the development of 
effective and safe drugs as well as improved delivery systems. 
Although the prediction of pharmacokinetics during drug discovery and development 
has improved in the current century such that today pharmacokinetic properties of new 
analogs are addressed early in drug discovery, improvements are still needed (Kola and 
Landis, 2004). There are several computational methods which can be applied in ADME 
research e.g. Quantitative Structure-Property Relationships (QSPR), pharmacokinetic 
models, rule-of-5 classification, and the Biopharmaceutics Classification System (Lipinski, 
2000, Lipinski et al. 2001, van de Waterbeemd and Gifford, 2003, van de Waterbeemd, 
2009). Typically, the in silico models utilize prior information from experiments and this is 
then used to predict the pharmacokinetic features of the new compound. In vitro methods 
are also being widely used to characterize absorption, binding and metabolism of new 
compounds. These methods include permeability studies with cultured epithelial cells, 
investigations with transporter expressing cells, drug metabolism studies with microsomes 
or hepatocytes, and binding studies with plasma proteins (Zhang et al., 2012a, Vellonen et 
al., 2014, Caldwell et al., 2009). Again, pharmacokinetic models are needed to interpret in 
vitro results, and to translate them to the in vivo situation (Jones et al., 2015, Shardlow et 
al., 2013). In vitro methods are suitable for screening studies where one has a large number 
of compounds and only small quantities of each compound (Caldwell et al., 2009). Finally, 
only the most promising drug candidates will undergo in vivo animal studies, usually with 
rodents (mice, rats) and dogs or monkeys. Scaling methods are then applied to translate 
these data to the human patient context (Knibbe et al., 2005, Mahmood, 2007). In clinical 
studies, pharmacokinetic analyses will be carried out during phase I in healthy volunteers 
and in phases II and III in patients (Lüllmann et al., 2011, Pandit and Soltis, 2012). Overall, 
data integration and reliable translation to the clinical situation are highly important goals 
for the pharmacokinetic investigations undertaken during drug discovery and development. 
Successful tools can help not only in the compound selection, but also assist in the 
pharmacokinetic study design, such as devising optimal dosing regimens and administration 
routes. 
The prevalence of ocular diseases affecting the posterior eye segment, such as age-
related macular degeneration and diabetic retinopathy, are increasing as the world’s 
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population ages (Zhang et al., 2012b). However, the treatment of these diseases is 
complicated, because it is difficult to deliver active drug to the retina or choroid. At the 
moment, local intravitreal injection is the best option to achieve effective drug 
concentrations in these tissues (del Amo and Urtti, 2008, Urtti, 2006). It is especially 
important to understand ocular pharmacokinetics after intravitreal injection, since 
intravitreal injection is such an invasive and unpleasant procedure that a long dosing interval 
(at least one month) is preferred (Bashshur et al., 2008, Cheung and Eaton, 2013). The dose 
and primary pharmacokinetic parameters of intravitreal drugs, volume of distribution and 
clearance determine the vitreal concentration profile of the drug. These parameters have not 
been investigated in a systematical manner and no QSPR models have been developed to 
predict intravitreal clearance or volume of drug distribution. One QSPR model has been 
developed for intravitreal half-life, but it has not been adequately validated (Durairaj et al., 
2009). Nonetheless, these kinds of models would be very useful both in their own right and 
as a component part of pharmacokinetic simulation models. This approach could be 
expected to advance design of drugs and delivery systems for ocular use. 
The rabbit is the most commonly used animal model in ocular pharmacokinetics; there 
is very little human ocular pharmacokinetic data due to the difficulties in ocular sampling. 
Recently, the criticism has been raised that the rabbit is a poor model of human intravitreal 
pharmacokinetics due to differences in eye size, vitreous humour viscosity, and retinal 
vasculature (Laude et al., 2010, Rowe-Rendleman et al., 2014, Vaishya et al., 2011). 
However, the rabbit and human pharmacokinetics after intravitreal injection have never 
been compared in a quantitative and systematic manner. Such information is needed if one 
wishes to assess the true clinical value of data obtained with the rabbit model i.e. translation 
of intravitreal pharmacokinetic data.  
One goal of thesis project was to build computational models which would describe 
pharmacokinetics after systemic and intravitreal drug administration. In particular, a QSPR 
model was developed that combines volume of drug distribution and free fraction in plasma. 
Furthermore, QSPR and pharmacokinetic models were devised for intravitreally 
administered drugs in rabbits. Finally, the intravitreal injection data from rabbit and human 
studies were systematically analysed to assess the translational value of the intravitreal 
rabbit data.  
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2 Review of the literature 
2.1 Pharmacokinetic processes 
2.1.1. ADME 
Pharmacokinetics can be defined as the study of the time course of the drug in the body after 
its administration. It consists of the processes of absorption, distribution, metabolism and 
excretion, abbreviated as ADME and represented in Figure 1. Drug absorption (A) is the 
process of drug permeation through body barriers such as skin, intestinal wall and so forth 
into the bloodstream. Drug distribution (D) is the reversible transfer of the drug from one 
location in the body (such as the vascular space) to another (such as the extravascular space). 
Metabolism (M) involves chemical or enzymatic reactions that transform the parent 
compound into active or inactive metabolites. Excretion (E) is the irreversible removal of 
the unchanged drug mainly via the kidneys into urine. Metabolism and excretion constitute 
the elimination process. ADME processes are interrelated and they determine the fate and 
time course of the drug in the body. The present thesis investigated ocular and systemic drug 
distribution and ocular elimination.  
 
Figure 1 The ADME processes shown schematically. 
2.1.2 Distribution 
After absorption or intravascular injection, the drug is distributed from the blood circulation 
to the organs and tissues. Distribution is a reversible process that strives to achieve 
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equilibrium at steady state. Drug distribution from blood to the tissues is influenced by tissue 
perfusion, drug permeability through the cell membranes (including active transport into or 
out of the cell) as well as drug binding to the blood and tissue components.  
Blood flow. The rate of blood flow in the tissue determines how quickly the drug reaches 
the tissues; this rate varies widely in different organs (Rowland and Tozer, 2011). For 
example, liver and kidney have high blood flow rates, whereas bone and adipose tissues are 
poorly perfused by blood. A drug will distribute faster to the well-perfused organs than to 
the poorly perfused ones. If the drug easily permeates across the vascular walls in the tissue, 
the rate of drug distribution is perfusion rate limited. On the other hand, if the vascular walls 
display resistance to the drug distribution, the rate is permeability limited. The rate of drug 
distribution determines how quickly the target site is reached.  
Drug permeation. In order to reach the target cells, the drug must permeate across the 
vascular walls (endothelial cells), reach the interstitial fluid, and pass across the cell 
membranes (in the common case where the drug’s target is intracellular). The drug may 
permeate through membrane barriers by several mechanisms.  
Paracellular diffusion refers to passage through the intercellular space between the cells. 
Depending on the leakiness of the intercellular space, this path can play a major or less 
important role in drug transport (Linnankoski et al., 2010). 
Transcellular transport relies on the passage of drug through the cell membranes (Sugano 
et al., 2010). This can take place as either transcellular passive diffusion or carrier mediated 
transport. In the first case, the molecules pass through the membrane from a higher to a 
lower concentration without any energy requirement. This mechanism is operative in all cell 
types. In this case, lipophilicity and molecular size are the important physicochemical 
properties of the drug that influence the transcellular diffusion of the molecule. Typically, 
increased lipophilicity (characterized with high LogD7.4 or LogP values or low hydrogen 
bonding capacity) and a small molecular weight favor transcellular passive diffusion (van 
de Waterbeemd and Gifford, 2003, van de Waterbeemd, 2009). The unionized fraction of 
the weak acids and weak bases is able to diffuse through the lipidic cellular membranes 
faster than the ionized species. 
The carrier mediated transport can be classified as either facilitated transport (without 
any need to consume energy) or active transport (with energy consumption). Active 
transport can transfer the molecules against their concentration gradient. There are two 
major superfamilies of transporters: solute carrier transporters (SLC) and ATP-binding 
cassette (ABC) transporters (e.g. efflux transporters that move the drug in the extruding 
direction) (International Transporter Consortium et al., 2010). Active transport depends on 
the expression of the transporter in the particular cell type, it is saturable, and selective i.e. 
it only transports compounds that are able to bind to the transporter (International 
Transporter Consortium et al., 2010, Sugano et al., 2010). The net direction of the transport 
depends on the type of transporter (influx or efflux transport) and the location of the 
transporter (apical or basolateral side of the cell membrane).  
All transport mechanisms coexist and may partly contribute to the overall net transport 
rate. The contribution of each mechanism depends on the cellular or tissue properties, the 
chemical features and the concentration of the drug. For example, drug distribution through 
the paracellular space in the vascular walls is high in those tissues with leaky fenestrated 
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vascular walls (e.g. liver, muscles), but negligible in the tissues with tight vascular 
endothelia (e.g. blood-brain barrier, blood-retinal barrier). Transcellular diffusion through 
the capillary endothelia is the primary mechanism of transport for lipophilic compounds, 
whereas structure specific distribution is usually associated with the expression of drug 
transporters.  
Drug binding. Drugs may bind to plasma proteins or blood cell components, while in 
the extravascular space, they may bind to many tissue components. Only the free form of 
drug in plasma is able to permeate across the vascular walls. This is a prerequisite for drug 
distribution and localization to the target sites. 
In plasma, drugs exist in a reversible equilibrium between the free and protein bound 
forms. The ratio of unbound to total drug concentration in plasma is the fraction unbound 
(fu), in most cases, this is a constant value although the fu value may change in special 
situations, such as renal and hepatic diseases (Rowland and Tozer, 2011). Albumin is the 
most abundant protein in plasma that binds acidic drugs (Hall and Guyton, 2011, Kwon, 
2001, Øie and Tozer, 1979). Basic drugs often bind to alpha1-acid glycoprotein and neutral 
lipophilic drugs to lipoproteins (Kwon, 2001). Furthermore, drugs may bind to extracellular 
and intracellular sites in the tissues. The free drug in the tissues is available for transcellular 
diffusion and carrier-mediated transport (Rowland and Tozer, 2011, Pandit and Soltis, 2012) 
(Figure 2).  
Drugs with a high affinity for tissue components will distribute extensively, which 
means that they have high values of volume of distribution (Tett et al., 1988). Basic drugs 
tend to display higher extents of distribution than acidic drugs (Rodgers and Rowland, 
2007). This may be due to the tissue composition, i.e. cell membranes consist primarily of 
acidic phospholipids (e.g. in liver, lungs, kidney) that can act as binding sites for positively 
charged basic drugs. Moreover, basic drugs can become entrapped inside the acidic 
lysosomes (pH about 5), and once there, an ionized basic drug cannot escape from these 
organelles and will accumulate extensively (e.g. chloroquine) (Ishizaki et al., 1998). 
Unionized and lipophilic compounds may favor distribution into the adipose tissue that has 
a high capacity for binding these types of drugs. 
In short, the rate and the extent of drug distribution are influenced by several factors 
linked 1) to the body, such as blood flow, vascular leakiness, pH, cellular and tissue barriers, 
and tissue composition and size; 2) to the drug, for example, its physicochemical properties 
(defining permeability, tissue partitioning) and binding to specific sites (e.g. transporters, 
other proteins). Birkkett has defined the extent of drug distribution as the ratio of the drug 
binding to plasma protein and tissue components (Birkett, 2010). 
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Figure 2 Schematic description of drug distribution from the vascular space to extravascular 
space (interstitial space and tissue). Only the free, not the bound, drug can permeate 
to tissues or blood cells. 
2.2 Pharmacokinetic parameters describing distribution 
Pharmacokinetic parameters make it possible to describe the ADME processes in a 
quantitative manner. There are two independent pharmacokinetic parameters for 
distribution and elimination i.e. volume of distribution (Vd) and clearance (CL), 
respectively.  
The Vd (units of volume, e.g., L) is defined as 
(1) ?? ? ??? 
where A is the amount of drug in the body and C is the drug concentration in plasma at 
any given time. Therefore, Vd is a hypothetical volume that increases with drug binding to 
the tissues (i.e. A/C increases); it is not an anatomically defined volume. As tissue binding 
of drugs varies substantially, their volumes of distribution display a wide range of values. 
For example, erythropoietin is confined to the vascular space and has Vd of 4 L (equal to 
the volume of the vascular space) (Lim, 1991), whereas hydroxychloroquine (Vd = 49 000 
L) extensively accumulates within the cells of many tissues (Tett et al., 1988). The Vd of 
hydroxychloroquine (700 L/kg) means that only 0.006 % of the drug in the body is present 
in plasma. 
There are different types of Vd values depending on the timing and situation for A/C 
ratio determination (Toutain and Bousquet-Melou, 2004). 
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Initial volume of distribution or volume of the central compartment (V1 or Vc) is the 
volume of distribution that is determined at the time of intravenous (i.v.) administration 
(time 0) (Eq. 2):  
(2) ?? ? ?????? 
where Div is the i.v. dose and C0 is the extrapolated initial concentration of drug (at t=0). 
 
Steady state volume of distribution (Vss) is measured after i.v. infusion at a steady state 
situation. In that case, the drug has reached an equilibrium distribution between the central 
compartment (including plasma and tissues where the drug easily distributes) and peripheral 
compartment(s) (where the drug distributes from plasma with some delay). Therefore, the 
concentration in plasma is constant, because drug infusion and elimination take place at 
equal rates.  
 
Terminal volume of distribution (Vz, Vβ or Varea) is the volume of distribution measured 
after i.v. injection during the elimination phase. In this case, pseudo-equilibrium prevails 
between the central and peripheral compartments. The drug concentration in plasma is 
decreasing due to its elimination and now the drug is diffusing back from the tissues into 
plasma. Unlike Vss, however, the value of Vz may vary if the elimination rate changes 
(Toutain and Bousquet-Melou, 2004, Fan and de Lannoy, 2014). 
Vz and Vss have often different values for the same drug. The Vz value is always larger 
than Vss, because the A/C ratio is higher during the terminal elimination phase than at steady 
state. During the terminal elimination phase, the drug is being eliminated from the central 
compartment, and drug will be diffusing from the tissues to the central compartment with 
some delay, leading to elevated A/C values. Vss represents the true equilibrium between the 
tissues and plasma and therefore, Vss is the best choice if one wishes to correlate the 
chemical structure with the volume of distribution.  
 
Vss can be compared with the anatomical tissue volumes (Eq. 3). 
(3) ??? ? ??????? ? ??? ? ??? ?????? ? ????? ? ???? ? ????? ? 
where Vplasma is the volume of plasma, VT describes the anatomical volumes of the 
tissues and Kp, T are the distribution coefficients between the tissues and plasma: 
(4) ?? ? ???? 
where CT is the concentration in tissue and C is the concentration in plasma including 
unbound (Cu) and protein-bound drug (Cbound). Likewise, CT includes the unbound (CuT) and 
bound drug (CboundT) in the tissue. The free fraction of drug in plasma (fu) is described as: 
(5) ?? ? ???? 
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and the unbound fraction of drug (fuT) in tissues as  
(6) ??? ? ?????? 
Since Cu and CuT are in equilibrium, Kp can be expressed as: 
(7) ?? ? ?? ????  
Thus, Vss can also be expressed as: 
(8) ??? ? ??????? ? ??? ? ? ???????????? ? ?
??
????
? ? ???? ? ? ???????? 
Thus, Vss depends on the anatomical tissue volumes and the relative extent of drug 
binding in the plasma and tissues. The equilibrium between tissue and plasma is expressed 
as fu/fuT. Therefore, extensive binding in the tissues, as compared to plasma, leads to smaller 
values of fuT than fu and high values of Vss. The equilibrium is schematically presented in 
Figure 3. 
             
 
Figure 3 Drug distribution between the vascular space and extravascular space. At equilibrium, 
Cu and CuT are equal, and binding in tissue and plasma define the fu/fuT and Vss. 
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2.3 Pharmacokinetics in drug discovery and development 
The drug discovery and development process usually last between 12 to 15 years and 
significant (about 90%) attrition takes place even in the costly clinical phases of drug 
development (Kola, 2008). It has been recommended that ADME parameters and 
pharmacokinetic profiles of lead compounds, drug candidates and investigational new drugs 
should be investigated at various stages of the development process (Zhang et al., 2012a). 
These investigations can involve in silico, in vitro and in vivo studies in animals and humans. 
Both computational and experimental studies are used to predict the pharmacokinetics in 
humans and to help in the selection of the best compound, optimal routes of administration 
and potential ways of delivery (Figure 4). In the clinical phase, the pharmacokinetics of the 
drug candidate will be investigated in healthy volunteers and patients (Figure 4). One 
important aim of the preclinical investigations is that they involve methods that enable 
reliable translation to the clinical phases to minimize the costly late stage attrition.  
ADME features can be investigated in drug discovery using predictive computational 
and in vitro models (for drug metabolism, lipophilicity, permeation) to help to choose and 
reject compounds during the early preclinical phases before proof of concept (Caldwell et 
al., 2009, Zhang et al., 2012a, Maltarollo et al., 2015). The number of compounds being 
screened at these stages may be enormous but the quantities of compounds available for 
experiments can be tiny. Therefore, rapid screening methods need to be able to operate 
either without the drug at all or with only miniscule amounts. In silico models can be 
advantageous in helping to predict volume of distribution and fu (Balakin et al., 2005, Ekins 
et al., 2007). 
Later, in vivo pharmacokinetic studies are conducted in animals (mice, rats, and dogs or 
monkeys) and the experimental data are used to predict pharmacokinetics in human by 
applying allometric scaling and physiologically based pharmacokinetic modelling (PBPK) 
(Zou et al., 2012, Fagerholm, 2007, Sui et al., 2008). 
Allometric scaling assumes that pharmacokinetic differences across the species are 
determined by body size alone. A power function of body weight (Eq. 9) is used for the 
predictions:  
(9) Y = a × BW b  
where Y is the predicted parameter (for example Vss), BW is the body weight, and a and 
b are empirically derived constants (Mahmood, 2007, Fan and de Lannoy, 2014). The 
constant a is a drug-dependent variable whereas b depends on its pharmacokinetic 
parameters. Allometric scaling predicts only values of the parameters, not concentration 
profiles. The method is more applicable for Vss prediction than clearance, because there are 
extensive species differences in drug elimination (e.g. differences in the metabolism). 
PBPK represents pharmacokinetics in a physiological context. This method is based on 
mechanistic equations taking into account the anatomy and physiology of the body. The 
tissues and organs are represented by different compartments and physiological data such 
as blood flow, organ size, tissue/blood partition coefficients and clearance in each tissue 
(Jones et al., 2015, Sy et al., 2014). The concept of physiologically based pharmacokinetic 
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modelling was introduced by Teorell already in 1937 (Teorell, 1937a, Teorell, 1937b), but 
this approach has gained significant popularity only after the methods for the prediction and 
measurement of individual parameters became feasible. In silico and in vitro parameters are 
used in building the PBPK model, where they are placed in the physiological and 
pharmacokinetic context. The model can be tested in animals and then scaled up to humans. 
The model requires considerable amounts of both in vitro and in vivo background data, but 
the ready-made model can be used to predict concentration profiles in plasma and tissues 
(Jones et al., 2015, Sy et al., 2014, Shardlow et al., 2013). In the Vss prediction, PBPK 
models based on tissue composition have been applied with in vitro data as the input values 
(Poulin and Theil, 2002, Rodgers and Rowland, 2007). Usually the prediction is carried out 
during drug development when in vivo pharmacokinetic data are available in order to 
confirm the lack/presence of transporter involvement in drug distribution. 
During clinical development, pharmacokinetic studies in humans are conducted first in 
healthy volunteer subjects (Phase I) in safety tests, then in selected volunteer patients (Phase 
II) in efficacy tests and finally in patient groups (Phase III) for new drug application 
approval. The Phase III is the most expensive stage in drug development. In the late stage, 
in Phase IV, population pharmacokinetics are carried out to determine the possible need for 
special dosing advice based on age, body weight, co-administered drugs, ethnic background 
or disease state of patients (Shardlow et al., 2013, Schmidt and Derendorf, 2014). 
 
 
Figure 4 Scheme of the drug discovery and development process.  
2.4 Quantitative Structure-Property Relationships  
Quantitative Structure-Property Relationship methods can be used to correlate 
pharmacokinetic properties with the chemical structure of the compounds, in this case the 
abbreviation QSPkR is also used (Quantitative Structure-Pharmacokinetic Relationships) 
(Mayer and Van de Waterbeemd, 1985). The method uses information from prior 
experimental ADME data and investigates the relationship between the computational 
molecular descriptors of the compounds and their measured ADME parameters (Mager, 
2006, Maltarollo et al., 2015). With QSPR, it is possible to relate, identify and quantify the 
structural descriptors that exert an effect on the pharmacokinetic parameter (Eq. 10): 
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(10) Pharmacokinetic property = f(structural descriptors) 
As shown in Eq. 10, the molecular descriptors constitute the X matrix to be correlated 
to the Y response i.e. the pharmacokinetic property. The molecular descriptors are 
calculated in silico and they range in complexity from one-dimensional, to two- and three-
dimensional descriptors (Mager, 2006, Ekins et al., 2007, Leach and Gillet, 2007). The 
values of the pharmacokinetic property e.g. pharmacokinetic parameters of drugs, are 
acquired from previous pharmacokinetic studies. After the QSPR model has been built, it 
can be used for prediction without any additional experiments. Therefore, the approach 
maximizes the information which can be gained from the experimental data and it can be 
utilized very early in drug discovery. Valid QSPR models may reduce the use of animals in 
the preclinical experimental studies. Moreover, QSPR models can be combined with other 
computational models, such as PBPK (Xu and Mager, 2011). 
The relationship between descriptors and a particular pharmacokinetic parameter can be 
investigated by applying multivariate statistical tools, such as Principal Component 
Analysis (PCA) and Partial Least Squares (or Projection to Latent Structures, PLS) 
regression (Eriksson et al., 2006a, Wold et al., 2001a). They are linear statistical methods 
based on the projection of the descriptor values (and response) into new vectors (principal 
components or latent variables), which summarize most of the variation of the variables 
(Eriksson et al., 2006a, Eriksson et al., 2006b). The PCA method can be illustrated by the 
following analogy: a searchlight is shone on the compounds floating in the descriptor space 
and the optimal direction is searched in order to obtain the maximum variation of the data 
in the projected shadow (Figure 5). The projection is graphically represented by the score 
plot where the axes represent the two latent variables capturing the most relevant 
information (Eriksson et al., 2006a). PLS adopts a similar approach but the latent variables 
strive to describe the projection of the variable space X that correlates best with Y (Eriksson 
et al., 2006a, Wold et al., 2001a, Wold et al., 2001b). The PLS method has the advantage 
that it allows many responses to be incorporated into one regression model. One should 
keep in mind that the compounds included in the QSPR should be sufficiently disparate to 
cause some difference in the response and yet not too heterogeneous that the modelling 
would be non-viable. The response should also display enough variance in order to be 
modelled. 
 
Figure 5 Pictorial presentation of the projection based methods. Scatter plot from SIMCAplus® 
summarizes graphically most of the variation in the original data. 
(http://www.umetrics.com/how-it-works/mva) 
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Validation of the model should be conducted by determining the cross-validation value 
(Q2), internal, external validations values (Qi2, Qe2) and performing the Y-randomization 
test (Eriksson et al., 2003). Q2 is the parameter that describes the goodness of prediction of 
the model. Part of the training data are left out and subsequently these are predicted based 
on a model trained by the remaining data. The goodness of fit (measured by the coefficient 
of determination, R2) is calculated for all the parallel models and re-expressed as the cross-
validation value Q2 (the “cross-validated R2”). Q2 can be calculated leaving out only one 
compound, which is not such reliable tool (Doweyko, 2008). In the present thesis, one 
seventh of the data was left out and seven parallel models were generated, Q2 (leave-1/7-
out) (Eriksson et al., 2006a). Qi2 and Qe2 correspond to R2 of the regression line of real 
versus predicted values in the test sets (internal and external respectively). The 
Y-randomization test involves permuting the response data, e.g. Vss values, to appear in a 
different order. The models fitted to the shuffled values are expected to display a 
significantly lower accuracy than the original model, proving the robustness of the original 
model i.e. that it is not based on chance correlations (Topliss and Edwards, 1979, Eriksson 
et al., 2003). Moreover, the applicability domain of the model should be investigated to 
determine the size of the chemical space in which the predictions are applicable (Eriksson 
et al., 2003, He and Jurs, 2005, Tropsha et al., 2003).  
QSPR models can be also classification models that relate the set of descriptor variables 
to a categorical value of the pharmacokinetic variable and can be developed using non-linear 
methods such as k-nearest neighbors, artificial neural network, support vector machines or 
recursive partitioning classification. The Recursive Partitioning classification is a decision 
tree tool that has been claimed to perform well when modelling complex property. The 
metrics used for assessing the success of classification model is sensitivity, specificity and 
the area under curve in receiver operator curve analysis. 
2.4.1 Impact of chemical structure on drug distribution and fraction of 
unbound drug in plasma 
The first QSPR model for Vd with purely in silico descriptors was built by Hirono and co-
workers in 1994 (Hirono et al., 1994) using the Fuzzy Adaptive Least-Squares technique. 
They modelled Vd using LogP and molecular weight descriptors, but this model failed. Vd 
is a very complex parameter that depends on drug passage through many cellular and tissue 
barriers, plasma protein binding, and affinity to the components in the tissues (Rowland and 
Tozer, 2011, Rodgers and Rowland, 2007, Toutain and Bousquet-Melou, 2004). These 
factors cannot be described with only a few molecular descriptors. For this reason, the use 
of too few descriptors can hamper Vd QSPR modelling. Another reason why the modelling 
may not succeed can be attributed to the inadequate pharmacokinetic in vivo data which 
have been used in building the model. Pharmacokinetic studies should be based on 
intravenous (not per oral) drug administration to healthy subjects. In this case, the drug dose 
in the blood circulation at the time of administration is known. Moreover, Vd must be Vss, 
not Varea or Vz, because Vss describes the distribution at true equilibrium. The 
aforementioned reasons are relevant for determining the quality of the input values in model 
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building. Additionally, it is preferable that the model is not based on a narrow range of 
molecular structures because that may lead to its limited applicability. This has been the 
case for some models of Vd and fu that have been based on small data sets (less than 70 
compounds) (Hirono et al., 1994, Karalis et al., 2003, Ghafourian et al., 2004, Ng et al., 
2004, Turner et al., 2004, Paul et al., 2010, Li et al., 2011). Such data sets are only suitable 
for modelling a specific chemical space. Another important point is that the model should 
be validated in a systematic way (including internal and external validation, and Y-response 
permutation). The model should be open, transparent and interpretable so that it can be used 
and understood by other investigators working in this field. In 2008, Obach and co-workers 
published a curated data set of Vss from intravenous pharmacokinetic studies in healthy 
subjects (Obach et al., 2008). Subsequently, a few QSPR models of Vss have been published 
(Berellini et al., 2009, Gombar and Hall, 2013). Tables 1 and 2, present in chronological 
order the in silico QSPR models for Vd and fu, respectively.  
In some of the Vss prediction models, fu was used as a descriptor (Karalis et al., 2003) 
or as a hybrid parameter (Vd/ fu) (Ghafourian et al., 2004). However, no one has used Vss 
and fu as responses in the same model for simultaneous prediction. This might well prove 
to be a valid approach, bearing in mind that the type of binding to tissues (relevant to Vss 
value) and to protein (affecting the fu value) may not always be identical (e.g. unspecific 
tissue binding and relatively specific protein binding). This difference may affect the model. 
The incorporation of both fu and Vss as endpoints within the same model is feasible if one 
utilizes the PLS technique. 
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2.6 Pharmacokinetics of intravitreal injections 
2.6.1 Routes of ocular drug administration 
The most common way to administer a drug to the eye is topical treatment (eye drops or 
ointments) onto the corneal and conjunctival surface. However, topical administration does 
not achieve therapeutic drug concentrations into the back of the eye (vitreous, retina, 
choroid) (Urtti, 2006, del Amo and Urtti, 2008). Therefore, topical drug administration is 
not useful in the treatment of those disorders affecting the posterior eye segment (e.g. 
macular degeneration, diabetic retinopathy, inherited retinal degenerations) (Zhang et al., 
2012b). Other routes of drug administration include systemic delivery and periocular 
(sub-conjunctival, sub-Tenon or parabulbar) and intravitreal administration (Figure 6). 
Systemic drug administration (oral, i.v., subcutaneous) is rarely a viable option, because the 
blood-ocular barriers limit drug entrance to the eye. To overcome these barriers, high 
systemic doses would be needed and these would most likely be associated with 
unacceptable side-effects (Urtti, 2006). After periocular administration, drug delivery to the 
retina is limited by choroidal blood flow and the retinal pigment epithelium (RPE) barrier 
(Ranta et al., 2010, Ranta and Urtti, 2006). 
            
Figure 6 Scheme of the various routes of ocular drug administration and the anatomy of the eye. 
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Intravitreal administration is the most reliable way of delivering adequate drug 
concentrations to the posterior segment tissues (Urtti, 2006, del Amo and Urtti, 2008). 
Intravitreal drug delivery can be accomplished either as intravitreal injections (solutions, 
suspensions) or via controlled release implants (del Amo and Urtti, 2008, Sanford, 2013, 
Totan et al., 2015). Clinical intravitreal drugs include corticosteroids, non-steroidal 
anti-inflammatory agents, antibiotics, antivirals, antineoplastics, monoclonal antibodies and 
soluble receptor (Zhang et al., 2012b, Peyman et al., 2009, Sarao et al., 2014).  
In addition to the aforementioned routes of ocular drug delivery in the clinics, there are 
experimental but rarely used routes of drug administration to the posterior segment. These 
include suprachoroidal delivery (between the sclera and choroid), intra-scleral delivery, and 
sub-retinal injections (between the neural retina and RPE). These routes of administration 
have not gained wider acceptance due to the associated risks and their unexplored 
pharmacokinetic features, but their clinical applicability may expand in the future with the 
development of novel drug delivery systems. 
2.6.2 Intravitreal pharmacokinetics 
The number of intravitreal injections has increased exponentially during the last decade. 
Earlier, intravitreal injections were used only for rare illnesses e.g. endophthalmitis, viral 
retinitis, but the situation changed after the introduction of new anti-angiogenic drugs for 
the treatment of age-related macular degeneration (AMD). Additionally, new generations 
of ophthalmic drugs for the treatment of AMD, diabetic retinopathy, glaucomatous retinal 
changes and inherited retinal degenerations are being investigated (Zhang et al., 2012b). 
These developments may increase further the number of intravitreal injections, since these 
illnesses are chronic and prevalent. For example, the majority of AMD patients are subjected 
to an intensive follow-up and injection regime at six weekly intervals (DaCosta et al., 2014, 
Severn and Hamilton, 2015). This constitutes a burden to the health care system and the 
patients since these injections are invasive and potentially risky (DaCosta et al., 2014, 
Dossarps et al., 2015). Therefore, it would be best if the dosing intervals could be as long 
as possible. In the case of viral and bacterial intraocular infections, shorter treatment periods 
may be adequate, but the drugs may need to be dosed more frequently (Peyman et al., 2009). 
It has been speculated that improved drug delivery systems would benefit intravitreal 
treatment by prolonging the drug residence in the eye for up to several months, thus 
decreasing the number of injections significantly (del Amo and Urtti, 2008, Sanford, 2013, 
Totan et al., 2015). For example, the biodegradable Ozurdex implant delivers 
dexamethasone for six months after its intravitreal administration (Totan et al., 2015).  
After intravitreal injection, drugs diffuse throughout the vitreous, distribute into the 
ocular tissues (lens, iris, ciliary body, retina) and are eliminated into the systemic circulation 
(Maurice and Mishima, 1984, Maurice, 1976). The ocular distribution of an intravitreally 
administered drug depends on its permeation and binding to the tissues, while drug 
clearance from the vitreous is influenced by the ability of the drug to cross the blood-ocular 
barriers: anterior blood-aqueous barrier (BAB) and posterior blood-retinal barrier (BRB) 
(Maurice and Mishima, 1984, Maurice, 1976) (Figure 7B). The BAB is formed by the 
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posterior iris and the inner non-pigmented ciliary epithelia and the tight endothelia around 
the iris capillaries (Bill, 1975, Freddo, 2013). The BRB consists of the endothelia of the 
retinal capillaries (inner BRB) and RPE (outer BRB) (Bill, 1975, Cunha-Vaz, 1979, Cunha-
Vaz et al., 2011). Intravitreally administered drugs are also eliminated via aqueous humour 
turnover anteriorly; aqueous humour flows through the pupil into the anterior chamber, and 
passes through trabecular meshwork into Schlemm’s canal and then via a system of collector 
channels, it is deposited into the venous system (Figure 7A). The anterior clearance 
corresponds to drug elimination only via aqueous humour outflow (Figure 7A), and 
posterior clearance refers to elimination through the BAB and BRB and via aqueous humour 
turnover (Figure 7B). The relative importance of the anterior and posterior routes depends 
on several properties of the drug (Maurice and Mishima, 1984, Maurice, 1976, Meredith, 
1993). Lipophilic drugs which are able to pass through blood-ocular barriers, are eliminated 
via posterior clearance (Maurice and Mishima, 1984, Maurice, 1976, Meredith, 1993). 
These kinds of drugs are mainly eliminated through the BRB into the highly vascularized 
choroid and systemic blood circulation that acts as a sink for the drug (Roh et al., 2006). 
Permeation across the BRB is the predominant route due to the large membrane surface area 
and extensive choroidal blood flow (4, in Figure 7B). This leads to relatively fast drug 
clearance from the eye (Gupta et al., 2000, Maurice, 1976, Shen et al., 2007) (Figure 7B). 
Large molecules (over 5 kDa) are believed to be eliminated mainly via the anterior route by 
aqueous humour outflow (Figure 7A), because they have low capabilities of crossing the 
blood-ocular barriers (Maurice and Mishima, 1984, Maurice, 1976, Meredith, 1993). 
Figure 7 Routes of drug elimination after intravitreal injection. (A) Anterior clearance of the 
drug via aqueous humour flow, drug permeates through the trabecular meshwork 
and reaches the venous system (1). (B) Drug clearance through blood-ocular 
barriers. The drug permeates through the posterior iris epithelium into the iris vein 
and is drained by the vortex veins (2), through the non-pigmented ciliary epithelium 
to ciliary muscles and from the ciliary plexus to the episcleral veins (3), to the retinal 
capillaries and through the RPE into the choroid and systemic circulation (4). 
33
 
 
 
 
The blood-ocular barriers can be disrupted in the diseased eye, for example RPE is 
compromised in AMD and posterior uveitis while the leakiness of the retinal endothelium 
of capillaries is increased in diabetic retinopathy and retinal vein-occlusive diseases (Zhang 
et al., 2012b). These types of changes in the BRB would be anticipated to impact on the 
intravitreal pharmacokinetics of drugs. On the other hand, there are age-related changes in 
the vitreous in which the gel volume decreases and the liquid volume increases and these 
have long been hypothesized to affect the movement of drugs in the vitreous and therefore 
on drug intravitreal pharmacokinetics (Laude et al., 2010). The diffusion of molecules could 
increase in the formed lacunae pockets of aged-vitreous. However, molecules encounter 
only a very modest diffusivity difference between vitreous-gel and vitreous-liquid; for 
example, only a 2.5-fold difference was observed between the diffusivity in pure water 
versus that in vitreous consisting of nanoparticles of 500 nm diameter (Xu et al., 2013). One 
would predict that for soluble small compounds and macromolecules, the difference in 
diffusivity would be even smaller (e.g. bevacizumab has a molecular diameter of 12 nm, 
other ocular drugs are smaller). This open question could be resolved by undertaking a 
systematical investigation of the effect of vitreous viscosity on intravitreal pharmacokinetics 
of small molecular weight drugs and macromolecules.  
The intravitreal pharmacokinetics is defined by the primary parameters: volume of 
distribution (Vss, ivt) and clearance (CLivt). In analogy with the systemic pharmacokinetics, 
Vss, ivt can be compared to the anatomical volumes of the ocular tissues: 
(11) ??????? ? ????????? ? ????? ? ?????????????????????? ? ??????????????? ?
???????? ? ????????? ? 
where V values indicate the anatomical tissue volumes and Kp, T are the distribution 
coefficients of the drug between each tissue and vitreous. High Kp, T values indicate effective 
drug partitioning to the tissues that should lead to higher Vss, ivt values than the anatomical 
volumes. The minimum of Vss, ivt would be Vvitreous. 
 
CLivt (units of volume/time, e.g., ml/h) describes the elimination of a compound 
irreversibly from the eye. CLivt is expressed as: 
(12) ?????? ? ??????????? 
where Divt is the intravitreal dose and AUCivt is the area under the drug concentration in 
the vitreous curve. 
 
Half-life (t1/2) is useful parameter with which to determine the regimen of administration 
of a drug and it is easy to understand. Although it is the most frequently reported of 
pharmacokinetic parameters, it is often misunderstood (Toutain and Bousquet-Mélou, 
2004). Moreover, t1/2 does not make it possible to conduct any mechanistic analyses, because 
it is not a primary pharmacokinetic parameter, but rather is dependent on Vd and CL.  
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(13) ???? ? ???? ??????   
Intravitreal pharmacokinetic parameters have not been related to the physiological 
factors (e.g. tissue volumes, blood flow, and aqueous humour flow) or to the molecular 
descriptors of the drug in a systematic manner.  
2.6.3 Intravitreal pharmacokinetic models: QSPR and pharmacokinetic 
simulations 
The availability of good predictive QSPR models for intravitreal pharmacokinetic 
parameters (Vss, ivt, CLivt, t1/2, ivt) would benefit ocular drug discovery and development. 
Previously, a QSPR model for intravitreal half-life (t1/2, ivt) has been generated using a 
multiple regression technique, but only a limited set of descriptors was investigated 
(molecular weight, lipophilicity, and solubility) (Durairaj et al., 2009). Moreover, the model 
was neither properly validated with either external test set nor evaluated for robustness 
(Y-permutation test).  
Even though t1/2, ivt is a useful practical parameter if one wishes to estimate the required 
dosing frequency, the QSPR prediction of the primary parameters, Vss, ivt and CLivt, can give 
deeper insights on the influence of the physiological factors on intravitreal 
pharmacokinetics. However, no QSPR models for Vss, ivt and CLivt have been generated and 
these values have not been comprehensively determined. Moreover, Vss, ivt and CLivt values 
can be utilized in pharmacokinetic simulations to predict vitreal drug concentration profiles.  
There are various software packages with graphical interfaces which can be used for 
pharmacokinetic simulations (e.g. STELLA® Modelling & Simulation software, Berkeley 
Madonna® Modelling & Analysis of Dynamic Systems). They are versatile tools that allow 
compartmental and physiologically based pharmacokinetic modelling, assuming a 
homogeneous distribution of the drug in each compartment. In addition, a specialized 
domain package such as Comsol Multiphysics ® Modelling software can be used for 
simulations based on finite element modelling where a 3D replica of the eye can be built 
and subdivided into thousands of voxels (Kotha and Murtomäki, 2014). Subsequently, the 
transfer between the voxels is described with equations for diffusion, partitioning and 
convective flow (Kotha and Murtomäki, 2014).  
Hybrid in silico tools for ocular pharmacokinetics can be built by combining QSPR 
models with pharmacokinetic simulations and one could predict that these kinds of 
simulation models could be very useful in the design of drug delivery systems and drug 
dosing regimens.  
2.6.4 Rabbit as an animal model for intravitreal pharmacokinetics 
Ocular pharmacokinetics has only rarely been studied in the human eye, because there are 
prohibitive ethical issues associated with the invasive sampling from the human eye. 
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Therefore, ocular pharmacokinetics relies on animal models, and in most cases, the animals 
have been rabbits. 
However, the rabbit has been criticized for being a poor model for intravitreal 
pharmacokinetics in humans. The criticism is based on the anatomical and physiological 
differences (Laude et al., 2010, Rowe-Rendleman et al., 2014, Bakri et al., 2007a, Bakri et 
al., 2007b). In comparison to the human eye, the rabbit eye has a smaller vitreal volume, a 
larger crystalline lens, a less vascularized retina, a smaller uveoscleral outflow, and less 
viscous vitreous (Bakri et al., 2007a, Bakri et al., 2007b, Vaishya et al., 2011, Rittenhouse 
and Pollack, 2000). Nevertheless, no systematic and quantitative analysis of the rabbit and 
human eye differences in intravitreal pharmacokinetics has ever been performed. 
Anatomical differences do not necessarily make the animal model invalid. For example, 
mice and rats are frequently used as animal models in preclinical pharmacokinetics, even 
though there are evident anatomical and physiological differences between these rodents 
and humans.  
Therefore, there is a need to assess the translational value of the rabbit as an animal 
model in intravitreal pharmacokinetics.  
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3. Aims of the study 
The overall aim of this thesis was to build predictive chemoinformatic and simulation 
models for the pharmacokinetics of lead compounds, drug candidates and drug delivery 
systems. The specific aims were: 
 
1. To develop a QSPR model which could estimate the volume of drug distribution and 
fraction of unbound drug in plasma based on intravenous drug data in humans. 
 
2. To collect and calculate pharmacokinetic parameters (volume of intravitreal distribution, 
intravitreal clearance and half-life) from intravitreal injection data in rabbits and humans.  
 
3. To build QSPR models for intravitreal clearance and half-life.  
 
4. To integrate intravitreal clearance and volume of distribution values (from the 
corresponding QSPR model and reference range) into pharmacokinetic simulation models 
to allow an estimation of vitreous concentrations of intravitreal drugs.  
 
5. To evaluate the translational value of the rabbit model in intravitreal pharmacokinetics.  
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4. Overview of the methods 
In the present thesis, the following steps and methods were used in assessing either the 
values or the in silico models for human Vss and fu (I), Vss, ivt, CLivt and t1/2, ivt, vitreal and 
aqueous concentration profiles in rabbits (II, III) and humans (IV): 
 
1. Literature search and data collection of the pharmacokinetic parameters or the 
concentration-time profiles of drugs (I - IV). 
 
2. Extraction of the intravitreal pharmacokinetic parameters from the concentration-time 
profile data in rabbits using curve fitting with WinNonlin® software (version 5.3, Pharsight 
Inc., St. Louis, USA). GetData Graph Digitizer® (version 2.24., Digital River, Inc., Cologne, 
Germany) was used to obtain concentration-time numerical values when only the graphs 
were available (III). For human data, Phoenix WinNonlin® software (version 6.3) and 
GetData Graph Digitizer® were applied when a balanced concentration profile was 
available, otherwise calculations of the apparent intravitreal clearance were carried out with 
Microsoft Excel® program (2003, Microsoft, Washington, USA) (IV).  
 
3. Generation of the 2-D structure of the compounds with ACD/Dictionary incorporated in 
ACDlabs® software (versions 11 and 12, Advanced Chemistry Development, Inc., Toronto, 
Canada) (I - III) or the PubMed compound database 
(http://www.ncbi.nlm.nih.gov/pccompound) and the 3-D structure with Concord within 
SYBYL® (version 8.0, Tripos International, St. Louis, USA) (I). 
 
4. Generation of molecular descriptors from the 2-D structures using ACDlabs® software 
(I - III) and from 3-D structures using Volsurf+® software (Cruciani et al., 2000) and 
MOE™, Molecular Operating Environment (Chemical Computing Group, Montreal, 
Canada, 2008) (I). 
 
5. QSPR modelling: 
 
5.1. By PLS Regression and PCA using SIMCAplus® software (version 10.5, Umetrics 
AB, Umeå, Sweden) (I, II, III). 
 
5.2. By Recursive Partition (RP) Classification using Discovery Studio® software 
(version 3.5, Accelrys Inc., San Diego, USA) (I). 
 
6. QSPR model validation: 
 
The QSPR regression models (in 5.1.) were validated by cross-validation, internal and 
external test set validation and by performing the Y-randomization test (I - III). 
The QSPR classification (in 5.2.) was validated by calculating values for sensitivity, 
specificity and the area under curve in receiver operating characteristics plot metrics as well 
as undertaking external test set validation and utilizing the Y-randomization test (I). 
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7. Applicability domain of the model to define the chemical space in which the model is 
able to predict accurately (I, II). 
 
8. Implementation of QSPR models into intravitreal pharmacokinetic simulation models 
using STELLA® Modelling & Simulation software (version 8.1.1, isee systems, Inc., 
Lebanon, USA) in order to simulate the intravitreal concentration profiles of compounds 
injected either as a solution or in control release systems (III). Rabbit and human kinetic 
data were further explored with the kinetic simulation model STELLA® Modelling & 
Simulation software (version 10.3) (IV). 
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Abstract
Volume of distribution and fraction unbound are two key parameters in pharmacokinetics. The fraction unbound describes
the portion of free drug in plasma that may extravasate, while volume of distribution describes the tissue access and
binding of a drug. Reliable in silico predictions of these pharmacokinetic parameters would benefit the early stages of drug
discovery, as experimental measuring is not feasible for screening purposes. We have applied linear and nonlinear
multivariate approaches to predict these parameters: linear partial least square regression and non-linear recursive
partitioning classification. The volume of distribution and fraction of unbound drug in plasma are predicted in parallel
within the model, since the two are expected to be affected by similar physicochemical drug properties. Predictive models
for both parameters were built and the performance of the linear models compared to models included in the commercial
software Volsurf+. Our models performed better in predicting the unbound fraction (Q2 0.54 for test set compared to 0.38
with Volsurf+ model), but prediction accuracy of the volume of distribution was comparable to the Volsurf+ model (Q2 of
0.70 for test set compared to 0.71 with Volsurf+ model). The nonlinear classification models were able to identify
compounds with a high or low volume of distribution (sensitivity 0.81 and 0.71, respectively, for test set), while classification
of fraction unbound was less successful. The interrelationship between the volume of distribution and fraction unbound is
investigated and described in terms of physicochemical descriptors. Lipophilicity and solubility descriptors were found to
have a high influence on both volume of distribution and fraction unbound, but with an inverse relationship.
Citation: del Amo EM, Ghemtio L, Xhaard H, Yliperttula M, Urtti A, et al. (2013) Applying Linear and Non-Linear Methods for Parallel Prediction of Volume of
Distribution and Fraction of Unbound Drug. PLoS ONE 8(10): e74758. doi:10.1371/journal.pone.0074758
Editor: Paul Taylor, University of Edinburgh, United Kingdom
Received May 20, 2013; Accepted August 7, 2013; Published October 7, 2013
Copyright:  2013 del Amo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work has been supported by the Graduate School in Pharmaceutical Research, the Academy of Finland, Biocenter Finland, the Finnish Cultural
Foundation, and OrionPharma Ltd. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: This work has been supported by Orion Pharma Ltd. The funding occurred through a TEKES (Finnish funding agency for Technology and
Innovation) project ‘‘IVIVRe’’. There is no financial or other competing interest by the authors or funders in this work, and this does not alter the authors’
adherence to all the PLOS ONE policies on sharing data and materials.
* E-mail: heidi.kidron@helsinki.fi
Introduction
The extent of drug distribution determines the access of a drug
to its sites of action and to other tissues, which might give rise to
adverse effects. A primary parameter for drug distribution is the
volume of distribution (Vd) that is defined as.
Vd~
A
C
where A is the amount of drug in the body, and C is the drug
concentration in plasma (both free drug and protein-bound drug).
Volume of distribution is an apparent volume that increases with
elevated drug binding in the extravascular space of the body and
not an anatomically defined volume. Consequently, extensive drug
binding outside the blood vessels leads to increasing values of A/C
ratio. As tissue binding of drugs varies considerably, volume of
distribution displays a wide range of values. For example,
erythropoietin is confined to the vascular space presenting a Vd
of 4 L (approximately the anatomical volume of vascular space)
[1], while hydroxychloroquine with a Vd of 49 000 L strongly
accumulates into the cells and tissues [2]. Volume of distribution at
steady state (Vss) is measured at equilibrium, therefore, it describes
the molecular tissue binding more reliably than other volume of
distribution parameters that are dependent on the time after
measurement. Vss depends on the access of the drug to the cells
and tissues, its affinity to plasma proteins and tissue components,
and number of binding sites in plasma and tissues.
Drug concentration in plasma (C) includes both unbound (Cu) and
protein-bound drug in plasma. However, only the fraction of free
drug in plasma permeates across the cellular membranes and vascular
walls in most tissues. The free fraction of drug in plasma (fu) is
described by the ratio Cu/C. Likewise the drug in the tissues also
includes both free (CuT) or tissue bound parts. The unbound fraction
of drug in tissues is: fuT = CuT/CT, where CT is the total drug
concentration in the tissue. Drug binding to plasma proteins and
tissue components influences drug partitioning between the tissues
and plasma. Thus, Vss can be presented using the following equation:
Vss~VpzVT1
fu
fuT1
 !
zVT2
fu
fuT2
 !
::::
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where Vp is the anatomical volume of plasma and VT is the true
anatomical volume of each tissue. Vss depends on the anatomical
volumes of the tissues, and the relative extent of drug binding in the
plasma and tissues described as fu/fuT ratios.
As volume of distribution describes the extent of drug
distribution, it is important to predict its value early in drug
development before experimental measuring in humans. Vss in
humans may be extrapolated from the in vivo animal data that is
obtained during the drug discovery process, but computational
approaches are useful at early stages before animal data has been
collected. The volume of distribution used for computational
modeling should be collected from intravenous and not from oral
pharmacokinetics studies as in some cases [3], [4]. The benefit of
intravenous administration is the defined quantity of the drug that
is subject to distribution, which avoids the uncertainty associated
with incomplete bioavailability after extravascular administration.
Even though quantitative structure-property relationship
(QSPR) has been widely used for prediction of Vss [3–16], it
remains a challenging problem that has not been adequately
solved. The early attempts for predicting volume of distribution
were based on small data sets and did not specify the type of
volume of distribution that was used as the endpoint or in some
cases used several types of volume of distribution for the model
building [3-8], [11], [13], [14], [17]. In 2008, a major advance was
the publication of a clean, manually curated dataset of Vss [18]
that subsequently has been used successfully to build predictive
models for Vss [12], [16].
The main difference in the work presented here compared to
the previously published models of Vss is that we have included
another pharmacokinetic parameter, fu, to the modeled respons-
es. The fu in plasma depends on the binding affinity and capacity
of plasma proteins, which also affect the volume of distribution.
The fraction of unbound drug in plasma can be estimated
relatively easily in vitro, but computational models for predicting
fu are also available [19-21]. The VolSurf+ software includes
prediction tools for both volume of distribution and plasma
protein binding, however, there is limited information of the
methodology behind the models and their prediction capacity
have not been evaluated in an unbiased manner in the literature.
The two parameters, Vss and fu, are expected to be affected by
similar physicochemical drug properties and our hypothesis was
that modeling them in parallel would benefit their prediction. We
have applied both linear and nonlinear multivariate approaches:
linear partial least square (PLS) regression combined with
principal component analysis (PCA) and non-linear recursive
partitioning (RP) classification. RP has been shown to perform
well when dealing with complex endpoints associated with
multiple mechanisms, while PLS allows many responses (in our
case Vss and fu) to be incorporated in one regression model, but
to our knowledge, this approach has not been used previously in
pharmacokinetic QSPR modeling.
Materials and Methods
1. Data Set
The initial dataset collated by Obach and co-workers [18]
contains 670 compounds with Vss and fu values determined after
intravenous administration to healthy people. The collection steps,
the quality and the diversity of the data have been meticulously
detailed in the publication.
The 2D structures of the compounds were obtained from the
ACD/Dictionary version 11 [22] or the PubMed compound
database (http://www.ncbi.nlm.nih.gov/pccompound Accessed
2010 October). If the compounds were represented as salts in
the 2D structure, the counter ion was discarded. The 3D structures
were generated using Concord within SYBYL 8.0 [23]. A set of 648
drugs with both 2D and 3D structures were obtained. For the
remaining 22 compounds in Obach’s data set either a 2D structure
or minimized 3D structure was not obtained or it was not possible
to calculate descriptors from the structures. The Vss of artesunate
was corrected to 1.5 L/kg based on the work of White [24].
Furthermore, we excluded ibadronic, pamodronic, risedronic and
zoledronic bisphosphonates from the set, since these compounds
are sequestered to the bones, preventing their detection in the
plasma, and leading to underestimated values of Vss [25]. The
antimalarial drugs hydroxychloroquine and chloroquine have Vss
values of 700 L/kg and 140 L/kg, respectively. These values are
far beyond the range of other Vss values (0.035–60 L/kg) and they
were excluded to avoid biasing the model.
The final data set of 642 drugs (Figure 1) displays Vss values of
0.035–60 L/kg and fu values (541 drugs) of 0.0002–1.
2. Calculation of Molecular Descriptors
In this study, molecular descriptors were calculated using
ACDlabs [26], Volsurf+ [17] and MOE [27]. Input molecular
structures were two-dimensional for ACDlabs and three-dimen-
sional for Volsurf+ and MOE, for the later Gasteiger-Huckel
charges were added. Identical descriptors (i.e. molecular weight,
molecular volume) were excluded before combining descriptor sets
for modeling. The descriptors that were used for model building
are listed in Table 1 and the calculated descriptor values for the
data set are available in File S1.
3. PCA and PLS Regression Models
QSPR models were built using linear multivariate analysis tools
PCA and PLS (Simca plus Version 10.5) [28]. All descriptors were
transformed with unit variance scaling and mean centering before
PCA and PLS analysis. Moreover, the descriptors with a broad
range or unequal distribution across the range were logarithmi-
cally transformed to obtain better distributions. Three sets of
molecular descriptors were assembled for the regression modeling:
(1) ACDlabs descriptors and MOE logS descriptor; (2) VolSurf+
descriptors; (3) the combination of ACDlabs, MOE and VolSurf+
descriptors.
A workflow of the modeling process is presented in Figure 2.
Before modeling, a foreign set of 101 drugs was randomly
excluded from the final 642 compound set. The descriptor matrix
of the remaining 541 drugs was analysed with PCA to identify the
drugs that fall outside the general chemical space of the compound
set and descriptors that should be excluded from the model (model
calibration). Drugs that were outliers based on their distribution in
the PCA plot and whose descriptor values fell outside the
boundaries outlined in Table 2 were excluded. Based on the
scatter plot of the final PCA plot, an external test set (Figure 3) of
101 compounds representative of the chemical space was selected.
The external set comprises molecules within the chemical space of
the model, while the foreign set, which was selected before the
PCA and model calibration, also includes compounds outside the
chemical space used for model building. The remaining
compounds constitute the training set for the PLS model building
(365 drugs for model 1; 357 drugs for model 2; 361 drugs for
model 3). The training sets were used to build PLS models that
relate the descriptors to the two simultaneously modelled
responses, log Vss and fu. During initial stages of the analytical
process, the number of highly correlated variables observed in the
PLS weight plot was gradually reduced in order to equilibrate the
influence of the overall set of descriptors on the responses.
Subsequent models with improved statistic parameters were
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obtained and variables deemed least influential to the modelled
pharmacokinetic parameters were excluded. The decisions were
based on the PLS weight plot and confirmed by the variable
importance plot results. Moreover, the distribution of the drugs
was followed up by the PLS score and Dmod plots, in order to
detect outliers.
4. Recursive Partitioning Classification Models
A RP analysis was carried out using Discovery Studio version 3.5
(Accelrys Inc.) to develop decision trees that categorize the
compounds into classes that are based on the Vss values or both Vss
and fu values (Table 3 and 4). Volume of distribution is defined by
drug interactions with the main volumes in the body: extracellular
space and cellular tissue space. We used these anatomical volumes
as rough guidance to classify the volumes into three classes. Class 1
represents the volume of the extracellular fluid (0–0.3 L/Kg), class
2 represents Vss values that take into consideration distribution to
the tissues (0.3–1 L/Kg), and class 3 values of Vss represent
significant binding to the cellular components (.1 L/Kg).
However, it should be noted that Vss is an apparent volume that
does not strictly obey anatomical volumes, therefore the anatom-
ical distribution of the compounds cannot be concluded from the
Vss. Distribution of compounds into the three classes is shown in
Figure 1A. When both Vss and fu values were predicted, each class
Figure 1. Distribution of compounds in the data set. (A) The distribution of logVss values in the final dataset. Lines have been draw at 0.3 L/kg
and 1 L/kg to indicate the boundaries between the three classes used in the RP models. B) Distribution of compounds based on both log Vss and log
fu values and coloring by compound charge (basic-red, neutral-yellow, acidic-green, zwitterionic-blue).
doi:10.1371/journal.pone.0074758.g001
Table 1. The descriptors included in modeling.
ACDlabs descriptors Volsurf+ descriptors MOE descriptors
ALogD5 V WO1 CW5 POL %FU4 LgS6 logS
ALogD5.5 S WO2 CW6 MW %FU5 LgS6
ALogD7 R WO3 CW7 FLEX %FU6 LgS7
ALogD7.4 G WO4 CW8 FLEX_RB %FU7 LgS7.5
APSA W1 WO5 ID1 NCC %FU8 LgS8
HDonors W2 WO6 ID2 DIFF %FU9 LgS9
HAcceptors W3 WN1 ID3 LOGP n-Oct %FU10 LgS10
FRB W4 WN2 ID4 LOGP c-Hex DRDRDR LgS11
Rule Of 5 W5 WN3 CD1 PSA DRDRAC L0LgS
Molar Volume W6 WN4 CD2 HAS DRDRDO L1LgS
MW W7 WN5 CD3 PSAR DRACAC L2LgS
Surface Tension W8 WN6 CD4 PHSAR DRACDO L3LgS
Polarizability D1 IW1 CD5 LgD5 DRDODO L4LgS
C ratio D2 IW2 CD6 LgD6 ACACAC DD1
N ratio D3 IW3 CD7 LgD7 ACACDO DD2
NO ratio D4 IW4 CD8 LgD7.5 ACDODO DD3
Num Rings D5 CW1 HL1 LgD8 DODODO DD4
Num Ar Rings D6 CW2 HL2 LgD9 SOLY DD5
D7 CW3 A LgD10 LgS3 DD6
D8 CW4 CP AUS7.4 LgS4 DD7
LgS5 DD8
doi:10.1371/journal.pone.0074758.t001
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Table 2. Statistical parameters of the PCA models and the chemical boundaries chosen during the PCA modelling.
A R2X Q2X Criteria of model calibration
Model 1 7 0.90 0.58 MWa,940 PSAb,205 POLc,71 HBDd,10 HBAe,15 and -7.71,LogSf,0.38
Model 2 7 0.79 0.73 MW,940 WO4g,100 WO6,2 PSA,205 SOLYh,0.93 Vi,1353 POL,71 LogS9j,5.3 W4k,483
Model 3 7 0.79 0.72 MW,940 WO4,100 PSA,205 SOLY,0.93 MVl,466 Rule of 5,3
aMW:molecular weight; bPSA: polar surface area; cPOL: polarizability; dHBD: hydrogen bond donors; eHBA: hydrogen bond acceptors; fLogS: log of solubility; gWO4
andWO6: hydrogen bond donor volume at different energy levels; hSOLY: intrinsic solubility; iV:molecular volume; jLogS9: log of solubility at pH 9; kW4: hydrophilic
volume; lMV: molar volume.
doi:10.1371/journal.pone.0074758.t002
Figure 2. Flowchart of the work process to obtain regression and classification models for Vss and fu. MFE= mean fold error, SI
= Sensitivity, SPEC= specificity.
doi:10.1371/journal.pone.0074758.g002
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was further divided into compounds with low to intermediate
(,0.7) or high (.0.7) fu. Compounds with missing fu values were
addressed by assigning them the mean value of all fu values and
distributing them equally in the training and external test set,
which is a standard approach to handle missing values in RP
analysis. In our study, balanced forest of RP was used, since it is
the appropriate method for imbalanced data [29]. This type of RP
contains a relatively small number of trees (in average 10) using a
separate bootstrap sample of the original data for each tree. For
each tree, the number of members in all classes is equal to the
number of members in the smallest class. The number of
descriptors that was used as split criterion within each tree was
set to the square root of total descriptors. The weighing method
was set to ‘‘uniform’’ and the equalize class sizes to true. All others
parameters were set to default.
A training set was used to build the decision trees and an
external test set was utilized to evaluate the predictive power of the
models. To generate the training and external test set for RP
analyses, all compounds were first clustered by similarity based on
root mean square deviation and each cluster was divided into
training and test sets to ensure that both sets included compounds
from each cluster. The data set used to train the model consisted of
382 compounds, while 260 compounds were used as an external
test set (Figure 2).
5. Model validation
The prediction accuracy of the PLS models was determined by
internal and external validation. The internal validation is based
on the cross-validation value Q2Y (Q2) that is calculated by leaving
out 1/7 of the data, and predicting these compounds based on a
model trained by the remaining data. The external validation is
conducted with the external test set. The model was used to
predict the log Vss and fu of the external test set. The predicted
responses were plotted against the observed responses (i.e.
experimental Vss and fu). The R
2 value of the regression line for
the plot was considered as the Qe
2 (goodness of prediction of the
external test set).
We estimated the predictive ability of the RP classification
models using out-of-bag statistics. The external test set was used to
estimate the fitting ability of the model on a new dataset that was
not used in the model construction. The performance of the RP
models is based on three metrics: true positive rate (recall or
sensitivity), specificity, and the area under the curve (AUC) of the
receiver operating characteristics (ROC) plot [30]. AUC repre-
sents the probability that a classifier will be estimated correctly,
with values .0.5 indicating better than random prediction and 1
signifying perfect prediction. In the case of more than two classes
(multiclassification), a confusion matrix is a square of NxN, where
N is the number of classes. AUC is computed as defined by Hand
and Till (2001) as an average over components generated from
several ROC plots for a Y property and cannot be plotted [30].
For instance, when N (A, B, C) is 3, the classifier’s performance is
computed per class as follows for class A:
Figure 3. PCA score plot. The final PCA score plot obtained after model 3 calibration where the two principal components explain 27% and 20%,
respectively, of the variance in the data set. The open squares represent the drugs in the external test set and the filled triangles the drugs in the
training set. The ellipse depicts the 95% confidence region of the model (Hotelling T2).
doi:10.1371/journal.pone.0074758.g003
Table 3. Division of training and test set compounds into
three classes according to observed Vss.
Class 1 Class 2 Class 3 Total
Vss =0–0.3
L/kg
Vss =0.3–1
L/kg Vss .1 L/kg
Training 105 96 181 382
Test 62 71 127 260
Total 167 167 308 642
doi:10.1371/journal.pone.0074758.t003
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Actual=predicted ClassA ClassB ClassC
ClassA TA FB1 FC1
ClassB FA2 TB FC2
ClassC FA3 FB3 TC
Sensitvity~
TA
TAzFB1zFC1
Specificity~
TBzTC
TBzFA2zTCzFA3
6. Y-randomization test
In addition to the internal and external validation, the Y-
randomization test (response permutation test) was performed,
which estimates the robustness of models [31]. The X data are left
intact, whereas the Y data are permuted to appear in a different
order (random shuffling). A model is then fitted to the permuted Y-
data and the model statistics are computed for the derived model.
It is expected that the models from randomized activities would
have significantly lower accuracy values.
7. The applicability domain of models
An applicability domain (AD) of the model is needed to avoid
making predictions for compounds, which differ substantially from
the training set molecules. The AD is used to estimate which
compounds are suitable for model predictions and avoid
unjustified extrapolation of predictions. We used a method
introduced by Zhang et al. (2006) for defining the AD based on
the distribution of similarities between each compound and its
nearest neighbours in the training sets [32]. The AD was
calculated as follows:
AD~vdwzZs
The average of Euclidean distances between all points of the
training set were calculated from Similarity and Clustering Canvas
of Schro¨dinger modeling package [33], with 32 bit linear Daylight
fingerprint. Data for estimation of the Euclidean distance and
application of the AD on new compounds are available in
Files S2-S5. Then, using the distances lower than the average, a
new average distance ,d. and standard deviation s between
these distances were calculated. Z is an arbitrary parameter to
control the significance level and considerably affects the number
of compounds within the applicability domain. Increasing Z will
include compounds that are more dissimilar in the AD. We set the
value of Z to 0.7 to calculate the compounds within the AD of the
models in the foreign test set.
Results
1. PLS Regression Models
The linear regression model of log Vss and fu was attempted
with three descriptor sets: (1) 19 descriptors from ACDlabs and
MOE, (2) 121 descriptors from VolSurf+ and (3) 140 descriptors
from the combination of the two previous sets. The three sets were
first analyzed with PCA. In Table 2, the final PCA model statistics
for the three strategies are presented as well as the criteria of
selection chosen in each case. In Figure 3, the score plot of the
final PCA model of data set 3 is shown as an example. Similar
plots were obtained for the other data sets.
The statistical values of the final models are present in Figure 2.
Model 1 resulted in a non-predictive model, yielding a Q2Y
smaller than 0.50, and therefore the analysis of this set was not
taken any further. The final models were based on 332 compounds
and 9 descriptors from Volsurf+ (model 2) and 353 compounds and
11 descriptors combined from Volsurf+, ACDlabs and MOE (model
3). The PLS weight plot of model 3 is presented in Figure 4,
showing the relationships between the X-descriptors and Y-
responses, Vss and fu, at the same time. A detailed description of
PLS weight interpretation is presented in the legend. The final
equations for model 2 and model 3 are:
Model 2.
logVss~0:1521{0:1173L1LgSz0:2858L3LgS
{0:0123SOLYz0:0122LOGPn{Octz0:0463LgD9
{0:0083WN5{0:0002W1z0:2811ID3z0:0026A
fu~0:8134{0:0348L1LgSz0:1096L3LgSz0:0733SOLY
{0:0523LOGPn{Oct{0:0227LgD9z0:0005WN5
{0:0001W1z0:5579ID3{0:0272A
Model 3.
logVss~0:2464z0:0909LgS3{0:0269LgS10{0:0099 logS
z0:3894L3LgSz0:0465LgD10z0:0514ALogD5:5
z0:0010%FU10z0:0004MV{0:0005W1z0:0023D4
z0:0174HD
Table 4. Division of training and test set compounds into six classes according to observed Vss and fu.
Class 1a Class 1b Class 2a Class 2b Class 3a Class 3b Tota
Vss = 0–0.3 L/kg Vss = 0–0.3 L/kg Vss = 0.3–1 L/kg Vss = 0.3–1 L/kg Vss .=1 L/kg Vss .=1 L/kg l
& fu .0.7 & fu ,0.7 & fu .0.7 & fu ,0.7 & fu .0.7 & fu ,0.7
Training 18 87 22 68 38 149 382
Test 11 51 17 51 21 109 260
Total 29 138 39 119 59 258 642
doi:10.1371/journal.pone.0074758.t004
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fu~0:7052z0:0091LgS3{0:0024LgS10z0:0600 logS
z0:0277L3LgS{0:0153LgD10{0:0583ALogD5:5
z0:0009%FU10{0:0007MVz0:0001W1{0:0025D4
z0:0026HD
Where L1LgS and L3LgS are solubility profiling coefficients, logS
is the logarithm of solubility, LgS3 and LgS10 are the logarithms
of solubility at pH 3 and pH 10, respectively, SOLY is intrinsic
solubility, LOGP n-Oct is the partitioning coefficient in octanol/
water, LgD9, LgD10 and ALogD5.5 are distribution coefficients at
pH 9, pH 10 and pH 5.5, respectively, WN5 is hydrogen bond
acceptor volume, W1 is hydrophilic volume, ID3 is hydrophobic
integy moment, A is amphiphilic moment, %FU10 is % of fraction
unionized at pH 10 (not to be confused with fu), MV is molar
volume, D4 is hydrophobic volume and HD is hydrogen bond
donor.
Model 2 and model 3 were internally validated by cross-
validation, gaining Q2 values of 0.58 and 0.55, respectively. In
external validation of the models we determined their accuracy in
predicting log Vss and fu with the external test sets. In log Vss
prediction by model 2, two outliers were excluded (ribavirin and
bilobalide), while in fu prediction by model 2, four outliers
(acetylcysteine, amiodarone, aripiprazole, repaglinide) were ex-
cluded and in fu prediction by model 3, five outliers were excluded
(ethambutol, atovaquone, beclomethasone dipropionate, drota-
verine, irbesartan). The statistical results of the predictions are
presented in Figure 2. The Y-randomization test after 50
permutations provided R2Y- and Q2Y-intercepts smaller than
the recommended limits of 0.3 and 0.05 for both log Vss and fu,
respectively (data not shown).
The AD was estimated from the compounds belonging to the
training set as:
A~24:22zZ2:03
With Z=0.7, AD is 25.641 that represent the maximum
distance between compounds in the training set and new
compound to be predicted. The compounds in the foreign test
set that fell inside this AD were selected, yielding a set of 35 drugs
for model 2, and 30 drugs for model 3. The statistical parameters
of log Vss and fu predictions for the foreign set are presented in
Table 5 and plots of the observed and predicted responses of
Figure 4. PLS weight plot of model 3. The plot illustrates the relationships between the eleven descriptors (in black) and Vss and fu (in red). The
dashed red line crosses the origo and the Vss response, and the continuous red line (perpendicular to the dashed line) represents the borderline
between negative and positive influences of the descriptors. The respective lines for fu are blue. Impact of descriptors is interpreted in the following
manner: the Vss descriptors that show orthogonal projection on the same side as Vss (on the right from red borderline) have positive impact on Vss,
and the descriptors on the left side of the borderline show negative impact on Vss. The farther away from the origo the projection of the descriptors
lies, the stronger is the impact on the corresponding response. As an example of the variables influence on Vss, two arrows have been drawn that
represent the orthogonal projections of variable LgS10 (negatively correlated to Vss) and %FU10 (positively correlated to Vss). Likewise, the
descriptors on the left side of blue borderline show positive impact on fu, and the descriptors on the right side of the borderline have negative
influence on fu.
doi:10.1371/journal.pone.0074758.g004
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model 3 and VolSurf+ ADME models are presented in Figure 5. A
comparison of the predicted and the observed values is found
Table S1. Increasing Z increases the number of compounds in the
foreign test set that are considered to be within the applicability
domain but decreases the accuracy of prediction due to inclusion
of dissimilar nearest neighbors (Figure 6).
2. RP Classification Models
The AUC for the in-bag training data for all trees in the forest
model is 0.96 and 0.92, and the out-of-bag AUC is 0.81 and 0.79
for the Vss and Vss & fu models, respectively. The in-bag results use
predictions for the records used to train the tree, while the out-of-
bag results use predictions for the left-out records. The statistics for
the training set data presented in Figure 2 are derived from the in-
bag results. The external test set including 260 compounds
(described in Methods section) was used to evaluate the predictive
ability of the two models. All compounds were classified according
to their Vss or Vss & fu values without applying AD. The overall
prediction accuracy, calculated as ROC curve, was 0.78 and 0.82,
respectively, and the sensitivity and specificity values are presented
Figure 5. Log Vss and fu prediction plots of model 3 versus VolSurf+ ADME models (Vd and protein binding). Dot lines represent 2-fold
error, dashed lines represent 3 –fold error and long dash lines represent 5-fold error. MFE: mean fold error.
doi:10.1371/journal.pone.0074758.g005
Table 5. Statistical parameters for log Vss and fu predictions
of the foreign set compounds inside the applicability domain
of the models, calculated with Z= 0.7.
Log Vss prediction of
foreign set fu prediction of foreign set
Qf
2 MFE % ,2-fold Qf
2 MFE %,2-fold
Model 2 0.62 2.85 60 0.59 5.58 54
Model 3 0.70 2.41 67 0.54 7.04 52
doi:10.1371/journal.pone.0074758.t005
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in Figure 2. The confusion matrices are presented in Tables S2-
S7.
In general, the sensitivity of the models is high for compounds
with a very low or high volume of distribution, while compounds
belonging to class 2, with Vss values between 0.3 and 1 L/kg are
more difficult to classify correctly. The Vss model performed well
on the training set, with sensitivity 0.79 in class 2, but less than half
of the class 2 compounds in the training set (42 of 93 compounds,
leading to a sensitivity of 0.45) were predicted to the correct class
in the out-of bag results (Table S3). Similarly, the model was able
to identify class 1 and class 3 compounds form the external test set
(sensitivity 0.71 and 0.81, respectively), while recognition of class 2
test set compounds was not as successful (sensitivity 0.32, Figure 2,
Table S6). Interestingly, in the Vss & fu model, compounds with
high fu were predicted more accurately, with 10 of 17 compounds
of the test set compounds correctly classified (sensitivity 0.59), but
only 7 of 51 compounds with low fu (sensitivity 0.14) (Figure 2,
Table S7). The Y-randomization test was performed four times,
and the AUC values for the model using the data set with
experimental Vss and Vss & fu values were significantly higher than
those obtained from the dataset with randomized values (data not
shown), indicating that our models are statistically robust. The AD
was applied to the test set and its effect analyzed on the Vss & fu
model (Figure 6). The prediction accuracy was highest with low Z
cutoff, as expected, and slowly decreasing as the cutoff was
increased to 1. However, increasing the cutoff from 1 to 20 did not
markedly affect the prediction accuracy, while increasing the
coverage of the test set from 39% to 100%. The small decrease in
prediction accuracy is probably due to the cluster-based approach
used to select the training and test set (described in Methods) that
make the chemical space covered by two set similar.
One aid for interpretation of forest models is a set of descriptor
importance measures, which indicate the relative importance of
the descriptors in distinguishing among the different classes in the
data. The percent selection frequency empirically appears to best
distinguish truly important descriptors from others. It represents
the percent of the time that the descriptor was selected for a split
when a split was possible. A summary of descriptors ranked as top
10 based on their frequency of occurrences in the models are given
in Table 6. It should be noted that size, polarity and lipophilicity
are predominant in all models. The simple importance measures
reported here are known to have bias in some cases [34].
However, if all descriptors have the same character as in our cases
(e.g. they are all continuous numerical properties), then bias is
generally not an issue.
Discussion
We have predicted Vss and fu with linear PLS models and
nonlinear RP classification models, aiming for models that rely on
in silico descriptors only and therefore are suitable for screening.
Vss is affected by the fu in plasma, and we wanted to explore if
predicting both parameters in parallel would help to find relevant
physicochemical descriptors affecting these parameters. PLS can
easily be used to correlate descriptors with several related
responses, but to our knowledge, this approach has not been used
in pharmacokinetic QSPR modeling.
The RP classification model was reasonably successful in
classifying compounds with high ($1 L/kg) or low (0–0.3 L/kg)
Vss, while it had difficulties to identify the compounds with
moderate (0.3–1 L/kg) Vss. Interestingly, the level of binding to
plasma proteins had an influence on the prediction accuracy,
which was seen most clearly in the moderate Vss class, where
compounds with high fu were correctly predicted in 59% of the test
set, but only 14% of those with low fu (Figure 2, Table S7). The
attempt to create a PLS model for Vss and fu (model 1) starting
with only 19 descriptors from ACDlabs and MOE was not
successful, but using a wider range of descriptors from Volsurf+
resulted in a predictive model (model 2) (Table 1 and Figure 2).
The combination of all descriptors to model 3 did not significantly
improve the prediction of the external set (Vss Qe
2 = 0.50, fu Qe
2
= 0.54) compared to model 2 (Vss Qe
2 = 0.52, fu Qe
2 = 0.51)
(Figure 2). However, model 3 had better success in predicting the
Vss of the compounds in the foreign set (model 3 Qf
2 = 0.70,
model 2 Qf
2 = 0.62) (Table 5). Notably, the prediction of the
compounds in the foreign set within the AD was better than for the
Figure 6. The effect of the AD on the prediction accuracy and chemical space coverage. Dashed black line: Q2 of the Vss foreign set
predicted with PLS model 3. Dashed purple line: percentage of compounds from the Vss foreign set predicted with PLS model 3. Black line: Q
2 of the
fu foreign set predicted with PLS model 3. Purple line: percentage of compounds from the fu foreign set predicted with PLS model 3. Dotted black
line: AUC of the test set predicted with RP classification. Dotted purple line: percentage of compounds from the test set predicted with RP
classification.
doi:10.1371/journal.pone.0074758.g006
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external set for both model 2 and 3. The AD was not used to filter
compounds for prediction in the external set, which might be one
reason for the improved performance on the foreign set. The use
of an AD prevents extrapolation beyond the limits of chemical
space that was used to build the model and can be used to identify
the compounds for which predictions are reliable.
The impact of the descriptors on the responses can be observed
graphically in the PLS weight plot (model 3 in Figure 4, model 2 in
Figure S1). In model 3, the descriptors L3LgS, %FU10 and
LgD10 have the highest positively correlated impact to Vss
(L3LgS, LogP n-oct and LgD9 in model 2, Figure S1), while LgS3,
D4, Molar Volume and ALogD5.5 have a more moderate positive
influence on Vss (A in model 2). LgS10 has the largest negative
correlation to Vss (L1LgS in model 2), while W1, HDonors and
LogS have smaller negative correlation in model 3 (Wn5, SOLY,
W1 and ID3 in model2). On the other hand, LogS, LgS3 and
LgS10 have the highest positive correlation with fu (SOLY in
model 2), while LogD10 and AlogD5.5 have the highest negative
correlation (LogD9 and LOGP n-Oct in model 2). All in all, this
suggests that charge and lipophilicity of the drug affect drug
distribution, albeit with an inverse relationship. Thus, the
lipophilicity descriptors have high correlation with the two
responses, positive with Vss and negative with fu, while reversely,
the charge and solubility descriptors have negative correlation with
Vss and positive with fu. There is a complex relationship between fu
and Vss and increasing the fu of a compound does not inevitably
lead to a higher volume of drug distribution, as is stated in many
pharmacokinetic textbooks [35], [36]. This is easy to understand,
since structural changes influencing the drugs ability to bind to
plasma proteins may also affect the tissue binding of the drug.
Similar descriptors were found to be important in both the RP
classification models (Table 6) and the PLS models. These include
solubility descriptors, LogD at pH 9 or 5, as well as hydrophilic
and hydrophobic area and volume descriptors. Due to the
complexity of Vss and fu, many descriptors were always required
to yield good prediction capability. Previously, trends have been
observed between Vss and LogP, polar surface area and hydrogen
bond descriptors for the data set we have used [18]. Using the
same data set, Berellini et al. (2009) found hydrogen bonding,
LogD at pH 5–10, flexibility of the molecule and the Volsurf+
descriptors DRDRDO, DRDRAC to be important in their Vss
model [12]. DRDRDO and DRDRAC are pharmacophoric
descriptors of the maximum area of the triangles derived from Dry
(DR), H-bond acceptor (AC) and H-bond donor (DO) points in a
molecule. DRDRDO and flexibility were among the ten most
influential descriptors in the RP models, but in the PLS models
they did not have equally high importance. However, when
comparing our descriptor selection to previous models of Vss it
must be kept in mind that we have modeled both Vss and fu
parameters. Therefore a comparison is not directly applicable as
descriptors having high influence on one parameter, but no
correlation with the other parameter, are likely to be removed in
our models.
Outliers are usually interesting, and the analysis of outliers can
sometimes give a deeper understanding of the mechanisms under
investigation. However, it is difficult to analyse the outliers in this
study, because we do not know the reason for their exceptional
behavior. Deviations in Vss may be due to the active transport
(influx or efflux) or compound specific binding to the tissues. As an
example, let’s consider the outliers in the prediction of Vss by the
PLS models (ribavirin, bilobalide, tamsulosin, decitabine). Riba-
virin and decitabine are substrates of widely expressed nucleoside
transporters, and extensive active transport might lead to outlier
profiles of ribavirin and decitabine [37]. Tamsulosin is a substrate
of alpha1 adrenergic receptors and bilobalide binds to GABA,
glycine, and 5-HT3 receptors [38]. We cannot be sure, however, if
these transport and binding phenomena take place substantially
enough to cause exceptional Vss values. Clearly, Vss and fu are
complex phenomena that are affected by numerous factors.
Therefore, explanations for the outlier behavior are not on firm
ground and the reasons can be identified only by extensive
experimental work.
We compared the performance of our model 3 with the volume
of distribution and plasma protein binding models available in the
Volsurf+ package (Figure 5). As no AD is reported for the Volsurf+
models, we have applied our AD with the Z cutoff value of 0.7 to
select the compounds from the foreign test set for both models. For
the practical use of AD in Vss and fu prediction, see File S2. It
should be noted that we are not aware of which compounds have
been used to train the Volsurf+ model, and it is possible that some,
or all, of the compounds used in our test set have been used to for
that purpose. The same considerations apply for the Volsurf+
plasma protein binding model. Our model achieved higher
accuracy than the Volsurf+ model in predicting fu (Qf2 = 0.54 and
Table 6. Most influential descriptors in the classification models.
Vss Vss and fu
Descriptor Type
Number of
Chances
Percent
Selection
Frequency Descriptor Type
Number of
Chances
Percent Selection
Frequency
Rule Of 5 Drug like 12 8.3 PSAR Polar area 4 25
CD3 Hydrophobic area 31 6.4 Num Rings Topology 5 20
FLEX_RB Size/Shape 69 5.8 W8 Hydrophilic area 5 20
L1LgS Solubility 53 5.7 R Size/Shape 10 10
CD6 Hydrophobic area 37 5.4 DRDRDO Pharmacoforic 12 8.3
CW8 Hydrophilic area 20 5 D8 Hydrophobic area 26 7.7
LgS11 Solubility 66 4.5 LgD9 LogD 32 6.3
C ratio Topology 45 4.4 ALogD5 LogD 34 5.9
NO ratio Topology 48 4.2 CP Shape 17 5.9
LgS5 Solubility 72 4.2 AUS7.4 Charge 35 5.7
doi:10.1371/journal.pone.0074758.t006
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Qf
2= 0.38, respectively) (Figure 5), while the prediction of Vss was
comparable to the Volsurf+ model (Vss Qf2 = 0.70 and Qf2 = 0.71
for model 3 and Volsurf+ models, respectively). The best
predictions with our model were obtained at fu values above
0.05. Predictions of the compounds with fu values above 0.05 in
the foreign set had a MFE of only 2.2 for model 3, compared to
7.04 for the whole foreign set (Figure 5, table 5). The predictions at
fu values below 0.05 give high FE values (.5-fold), whereas %
error in this region is low. However, FE is pharmacologically a
more relevant parameter, because the free drug concentration in
plasma, Cu, is defined as fu x C. Therefore, 3-fold change in fu is
expected to result in 3 fold change in Cu Unfortunately, we do not
have an explanation for the poor results for the compounds that
have very low fu values, however, the compounds that were badly
predicted by our models were also badly predicted by the Volsurf+
model (Table S1), suggesting that the exceptional behavior is drug
dependent and not due to the model.
The physical complexity of the Vss and fu parameters makes
their prediction very challenging, and we were not able to reach
models with optimal predictability. One way to improve predic-
tion accuracy is to build the model using a narrower range of more
similar compounds. We divided the data set of 642 compounds
based on structural features or chemical properties and used these
data sets to build several sub-models. However, the models were
not able to achieve much higher accuracy than the more global
models presented here (data not shown), but presented a much
narrower AD and therefore more limited use.
Conclusions
The PLS models of Vss showed similar performance to the
commercial Volsurf+ model, while the fu prediction accuracy was
slightly better. The RP classification models were able to
distinguish between compounds with high or low Vss values, but
accurate classification of moderate Vss or of low fu values were not
as successful. Due to the complex nature of Vss and fu parameters,
a fairly large number of descriptors were needed for meaningful
models. The advantages of the models compared to previous
models is that they are based on a large set of structurally
unrelated compounds, they are open, and they have a defined AD,
which aids in identifying compounds for which reliable predictions
can be made.
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ABSTRACT
Purpose To build a fast, user-friendly computational model to
predict the intravitreal half-lives of drug-like compounds.
Methods We used multivariate analysis to build intravitreal
half-life models using two data sets, one with experimental
data derived from both pigmented and albino rabbits and
another including only data from experiments with albino
rabbits.
Results The final models had a Q2 value of 0.65 and 0.75 for
the mixed and albino rabbit models, respectively. The models
performed well in predicting the intravitreal half-life of an exter-
nal test set. In addition, the models are physiologically inter-
pretable, containing mainly hydrogen bonding and lipophilicity
descriptors.
Conclusion The developed models enable reliable predic-
tions of intravitreal half-lives for use in the early drug
development stages, without the need for prior experimental
data.
KEY WORDS blood-retinal barrier . intravitreal injection .
multivariate analysis . ocular drug delivery . QSPR
ABBREVIATIONS
FRB freely rotatable bonds
HA number of hydrogen bond acceptors
HD number of hydrogen bond donors
Htot total number of putative hydrogen bonds, i.e. HD
+HA
logP the logarithm of the octanol-water partition coeffi-
cient of the neutral form
log t½ the logarithm of the intravitreal half-life, logDx, the
logarithm of the octanol-water partition coefficient at
pH x
MW molecular weight
PCA principal component analysis
P-gp P-glycoprotein
PLS partial least squares
QSPR quantitative structure-property relationship
RMSE root mean squared error
RMSEP root mean squared error of prediction
VIP variable importance in the projection
INTRODUCTION
Intravitreal therapy is used to treat ocular diseases in the
posterior segments of the eye, for example, age-related
macular degeneration and diabetic macular edema. Intra-
vitreal drug administration must be used, because topical
eye drop treatment does not lead to adequate drug concen-
trations in the posterior target sites (retina, choroid, vitre-
ous). The drug is injected directly into the vitreous, which is
a hydrophilic gel consisting of a network of well separated
hyaluronic acid and collagen type II fibers, allowing diffu-
sion of drug molecules, even macromolecules, to the retina
and choroid. One advantage of the intravitreal injections is
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that it generally leads to minimal systemic exposure of the
drug. However, due to the invasive nature of the injections,
other ways of delivering drugs to the posterior eye segment
have been attempted, but the topical, systemic and subcon-
junctival delivery routes generally fail in reaching effective
concentrations in the vitreous body (1).
After an injection into the vitreous there are two routes
by which the molecule can be eliminated: 1) anteriorly via
flows of aqueous humor and uveal blood circulation; 2)
posteriorly through the blood-retinal barrier to retinal and
choroidal blood circulation (2). The blood-retinal barrier is
composed of the retinal pigment epithelium and the tight
walls of retinal capillary. The cells in the blood-retinal
barrier express transporters, which in principle may affect
drug elimination from the vitreous, but the effect of trans-
porters on drug elimination in vivo is still unclear (3). The
posterior route presents a large surface area surrounding the
vitreous, but the cells in the blood-retinal barrier form a
tight layer, allowing efficient elimination of lipophilic
compounds. The anterior route, in contrast, is limited
by the small area that is available for diffusion from the
vitreous into the posterior and anterior chambers. In
general, elimination through the posterior route takes
place rapidly, whereas drug elimination via the anterior
route is slower (2).
Intravitreal drugs can be administered as injections or
implants that release drug over prolonged times. In all cases,
drug concentrations in vitreous are dependent on the rate of
drug elimination from the vitreous. Slow intravitreal drug
elimination is desirable, since it will prolong the duration of
drug action after intravitreal injections and minimizes the
required drug loading in the controlled release formulations.
The intravitreal half-life of a compound must be determined
in vivo by injecting the compound into the vitreous of an
animal, usually rabbit, and measuring the concentration of
the compound in the vitreous at certain time-points after the
injection. Pharmacokinetic evaluation is typically carried
out using many time points (often 5–10) and several repli-
cates of each time point is needed (more than 5). Thus, for
plotting a reliable time-concentration curve at least 20 ani-
mals are needed, which makes this method unacceptable for
drug screening. There is a need for an alternative method
that would enable screening of molecules before in vivo
studies and also reduce and refine animal experiments re-
lated to development of ocular drugs and intravitreal drug
delivery systems.
A computational method like quantitative structure-
property relationships (QSPR) modeling is optimal for rapid
virtual evaluation and pre-selection of compounds. Even
though QSPR models are widely used to study the relation-
ship between physicochemical properties and the pharma-
cokinetic properties of molecules, surprisingly few attempts
have been made to predict the intravitreal half-life of
injected drugs. Some prior studies have established that
compounds with a high molecular weight are preferably
eliminated by the anterior route (4), and that molecular
weight (MW) and lipophilicity do have an influence on the
intravitreal half-life (5–7). However, some studies (5,6) have
been done using small sets of structurally and chemically
similar compounds and, therefore, those models are not
broadly applicable to diverse compounds. Durairaj and
co-workers used a large set of molecules, including small
molecules and macromolecules, with a MW range from
32 to 149 000 Da, but explored only a limited set of
variables, including only molecular weight, lipophilicity
and solubility variables to derive QSPR models by mul-
tiple regression (7).
We aimed to build a computational model for virtual
prediction of drug elimination from the vitreous. The
models are focused on compounds with molecular weight
below 1500 Da, thus excluding macromolecules. The use
of a lower, narrower MW range will make the model
more applicable for prediction of small molecules. We
have made a careful literature search and collected ex-
perimental data on the intravitreal half-lives of 47 com-
pounds in albino and pigmented rabbits. The data set
contains molecules with diverse structural and chemical
features. The relationship between the intravitreal half-
life and 33 physicochemical descriptors was determined
by multivariate analysis. Simple mathematical equations
were derived, enabling reliable prediction of the intra-
vitreal half-life for a compound without any experimental
data.
MATERIALS AND METHODS
Compound Data Set
A data set of 47 compounds (Table I) was collected from an
an extensive literature search for intravitreal injections
(5,8–49). The half-lives of the compounds included in the
dataset have been measured in either albino or pigmented
rabbits. A subset was constructed from this dataset, contain-
ing 39 compounds with experimental data collected from
only albino rabbits (Table I). An average value was calcu-
lated for compounds with more than one reference. The
model is focused on molecules with molecular weight less
than 1500 Da. In addition, we only included data from
experiments with compounds that were dissolved in water
or buffer solution and injected into normal, healthy eyes.
When the intravitreal half-life had not been reported for a
compound, the half-life was calculated from the reported
concentrations. Compounds for which the intravitreal con-
centrations had been measured during a time-span that was
less than two half-lives, were excluded from the data set.
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Data that was deemed of insufficient quality due to for
instance large standard deviations or an irregular time-
concentration curve was also excluded. For two-
compartment models, the half-life of the terminal phase
was used, except for moxifloxacin and fluorouracil, where
the alpha phase was dominant.
Table I Calculated Descriptors Used in the Final Models and Experimentally Determined Intravitreal Half-Life of Compounds in the Data Sets
compound albino/pigmented t1/2 (h)mix t1/2 (h)alb Htot LogD7.4 FRB Reference
1-heptanol albino 2.6 2.6 2 2.37 6 (8)
1-pentanolb,d albino 1.2 1.2 2 1.35 4 (8)
1-propanol albino 1.0 1.0 2 033 2 (8)
Å6 peptide albino 19.4 19.4 38 −8.68 28 (9)
acyclovird albino 3.0 3.0 12 −0.62 5 (10)
amikacina,c albino 25.9 25.9 35 −10.59 22 (11)
ampicillinb albino 8.8 8.8 11 −1.84 5 (12)
aztreonam albino/pigmented 7.9 8.3 18 −4.32 7 (12,13)
candesartan abino 6.8 6.8 11 1.45 7 (14)
carbenicillin albino/pigmented 4.3 3.5 11 −3.62 5 (15,16)
cefazolin albino 3.8 3.8 14 −4.41 7 (17)
cefepimea pigmented 14.6 – 15 −2.29 7 (18,19)
ceftazidimeb pigmented 18.0 – 18 −2.95 9 (19)
ceftizoxime pigmented 5.7 – 14 −4.35 5 (19)
ceftriaxonec albino/pigmented 11.6 14.1 20 −4.58 8 (19,20)
cephalexind albino 3.1 3.1 11 −2.93 5 (17)
cephalothin albino 2.4 2.4 10 −3.62 7 (17)
cidofovira albino 21.0 21.0 14 −5.41 7 (21)
ciprofloxacin albino 4.4 4.4 8 −0.29 3 (5)
clarithromycinb,d albino 2.0 2.0 18 2.06 12 (22)
clindamycinc albino 3.0 3.0 11 0.70 10 (23)
cyclosporin A albino 7.6 7.6 28 2.79 16 (24)
dexamethasoneb pigmented 3.5 – 8 2.03 5 (25)
fleroxacina albino 3.4 3.4 7 −3.09 4 (5)
fluconazoled albino 3.2 3.2 8 0.45 6 (26)
fluorescein albino 2.5 2.5 7 2.68 2 (27,28)
fluorouracil pigmented 12.8 – 6 −1.64 0 (29)
ganciclovirb albino/pigmented 6.0 5.3 14 −0.74 7 (10,30–32)
gentamicinc albino/pigmented 22.7 22.0 23 −7.81 13 (33,34)
grepafloxacina albino/pigmented 3.5 3.5 8 0.62 3 (35)
kanamycinb,d albino 10.3 10.3 30 −8.86 17 (36)
lincomycin albino 12.6 12.6 13 −0.36 11 (37)
methanol albino 0.9 0.9 2 −0.69 0 (8)
methicillin albino 6.2 6.2 10 −2.71 5 (38)
methotrexatec albino 7.6 7.6 20 −5.10 9 (39)
moxalactama albino 16.1 16.1 19 −7.31 10 (40)
moxifloxacin pigmented 1.7 – 9 0.31 4 (41)
netilmicinb,d albino 26.6 26.6 23 −6.79 14 (12,42)
ofloxacinb albino 3.0 3.0 8 −0.39 2 (5)
penicillin not known 4.2 – 8 −1.81 4 (43,44)
piperacillin albino 8.9 8.9 15 −2.73 6 (12)
quinidinea albino 2.0 2.0 5 0.98 5 (28,45)
sparfloxacinc albino 2.8 2.8 11 0.83 4 (5)
tobramycin albino 31.5 31.5 29 −9.54 16 (46)
trifluorothymidineb albino 3.2 3.2 10 −0.20 4 (47)
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Molecular Descriptors
The chemical structure of the compounds in the data set
were retrieved from ACD/Dictionary (50), or the the Pub-
Chem database (http://pubchem.ncbi.nlm.nih.gov/). The
ACDLabs software package version 12 was used to calculate
the molecular descriptors for these compounds (50). A total
of 33 descriptors were chosen for this study; pKa, LogD at
pH 2, 5.5, 6.5, 7, 7.4 and 10, LogP, MW, PSA (polar surface
area), FRB (freely rotatable bonds), HD (hydrogen bond
donors), HA (hydrogen bond acceptors), Htot (HD+HA),
molar refractivity, molar volume, parachor, index of refrac-
tion, surface tension, density, polarizability, C ratio, N ratio,
NO ratio, hetero ratio, halogen ratio, number of rings and
number of aromatic, 3-, 4-, 5- and 6-membered rings.
Multivariate Data Analysis
Before data analysis, an external data set of seven compounds
was randomly extracted from the collected data set of 47
compounds from pigmented and albino rabbits (mixed set),
while six compounds were randomly extracted from the albino
data set of 39 compounds (Table I). The compounds in the
external data sets were not used for model building or training.
A logarithmic transformation was performed for those varia-
bles that had a broad range or were not equally distributed
over the range. A principal component analysis (PCA) includ-
ing all molecular descriptors was calculated to analyze the
diversity of the data set. The logarithm of intravitreal half-life
(logt1/2) was correlated to the molecular descriptors by Partial
Least Squares (PLS) analysis using Simca-P (version 10.5) (51).
Based on the distribution of the compounds in the PCA plot
training sets of 30 and 25 compounds and internal test sets of
ten compounds and eight compounds were generated, respec-
tively, for the mixed and albino data set. Only the compounds
in the training set were used to calculate themodels. Both cross-
validation and prediction of the intravitreal half-life of the
compounds in the internal tests sets were used to evaluate the
predictive capability of the models. For cross-validation, the
training set is divided into seven groups and the intravitreal
half-life for the compounds in each group is predicted using the
data in the other groups. The sum of squared errors between
the actual and predicted data is calculated and converted into
the Q2 value (cross validated R2). The half-life for the com-
pounds in the internal test sets were predicted for further
evaluation of the models. Ultimately, the final models were
assessed by predicting the half-life of the external data sets that
were extracted before data analysis (Table I).
The statistical significance of the models was assessed by Y-
scrambling, i.e. the model is fitted to scrambled half-life values
and R2Y (equivalent to the R2 coefficient) and Q2 are calcu-
lated. After repeating the process 50 times, the results are
plotted with the R2Y values on the Y-axis and the Q2 values
on the X-axis and regression lines are fitted to the points. For
statistically valid models, the intercepts should be below 0.3
and 0.05 for R2Y and Q2, respectively.
RESULTS
Literature Search
Initially, we found 83 reported intravitreal half-lives for com-
pounds by literature searches. Twenty of these half-lives were
excluded from the data set, since they did not fulfill the criteria
as described in theMaterials andMethods section. Among the
compounds that were left out from the data set is triamcino-
lone acetonide, which is a well-studied and widely used drug
in ocular therapy. However, it was excluded from the study as
it is poorly soluble and precipitates in the vitreous after injec-
tion, thus, its long half-life is due to the slow dissolution of the
drug particles in the vitreous. The remaining 63 reported half-
lives were used to build the mixed data set of 47 compounds,
containing data from both pigmented and albino rabbits, as
well as the subset of 39 compounds from albino rabbits
(Table I). An average value was calculated for those com-
pounds with more than one study that reported a half-life.
The terminal half-life, in the case of two-compartment mod-
els, was used as the elimination half-life in all cases except two:
moxifloxacin and fluorouracil. For moxifloxacin the half-life
of the first phase was used, since it is the dominant phase,
while an effective half-life was calculated for fluorouracil,
taking into account both the first phase (alpha) and the termi-
nal phase (beta), (t1/2, eff0 (AUCalpha/AUCtot)x t1/2alpha+
(AUCbeta/AUCtot)x t1/2beta)(52). For fluorouracil, the first
phase accounted for approximately one third of the total
Table I (continued)
compound albino/pigmented t1/2 (h)mix t1/2 (h)alb Htot LogD7.4 FRB Reference
vancomycin pigmented 62.3 – 54 −4.49 23 (48)
voriconazoled albino 2.5 2.5 7 1.21 6 (49)
a The compound was excluded from the mixed data set prior to model building and included in the external test set, b The compound was selected to the
internal test set from the mixed data set based on the PCA, c The compound was excluded from the albino data set prior to model building and included in
the external test set, d The compound was selected to the internal test set from the albino data set based on the PCA.
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elimination based on the AUC of the alpha phase. Therefore,
the effective half-life deviates from terminal half-life and is a
more representative indicator for drug concentration decay in
the vitreous. The unusual elimination profile of moxifloxacin
might be due to its ability to strongly bind to melanin (53).
Molecular Diversity of the Compounds
The compounds in the mixed data set cover a broad range
of structurally and chemically diverse molecules, with an
intravitreal half-life from 0.9 to 62.3 h. The molecular
weights of the compounds varied from 32 to 1449 Da and
the LogD7.4 from -10.60 to 2.68. All calculated descriptors
were used to perform PCA for both mixed and albino
dataset (Fig. 1). The mixed data set resulted in a PCA model
with five principal components that explained 81% of the
variance in the data set, while the PCA model for the albino
data set contained four principal components explaining
80% of the variance. The PCA score plots of the two first
principal components, explaining 44% and 18%,
respectively, of the variance in the mixed data set and
42% and 18%, respectively, of the variance in the albino
data set, are shown in Fig. 1. Methanol lies outside the
elliptic 95% tolerance volume of both the mixed and albino
PCA models, but it was not excluded from model building,
since 5% of the data set is allowed outside the tolerance
volume. The compounds in the data sets were divided into
training sets (30 and 25 compounds in the mixed and albino
training sets, respectively) and internal test sets (10 and
8 compounds in the mixed and albino test sets, respectively)
based on their distribution in the PCA score plot (Fig. 1,
Table I).
PLS Analysis of Training Set Compounds and
Evaluation of Derived Models with Internal Test Set
Compounds
The PLS model using all the 33 calculated descriptors and
the 30 compounds of the mixed training set had a R2Y0
0.65 and Q200.59, and the PLS model with all descriptors
Fig. 1 PCA score plot of (a) the
47 compounds in the mixed data
set and (b) the 39 compounds in
the albino data set. The black
triangles represent compounds in
the training set and the unfilled
triangles the compounds in the
internal test set. The ellipse
depicts the 95% tolerance
volume based on hotelling T2
(0.05).
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for the albino set had similar values, R2Y00.69 and Q20
0.55 (Table II). In order to construct a simpler model, we
excluded those descriptors that according to SIMCAs vari-
able influence on projection (VIP) function were deemed the
least influential (Fig. 2). A VIP value above 1 specifies the
descriptor as more influential than average in explaining the
modeled response. A threshold of 1.2 and 1.1 was chosen for
the mixed and the albino data set, respectively, leading to
models with 14 descriptors for both data sets. The models
had improved statistics with higher R2 and Q2 values than
the initial models (Table II). The descriptors were related to
lipophilicity (LogD at pH 5.5, 6.5, 7 and 7.4), hydrogen
bonding (Htot, HD, HA and PSA) and mass (MW, MV,
polarizability, molar refractivity and parachor), as well as
the amount of rotatable bonds, defined with the variable
FRB. Subsequently, we excluded the descriptors with high
correlation coefficients (> 0.9) with Htot, LogD7.4 or MW.
The Htot variable was chosen since it combined the infor-
mation from the HD and HA descriptors, which it is highly
correlated to. The MW descriptor was selected since it had
the highest VIP value of the correlated coefficients, while the
LogD7.4 descriptor was chosen for its physiological rele-
vance. This resulted in a four-variable model for both data
sets, including the descriptors Htot, MW, LogD7.4 and FRB.
Both models had good statistics, with R2Y00.64, Q200.61
for the mixed model and R2Y00.73, Q200.71 in the albino
model. The predictability of these models was evaluated on
the internal test set, with a Q2int value of 0.61 and 0.67 for
the mixed and albino model, respectively. Exclusion of the
FRB descriptor in the mixed model improved the statistics
and the prediction of the internal test set (Table II), while
creating a three-variable model by removing any of the
other descriptors led to markedly decreased predictability
of the internal test set (data not shown). Similarly, exclusion
of the MW descriptor in the albino data set improved the
model statistics and predictability of the internal test set,
while creating a three-variable model by exclusion of any
of the other variables did not have a beneficial impact.
Furthermore, a two-variable model with good statistics
and better predictability for the internal data set was
obtained for the mixed data sets using only the Htot and
LogD7.4 descriptors (Table II). A two-variable model for the
albino data using the same descriptors resulted in a model
with a lower Q2 value, but good predictability of the inter-
nal test set.
The two-variable model was chosen for the mixed data
set, while the three-variable model was chosen for the albino
data set for further evaluation. The final models are de-
scribed by the following equations:
log t1=2;mixed ¼ 0:046 0:051 logD7:4ð Þ þ 0:640 LogHtotð Þ
log t1=2;albino ¼ 0:164 0:032 logD7:4ð Þ þ 0:435 LogHtotð Þ
þ0:461 Log FRB þ 1ð Þð Þ
The statistical significance of the predictive capability of
these final models was evaluated with the validate function in
Simca-P. The R2Y and Q2 Y-intercepts were -0.06 and -0.16
for the mixed model and -0.02 and -0.18 for the albino
model, respectively. Both are well below the upper limits of
a statistically valid model.
Evaluation of the Final Models on an External Test Set
The final models were used to predict the intravitreal half-
life of the compounds in the external data sets that were
removed prior to model building (Table I). Both models
predicted the compounds in the external data sets with good
accuracy, with an external Q2 value of 0.81 and 0.88,
respectively, for the mixed and albino models.
Table II PLS Models Obtained
from the Mixed Data Set Com-
pounds and the Albino Dataset
Compounds
aNumber of principal components
in the PLS model. bRMSEE, Root
Mean Squared Error of Estimation.
cRMSEP, Root Mean Squared Error
of Prediction
Variables Aa R2X Training set RMSEEb Internal test set
R2Y Q2 Q2 RMSEPc
Mixed data set
33 1 0.42 0.65 0.59 0.256 0.68 0.229
14 1 0.72 0.66 0.63 0.252 0.60 0.255
Htot, MW, LogD7.4, FRB 1 0.74 0.64 0.61 0.260 0.61 0.255
Htot, MW, LogD7.4 1 0.75 0.66 0.65 0.232 0.63 0.245
Htot, LogD7.4 1 0.80 0.66 0.64 0.250 0.69 0.225
Albino data set
33 1 0.43 0.69 0.55 0.220 0.70 0.256
14 1 0.68 0.72 0.68 0.206 0.74 0.263
Htot, MW, LogD7.4, FRB 1 0.74 0.73 0.71 0.205 0.67 0.287
Htot, LogD7.4, FRB 1 0.75 0.75 0.75 0.196 0.74 0.276
Htot, LogD7.4 1 0.79 0.70 0.66 0.218 0.76 0.239
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DISCUSSION
Two models for the prediction of intravitreal half-life were
obtained, one specifically for albino rabbits and one that is
suitable both for albino and pigmented rabbits. Due to the
limited amount of data available for pigmented rabbits (only
13 compounds), we did not attempt to build a specific model
for pigmented rabbits. Both of the final models had good
statistical values, with the R2Y and Q2 of the albino higher
(both values 0.75) compared to those of the mixed set model
(0.66 and 0.64, respectively). The ability of the models to
predict the intravitreal half-life was verified both on internal
test sets as well as on randomly selected external test sets
(Fig. 3). The models performed well, as the difference in
observed and predicted half-life for the most poorly pre-
dicted compound in the mixed test sets was 2.3-fold (cido-
fovir in the external test set) and all in all, only four other
compounds had more than a two-fold difference to the
experimental value. In the albino test sets, clarithromycin
was predicted to have a 3.4-fold longer half-life than ob-
served experimentally, but on the other hand, there was
only one other compound, kanamycin, with a two-fold error
in its predicted half-life, while all the other compounds had
less than two-fold error-prediction.
The final models contained only two or three variables,
Htot and LogD7.4 in the model for the mixed data set, and
Htot, LogD7.4 and FRB for the albino set. Both models had
better R2Y and Q2 values than the models using all 33
calculated variables and also slightly improved values com-
pared to the four-variable models (Table II). Furthermore,
the variables that are included in the final models are easily
interpretable. A higher LogD7.4 value leads to a shorter half-
life, which is likely due to increased permeability of the cell
membranes in the blood-retinal barrier, while increasing the
amount of hydrogen bond donors and acceptors results in
longer half-lives, as polar compounds have more difficulties
to permeate membranes. According to the albino model,
flexible compounds that have a high amount of rotatable
bonds have longer half-lives.
Previous studies have linked intravitreal half-life to MW
and lipophilicity (4–7). In our study, MW was also an influen-
tial descriptor with a relatively high VIP value, but still its
exclusion improved the predictivity of the models. One possi-
ble explanation is that our model focuses on low MW
Fig. 2 VIP plots, with confidence
intervals, from PLS analysis using
all variables and the training set
compounds for (a) the mixed
data set and (b) the albino data
set. A horizontal line has been
drawn in (b) to indicate the 1.1
VIP threshold.
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compounds and, thus, does not highlight the effectMWon the
half-life, and a more clear effect might only be observed when
significantly larger compounds, like macromolecules with
MW of several thousand Da are included. Macromolecules,
like proteins, have a slower rate of diffusion in the vitreous and
they are predominantly eliminated from the vitreous through
the anterior route. These compounds have significantly longer
half-lives than molecules that can permeate the blood-retinal
barrier. However, we have only included compounds that
have MW <1500 Da in our study, and therefore this size
effect may not be evident in our data set. Another likely
explanation could be that the number of rotatable bonds as
well as hydrogen bonds generally tends to increase with the
size of molecules and, therefore, the successful use of MW in
describing membrane permeability is due to its correlation
with increased polarity and flexibility (54), which in our model
is described by the Htot and FRB variables. However, Veber
and co-workers found that the number of FRB influences
membrane permeability of compounds independently of
MW (54).
Some compounds in the data set are known substrates for
transporters in the retinal pigment epithelium cells. For
example, carbenicillin and quinidine have been identified
as substrates for P-glycoprotein (P-gp) (15,28,45). Interest-
ingly, these compounds are not outliers in our model, which
might be due to the relatively small increase (1.5–2.5-fold) in
intravitreal half-life of these compounds when a P-gp inhib-
itor is coadministered. For the same reason the model is
quite accurate in predicting the half-lives of these transport-
er substrates, as the effect of active transport apparently falls
within the 3-fold prediction error of the model for the
compounds in this study. The lack of influence of active
transport on the estimation of half-lives suggests that active
transport is not highly significant for intravitreal elimination
for the compounds included in this study.
The two models that were generated in this study are quite
similar, which either can point to similar pharmacokinetics in
Fig. 3 Predicted versus observed log t1/2 values based on the final models. Prediction of the mixed data set compounds in the internal test set (a) and
external test set (b) and the albino data set compounds in the internal test set (c) and external test set (d). A diagonal line has been drawn in R2Y 01 to
facilitate interpretation and the dashed lines represent a 3-fold prediction range.
Table III Comparison of Half-Lives Obtained in Both Albino and Pig-
mented Rabbits
compound t1/2,albino (h) t1/2, pigmented (h) references
aztreonam 8.3 7.5 (12,13)
carbenicillin 3.5 5 (15,16)
ceftriaxone 14.1 9.1 (19,20)
ganciclovir 5.24* 7.9 (10,30–32)
gentamicin 22* 24 (33,34)
grepafloxacin 3.5 3.5 (35)
*average value
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the eye of albino and pigmented rabbits, or to a bias of albino
rabbits due to the majority of data acquired from albino
rabbits. However, based on a comparison of the half-lives of
six compounds for which the half-life had been reported both
in albino and pigmented rabbits (Table III), there is no clear
trend for longer elimination times in either albino or pig-
mented, suggesting similar rate of vitreal elimination. It is well
known that many drugs are able to bind to the pigmentation
(e.g. ganciclovir (10,30–32), gentamicin (33,34) and grepaflox-
acin (35) in our data set) and this may affect drug distribution
in the tissues, such as retinal pigment epithelium. This is not
reflected in the elimination rate constants, because even
though some fraction of the intravitreally injected drug would
bind to the melanin granules in the retinal pigment epitheli-
um, it will mostly enter plasma that acts as a sink rather than
distributing back to the vitreous.
The QSPR model presented is expected to be a useful tool
in ocular drug research. Themodel will provide an early virtual
estimate of the drug elimination rate. Thus, it will be easy to
estimate drug concentration profiles after intravitreal injections
at different dosing levels. With straightforward modeling
approaches concentration predictions can be extended to ad-
ministration of suspensions and drug delivery systems. In that
case, drug dissolution or release rate can be used as input rate
and the QSPR based elimination as output rate. There are
some limitations in the use of the QSPR model. Firstly, we
recommend that the models are used to predict the intravitreal
half-life for compounds in the same chemical space as the test
compounds, i.e. the descriptor values should be in the same
range as the descriptor values in the model. Secondly, the half-
lives in the human eyemay not be the same as in the rabbit eye.
The dimensions of the human eye are slightly bigger than in the
rabbit eye, but the physiological factors of drug elimination
(blood retina barrier, aqueous humor flow, blood aqueous
humor barrier) are similar. Geometrical scaling methods can
be used to obtain estimates for elimination in human eyes.
CONCLUSIONS
We have built a QSPRmodel for the prediction of intravitreal
half-life of drug-like compounds. The model encompasses a
broad chemical space and 33 in silico descriptors were used to
build an optimal model. Overall, the QSPR model will be a
useful tool in ocular drug discovery and development as it will
help to reduce and refine animal experiments.
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a b s t r a c t
The aims of this research were to (1) create a curated universal database of intravitreal volumes of dis-
tribution (Vss, ivt) and clearances (CLivt) of small molecular weight compounds and macromolecules and
(2) to develop quantitative structure property relationship (QSPR) and pharmacokinetic models for the
estimation of vitreal drug concentrations based on the compound structure.
Vss, ivt and CLivt values were determined from the available literature on intravitreal drug administra-
tion using compartmental models and curve ﬁtting. A simple QSPR model for CLivt of small molecular
weight compounds was obtained with two descriptors: LogD7.4 and hydrogen bond donor capacity.
The model predicted the internal and external test sets reliably with a mean fold error of 1.50 and
1.33, respectively (Q2Y = 0.62). For 80% of the compounds the Vss, ivt was 1.18–2.28 ml; too narrow range
for QSPR model building. Integration of the estimated Vss, ivt and predicted CLivt parameters into pharma-
cokinetic simulation models allows prediction of vitreous drug concentrations after intravitreal adminis-
tration.
The present work presents for the ﬁrst time a database of CLivt and Vss, ivt values and the dependence of
the CLivt values on the molecular structure. The study provides also useful in silico tools to investigate a
priori the intravitreal pharmacokinetic proﬁles for intravitreally injected candidate compounds and drug
delivery systems.
 2015 Elsevier B.V. All rights reserved.
1. Introduction
Diseases affecting the posterior segment of the eye are
becoming more and more prevalent in the ageing populations.
These disorders include age-related macular degeneration, diabetic
retinopathies, glaucoma, and rare retinal degenerations [1]. Cur-
rently, intravitreal drug administration is the best option to ensure
therapeutic concentrations of drug in the vitreous humour, retina
http://dx.doi.org/10.1016/j.ejpb.2015.01.003
0939-6411/ 2015 Elsevier B.V. All rights reserved.
Abbreviations: BAB, blood-aqueous barrier; BRB, blood-retinal barrier; CL, clearance; CLivt, intravitreal clearance; Css, ivt, steady state drug concentration in the vitreous;
CV%, coefﬁcient of variation; E, extraction ratio; Eaqueous humour, extraction ratio from vitreous to the anterior chamber; Eciliary body, ciliary body extraction ratio; Echoroid, choroid
extraction ratio; Eiris, iris extraction ratio; Eocular, ocular extraction ratio; Eretina, retina extraction ratio; DDS, drug delivery system; FRB, freely rotatable bonds; HA, hydrogen
bond acceptors; HD, hydrogen bond donors; Htot, total number of putative hydrogen bonds i.e. HD + HA; Kp, distribution coefﬁcient between the tissue and vitreous; MW,
molecular weight; PCA, principal component analysis; PLS, linear partial least square; PSA, polar surface area; Q, blood ﬂow; Qaqueous humour, aqueous humour ﬂow; Qciliary body,
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and choroid [2]. The drug concentrations in the vitreous are gov-
erned by Vss, ivt and CLivt of the drug. After intravitreal injection
the dissolved drug will diffuse throughout the vitreous, distribute
into the ocular tissues and eliminate into the systemic circulation.
There are two main ocular barriers in the eye that affect the intrav-
itreal pharmacokinetics: the blood-aqueous barrier (BAB) located
in the anterior part of the eye and the blood-retinal barrier (BRB)
located in the posterior part. Both barriers have epithelial and
endothelial components with intercellular tight junctions. The
BAB is formed by the inner non-pigmented ciliary epithelium
and posterior iris epithelium and the endothelium of iris capillar-
ies. The BRB consists of the endothelium of retinal capillaries and
retinal pigment epithelium (RPE).
The volume of distribution (Vss) is an apparent volume that
describes the extent of drug distribution and binding to the tissues.
As we have described elsewhere [3], the systemic Vss values after
intravenous administration can oscillate between 4 l (Vss of
erythropoietin contained in plasma) and 49,000 l (Vss of
hydroxychloroquine that accumulates in tissues). After intravitreal
administration, the Vss, ivt should reﬂect the extent of drug distribu-
tion and binding to the ocular tissues, but these values are still
mostly unknown. The CLivt represents the ocular volume that is
being cleared of drug per unit of time. Thus, CLivt quantitatively
describes irreversible drug elimination from the vitreous. In gener-
al, clearance (CL) can be deﬁned by the Eq. (1):
CL ¼ Q  E ð1Þ
where Q is the blood ﬂow of the organ and E the extraction ratio
that varies between zero and one. Thus, CLivt is dependent on the
aqueous humour ﬂow (Qaqueous humour), the blood ﬂow in the ocular
tissues (Qocular), the ability of the drug to reach the anterior chamber
and get across the barriers (BRB, BAB) to the blood circulation
(ocular extraction ratio or Eocular). The CLivt values are rarely deter-
mined or related to the chemical structure of the drug or to the ﬂuid
ﬂow (blood, aqueous humour) values in the eye. The intravitreal
half-life (t1/2, ivt) is more widely used, but this is a secondary
parameter that is dependent on the primary pharmacokinetic para-
meters (Vss, ivt and CLivt) according the general equation of half-life
(t1/2):
t1=2 ¼ ln2 V ssCL ð2Þ
QSPR approach is used to establish relationship between the chemi-
cal structure and pharmacokinetics. Intravitreal t1/2 of compounds
can be predicted with QSPR models [4,5], but the values and predic-
tion tools of the primary intravitreal pharmacokinetic parameters,
Vss, ivt or CLivt, are not available. Universal Vss, ivt and CLivt values
and derived QSPR models would be very useful allowing structure
based calculation of these parameters early in drug discovery.
Unlike t1/2, ivt, the estimated Vss, ivt and CLivt values can be used to
predict vitreal drug concentrations after their inclusion in the
pharmacokinetic simulation models.
In this study, we determined the Vss, ivt and CLivt values using all
published literature reports with adequate quality. These values
for small molecular weight (MW) compounds were used for QSPR
and pharmacokinetic model building to provide tools for vitreal
drug concentration predictions in drug discovery and
development.
2. Materials and methods
2.1. Intravitreal primary pharmacokinetic parameters
The primary pharmacokinetic parameters for intravitreally
injected compounds (CLivt, Vss, ivt) were calculated from all
published studies that met the quality requirements using the fol-
lowing procedure.
A search in PubMed database was conducted using different
combinations of the key words: ‘‘intravitreal’’ ‘‘rabbit’’ and ‘‘phar-
macokinetic’’ or ‘‘clearance’’. The intravitreal rabbit studies were
used, since the available human data are too limited. The search
yielded 367 references (1947–2013), but the number was reduced
to 158 studies. For example, the studies in diseased or manipulated
rabbit eyes or with suspensions and drug delivery systems (DDS)
were removed, because suspensions and DDS retain in the vitreous
much longer than free drug and they release drug gradually. There-
fore, total and free intravitreal drug concentrations after suspen-
sion and DDS administration do not represent purely
pharmacokinetics (CLivt, Vss, ivt) of the drug. Further selection of
data from injected intravitreal solutions was carried out (Fig. 1).
When drug quantities instead of concentrations were used in the
publications, the amounts were divided by the reported volume
of the vitreous or by the reference value of 1.15 ml (for reference
volume, see Supplementary data, Table A.1a). Average concentra-
tion values were used in the pharmacokinetic analyses.
Curve ﬁtting with WinNonlin software (version 5.3, Pharsight
Inc., St. Louis, USA) was used for the analysis of Vss, ivt and CLivt.
The numerical values were collected from the tables or they were
extracted from the pharmacokinetic graphs using GetData Graph
Digitizer (version 2.24. Digital River, Inc., Cologne, Germany). For
salts the equivalent dose of the free drug was used. Different com-
partmental models and weighting schemes were used to achieve
the optimal data ﬁtting. The level of correlation between the pri-
mary pharmacokinetic parameters had to be below 0.95 and their
coefﬁcient of variation (CV%) below 35%. The model with the low-
est Akaike’s information criterion (AIC) was considered to be the
best one.
2.2. Generation of molecular descriptors
From small molecules, the ⁄.sdf format of the structure was
obtained and used as input in ACDlabs software (version 12,
Advanced Chemistry Development, Inc., Toronto, Canada) to generate
30 molecular descriptors: pKa for the most acidic molecular form,
pKa for the most basic form, LogD at pH 5.5 and 7.4, LogP, MW,
PSA (polar surface area), FRB (freely rotatable bonds), HD (hydro-
gen bond donors), HA (hydrogen bond acceptors), Htot (HD + HA),
rule of 5, molar refractivity, molar volume, parachor, index of
refraction, surface tension, density, polarizability, C ratio, N ratio,
NO ratio, hetero ratio, halogen ratio, number of rings and number
of aromatic, 3-, 4-, 5- and 6-membered rings. No computational
descriptors were generated for macromolecules, because their 3D
structures were not accessible.
2.3. Multivariate QSPR model generation
Multivariate QSPR models were generated for the 40 small MW
molecules with Vss, ivt and CLivt values (Fig. 2). Principal component
analysis (PCA) and linear partial least square (PLS) (Simca plus,
version 10.5, Umetrics AB, Umeå, Sweden) were used to analyse
the chemical space and the relationship between the primary
kinetic parameters (Vss, ivt and CLivt) and the molecular descriptors
of the compound set. The descriptors were transformed with unit
variance scaling and mean centring. The parameters requiring
normal distribution were logarithmically transformed. Before
data analysis, an external set was randomly chosen. These
compounds were not used for model building, but for validating
the model.
In the PCA analysis the chemical space of the compounds was
deﬁned, and outlier compounds and descriptors with too narrow
range were excluded. Based on the scatter plot of the ﬁnal PCA
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model, a representative internal test set was selected. The training
set compounds were used to calculate the PLS models of Vss, ivt and
CLivt. Highly correlated variables and the variables with small
inﬂuence were excluded based on the plots of PLS weight and
coefﬁcient. Furthermore, the predictions with the internal test set
were carried out to conﬁrm the improvement in the prediction
accuracy.
2.4. Validation of the models
The PLS models were validated by an internal and external
validation. The internal validation involved cross-validation (Q2Y)
and the regression coefﬁcient (Qi2) when plotting the prediction
of the internal test set against the observed experimental values.
The external validation was presented as the regression coefﬁcient
(Qe2) when plotting the prediction of the external test set against
the observed experimental values. For the three parameters (Q2Y,
Qi
2, Qe2), values above 0.5 were regarded as acceptable (for more
detailed description of the parameters see Supplementary material,
Doc. 1).
The Y-randomization test (response permutation) was per-
formed to estimate the robustness of the model [6]. The perfor-
mance of the original model was compared with models built
with the response data (i.e. CLivt values) randomly shufﬂed
(appearing in a different order). When the accuracy of the permu-
tated models was statistically signiﬁcantly lower than the original
one, the validity of the original model was proved (Supplementary
data, Doc. 1).
2.5. Pharmacokinetic simulations
The QSPR equation for the CLivt was linked as a parameter in
pharmacokinetic simulation models using STELLA Modelling &
Simulation software (version 8.1.1, isee systems, Inc., Lebanon, USA).
Intravitreal concentration proﬁles of the small MW compounds
were simulated with the predicted and observed values of CLivt
and Vss, ivt using one-compartmental simulation model. Moreover,
simulations of intravitreal controlled release systems were
conducted. Firstly, ﬁrst-order release kinetics (rate constant
0.0016 h1) at different drug loading levels was simulated. We
investigated the required loading levels to reach concentrations
of 1, 10, 100, 1000, 10,000, and 100,000 nM in the vitreous three
months after a single injection. Secondly, we examined the rela-
tionship between zero-order release rate and steady state drug
concentration (Css, ivt) in the vitreous humour at three months after
drug dosing. The simulations were conducted using a fourth-order
Runge–Kutta algorithm using time intervals (DT) of 0.1 h for the
DDS of small compounds.
Fig. 1. The chart of the work ﬂow.
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3. Results
3.1. Literature search and pharmacokinetic analysis
The selected 158 studies reported the concentration–time pro-
ﬁle and the dose. For most of them, Vss, ivt and CLivt were deter-
mined. Most of the compounds followed one-compartment
model, but a few obeyed two-compartmental kinetics (for indi-
vidual cases, see Supplementary material, Table A.2). Many studies
(92, data not shown) were excluded from the analysis due to qual-
ity reasons (i.e. they did not fulﬁll the selection criteria in Fig. 1).
The ﬁnal set of 40 small compounds and 12 macromolecules with
CLivt and Vss, ivt was collected (Table 1). More detailed information
of the analyses based on the 66 accepted studies has been com-
piled in Table A.2 (Supplementary material). The ﬁnal set included
the intravitreal rabbit studies that used whole vitreous analysis or
microdialysis and fulﬁlled the quality criteria (Fig. 1).
3.2. MW vs Vss, ivt and CLivt of macromolecules and small compounds
The MW of the 52 compounds ranged from 18 Da to 148 kDa.
The CLivt values spanned over a wide range of values from 0.011
to 1.530 ml/h (Table 1, Fig. 3A). The Vss, ivt values showed narrow
range of 0.72–3.6 ml (Table 1, Fig. 3B). No correlation between
MW and Vss, ivt was observed, but an inverse proportionality
between MW and CLivt was seen (regression coefﬁcient = 0.67)
(Fig. 3). Semi-logarithmic plot of MW vs Vss, ivt and logarithmic plot
of MW vs t1/2, ivt were also included in Supplementary material
(Figs. A.1 and A.2, respectively).
3.3. Multivariate QSPR with small MW compounds
The QSPR modelling was done with small MW compounds
(range of 18–1449 Da). For these compounds, the range of the
Vss, ivt and CLivt values was 0.72–3.14 ml and 0.031–1.530 ml/h,
respectively. The values of LogD7.4 and HD varied from 10.59 to
2.79 and from 1 to 21, respectively (Table 1). After exclusion of
the external set (Table 1), the QSPR analysis was carried out with
the remaining 34 compounds. Their chemical space is represented
in the PCA score plot (Fig. 4), where two ﬁrst principal components
(t[1] and t[2]) explained the 42% and 21% of the variance in the
data set, respectively.
Based on the PCA score plot the data set was divided in training
set (28 compounds) and internal test set (6 compounds) that were
well distributed all over the chemical space (Fig. 4, Table 1). The
training set was used to build the PLS predictive models, and the
internal set was used for the internal validation. Due to the narrow
range of values, no PLS model could be generated for the Vss, ivt
response. However, a PLS model for predicting LogCLivt was
obtained and optimized. During the modelling process water was
excluded as an outlier (Fig. 4) and the least inﬂuential descriptors
were discarded.
As ﬁnal output, a model based on the descriptors HD, LogD7.4
and PSA with a goodness of ﬁt R2X of 0.784 and R2Y of 0.663 and
a goodness of prediction Q2Y of 0.633 was obtained (model a in
Table 2). The exclusion of the PSA descriptor yielded model b with
a goodness of ﬁt R2X of 0.835 and R2Y of 0.637. The goodness of
prediction Q2Y was lower in model b (0.620; shown in Table 2).
Both ﬁnal models were built on 27 compounds and their corre-
sponding equations were bestowed in Table 2.
Model b presented better predictability of the internal test set
than model a (Qi2 of 0.853 vs 0.749) (Table 2). The CLivt predictions
of all the compounds in both models were within the 3-fold error
range (Fig. 5).
Moreover, the models were externally validated and the predic-
tive plots and prediction accuracy are presented in Fig. 5, with a Qe2
of 0.905 for model a and improved Qe2 of 0.919 for model b. For
both models, all predictions of external test set were within 3-fold
error limits.
The statistical robustness of these ﬁnal models was evaluated
by Y-randomization after 50 permutations showing the validity
of the models (data shown in Supplementary data, Doc. 1).
Fig. 2. The scheme of the QSPR model process.
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3.4. Pharmacokinetic simulations
Primary intravitreal pharmacokinetic parameters were integrat-
ed to pharmacokinetic simulation models for prediction of drug
concentrations in the vitreous. Since no QSPR model for Vss, ivt was
obtained, upper and lower reference values were incorporated in
the simulations. This range (1.18–2.28 ml) (Table 3) represented
80% of the Vss, ivt values in the dataset. In the case of CLivt, the QSPR
modelb equationwas integrated to the pharmacokinetic simulation
model. The selected compounds for the simulations were heptanol
and amikacin with typical high and low CLivt levels, respectively
(Fig. 3). In Table 3, we presented the predicted and observed prima-
ry pharmacokinetic parameter values for the compounds.
Firstly, pharmacokinetic simulation models with the dose of
100 lg of intravitreal solution of the compounds were performed
and presented (Fig. 6). The simulations with CLivt values from QSPR
model yielded concentration proﬁles that were close to the simula-
tions with the observed CLivt values.
Table 1
The list of Vss, ivt, CLivt, t1/2, ivt, MW, LogD7.4 and HD values of the curated selection of intravitreal compunds. A solid line separates the small MW molecule set and the
macromolecule set.
Compound Albino/pigmented Vss, ivt (ml) CLivt (ml/h) t1/2, ivt (h) MW LogD7.4 HD References
1-Heptanol Albino 1.84 0.718 2.92 116.2 2.37 1 [7]
1-Pentanol Albino 2.16 1.530 0.98 88.15 1.35 1 [7]
Amikacin Albino 1.37 0.035 26.94 585.6 10.59 17 [8,9]
Aztreonam Pigmented 1.39 0.125 7.73 435.43 4.32 5 [10]
Carbenicillin Albino/pigmented 1.22 0.176 4.90 378.4 3.62 3 [11,12]
Cefazolin Albino 1.72 0.165 7.24 454.51 4.41 2 [13]
Cefepime Pigmented 1.30 0.060 15.09 481.57 2.29 4 [14]
Cefotetan Pigmented 1.36 0.109 8.69 575.62 3.43 5 [15]
Ceftazidime Pigmented/albino 1.47 0.070 14.48 547.58 2.95 5 [16–18]
Ceftriaxonea Albino 1.45 0.109 9.21 554.58 5.32 5 [19]
Cefuroxime Pigmented 1.29 0.235 3.80 424.39 3.48 4 [20]
Ciproﬂoxacin Albino/pigmented 1.32 0.336 2.84 331.34 0.29 2 [21,22]
Clarithromycin Albino 0.72 0.320 1.55 747.95 2.06 4 [23]
Cyclosporine A Albino 3.06 0.484 4.38 1202.61 2.79 5 [24]
Dexamethasone phosphate Albino/pigmented 1.54 0.324 18.15 472.44 4.64 4 [25,26]
Erythromycina Albino 1.40 0.190 5.11 733.93 1.16 5 [27]
Flomoxefb Albino 1.46 0.179 5.64 496.47 6.03 3 [28]
Fluconazole Albino 1.93 0.753 4.69 306.27 0.45 1 [29]
Fluorouracilb Pigmented 1.49 0.173 5.97 130.08 1.64 2 [30]
Fluorouridinea Pigmented 1.77 0.267 4.59 262.19 1.97 4 [31]
Fluorouridine-50phosphate Albino 3.14 0.315 21.16 342.17 8.09 5 [32]
Foscarnet Pigmented 1.39 0.057 16.86 126.01 6.91 3 [33]
Ganciclovir Pigmented/albino 1.34 0.153 7.18 255.23 1.61 5 [34–36]
Gentamicinb Albino/pigmented 1.18 0.031 26.50 463.57 8.36 12 [37–39]
Hesperetin Albino 1.31 0.501 1.82 302.28 1.52 3 [40]
HPMPC (cidofovir)b Albino 2.44 0.095 24.84 279.19 5.41 5 [41]
Kanamycin Albino 1.63 0.115 9.81 484.5 8.67 14 [42]
Ketorolacb Albino 1.48 0.283 5.98 255.27 0.34 1 [43]
Methanol Albino 1.17 1.300 0.62 32.04 0.69 1 [7]
Methicillin Albino 2.19 0.218 7.66 380.42 2.71 2 [44]
Methotrexate Albino 1.72 0.197 6.05 454.44 5.1 7 [45]
Netilmicin Albino 1.74 0.055 22.06 475.58 6.79 11 [46]
Oxacillinb Albino 2.29 0.310 5.11 401.44 1.18 2 [47]
Penicillin – 1.06 0.126 5.85 334.39 1.81 2 [48]
Quinidine Albino 0.93 0.448 1.44 324.42 0.98 1 [49]
Sulphacetamidea – 2.28 0.148 10.71 214.24 2.52 3 [48]
Tobramycina Albino 1.22 0.040 23.58 467.51 9.54 15 [50,51]
Vancomycin Albino/pigmented 1.46 0.039 25.89 1449.25 4.49 21 [52,53]
Voriconazolea Albino 1.37 0.421 2.25 349.31 1.21 1 [54]
Waterc Pigmented 1.250 18.02 1.38 2 [55]
Aﬂibercept Pigmented 1.57 0.019 56.44 97,000 [56]
Bevacizumab Pigmented 2.02 0.019 77.17 149,000 [57,58]
Bevasiranib Pigmented 1.10 0.022 34.83 14,224 [59]
Conbercept Pigmented 2.10 0.015 93.73 143,000 [60]
Erythropoietin Albino 1.21 0.014 58.14 34,000 [61]
Fomivirsen (ISIS2922) Albino 2.22 0.027 56.18 7122 [62]
Pegaptanib Albino 1.45 0.011 91.64 50,000 [63]
PF-04523655c Pigmented 3.60 0.071 35.00 12,000 [64]
Ranibizumab Pigmented 1.91 0.025 53.18 48,000 [58,65]
rhuMAbHER2c Albino 1.78 0.015 134.40 148,000 [66]
Rituximab Albino 2.76 0.016 119.34 145,000 [67]
sEphB4 – 2.28 0.011 143.58 57,800 [68]
The t1/2, ivt values in italics correspond to the terminal t1/2, ivt of two-compartmental drug, for dexamethasone phosphate and ganciclovir many pharmacokinetic studies with
different compartmental models were available, then an average of the terminal and one-compartmental t1/2, ivt was calculated and marked in italic. In other cases, t1/2, ivt is
based on one-compartment model.
a The compounds of the external test set.
b The compounds of the internal test set.
c Vss, ivt and CLivt values are from the original reference (for justiﬁcation, see Supplementary material, Table A.2).
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Moreover, we simulated the administration of compounds in
DDS with ﬁrst-order and zero-order release kinetics. During the
ﬁrst-order drug release, the doses that were required to keep
minimum concentrations at 1–100,000 nM for three months were
simulated (Fig. 7B). Also, the intravitreal Cmax values after different
drug loadings in the DDS were modelled using the real and predict-
ed pharmacokinetic parameters (Fig. 7C). For a dose of 10 mg (fea-
sible with DDS injection volume of 100 ll), we estimated the
intravitreal concentrations (Fig. 7A). At three months, for the high
CLivt compound concentration of 6 lM was reached, while low
CLivt drug had a simulated concentration of 26 lM (Fig. 7B). Thus,
the minimum concentration for drug activity should be below
those levels. Moreover, the expected Cmax after delivery of 10 mg
was about 190 lM for the high CLivt compound and 650 lM
for the drug with low CLivt (Fig. 7C).
We used the simulations also the other way: knowing the mini-
mum therapeutic concentration, we simulated the release rate and
dose required to maintain the vitreal drug concentrations (Css, ivt)
above a threshold levels. In the case of DDS with zero-order
release, the release rate constants and doses required to reach
Css, ivt in the range of 1–10,000 nM were presented in Fig. 8. The
simulation results based on the observed and predicted CLivt
parameter overlapped. The Vss, ivt had no inﬂuence on the level of
Css, ivt.
Fig. 3. The relationships between (A) MW and CLivt and (B) MW and Vss, ivt for the whole set of compounds (40 small molecular compounds and 12 macromolecules). The
diamonds represent the small MW compounds with LogD7.4 below 0 (blue symbols) and LogD7.4 above 0 (red symbols). The triangles represent the macromolecules. In (A)
the long dashed line represents the sum of the choroidal, retinal, iridial and ciliary body blood ﬂows [69] and the aqueous humour ﬂow [70], the short dashed lines correspond
to the choroidal blood ﬂow [69] (red) and aqueous humour ﬂow [70] (blue). The two small compounds with the typical levels within CLivt range are pointed out. In (B) the
dotted line represents the anatomical volume of the vitreous 1.15 ml (Supplementary data, Table A.1a). (For the interpretation of the references to colour in this ﬁgure legend,
the reader is referred to the web version of this article.)
Fig. 4. The PCA score plot of the 34 intravitreal compounds that were acidic (blue), basic (red), neutral (green) and zwitterionic (grey). The ellipse depicts the 95% tolerance
volume based on hotelling T2. (For the interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 2
The PLS models for CLivt of small MW compounds with the statistical parameter values.
Variables Aa R2X Training set Internal test set External test set
R2Y Q2Y Qi
2 Qe
2
Model a
LogCLivt = 0.17411  0.38180 (LogHD)  0.00117 PSA + 0.03686 (LogD7.4) +LogD7.4 – HD–PSA 1 0.784 0.663 0.633 0.749 0.905
Model b
LogCLivt = 0.25269  0.53747 (LogHD) + 0.05189 (LogD7.4) +LogD7.4  HD 1 0.835 0.637 0.620 0.853 0.919
a Number of principal component.
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4. Discussion
4.1. Intravitreal clearance
Even though the intravitreal pharmacokinetics are dependent
on both Vss, ivt and CLivt, the CLivt seemed to have the main role
in deﬁning the ocular drug concentrations. The Vss, ivt had very nar-
row range of values (about 4-fold), whereas the CLivt spanned more
than 100-fold range of values (Fig. 3). Therefore, the t1/2, ivt was
principally affected by the CLivt.
QSPR models for CLivt of small MW compounds were built with
good statistical values (R2X and R2Y over 0.5), namely model b
showed a good prediction ability for both internal and external test
sets (Fig. 5) with a mean fold error of 1.50 and 1.33, respectively.
The model b descriptors (LogD7.4, and HD) showed positive and
negative inﬂuence on the CLivt. Similar dependence is seen for
t1/2, ivt in the rabbit eyes [5]. The hydrogen bonding capacity and
LogD7.4 correlate with drug permeability in biomembranes sup-
porting the role of blood-retina barrier as deﬁning factor of CLivt.
The CLivt of the whole compound set, including macro-
molecules, varied between 0.011 and 1.53 ml/h. The macro-
molecules had smaller CLivt than the small molecules (Fig. 3),
which is in line with the previous study [4]. However, MW did
not determine CLivt of the small molecular compounds indicating
that their diffusion in the vitreous was not rate-limiting factor or
determinant of CLivt.
Intravitreal drugs can be eliminated from the eye via aqueous
humour ﬂow (1, Fig. 9A) and via permeation into the ocular vascu-
lar system, i.e. across the blood-ocular barriers to the systemic cir-
culation (2–4, Fig. 9B). The ﬁrst mechanism is operative for all
drugs. The aqueous humour is formed in the ciliary processes
and its convective ﬂow drags drugs from the vitreous into the ante-
rior chamber, where they are eliminated via the trabecular mesh-
work (Fig. 9A). Elimination to the ocular blood stream is relevant
for the molecules that are able to cross BAB and BRB (Fig. 9B) in
the anterior part (iris and ciliary body capillaries) or in the poste-
rior part (retinal and choroidal capillaries). The posterior route of
elimination is dominating due to the wide surface area of perme-
ation and high choroidal blood ﬂow. Lipophilic compounds have
higher CLivt in line with their permeation across the BRB.
The aqueous humour ﬂow mediated CLivt (Fig. 9A) can be
deﬁned as equation (Fig. 10):
CLivt ¼ Q aqueous humour  Eaqueous humour ð3Þ
where Eaqueous humour is the extraction ratio from vitreous to the
anterior chamber of the eye. The average Qaqueous humour in rabbits
Fig. 5. The LogCLivt prediction plots of model a and model b. The diamonds represent the internal test set and the triangles represent the external test set. The dotted lines
represent 3-fold error range.
Table 3
The primary PK parameter values in the simulations (1 and 2 based on predicted values and 3 in observed values).
High CLivt compound (heptanol) Low CLivt compound (amikacin) Simulation numbers (shown in Figs. 6–8)
CLivt (ml/h) Vss, ivt (ml) CLivt (ml/h) Vss, ivt (ml)
Predicted values 0.742 1.18a 0.034 1.18a 1
2.28b 2.28b 2
Observed values 0.718 1.84 0.035 1.37 3
a,b Lower and upper reference values of Vss, ivt respectively.
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is 0.18 ml/h [70]. The compounds that are eliminated mainly by the
aqueous humour ﬂow are expected to be macromolecules that are
incapable to get across BRB and BAB. Their CLivt values are 0.01–
0.07 ml/h, meaning that the Eaqueous humour is 0.06–0.55. This may
be due to the barriers of lens, iris, ciliary body and zonules that
are limiting drug transfer between the vitreal cavity and anterior
chamber [71]. Interestingly, removal of the lens in rabbits decreases
the t1/2, ivt of small CLivt drug, amikacin, from 25.5 to 14.3 h [9] (CLivt
estimates of 0.08 and 0.05 ml/h). Even though the lens removal
increased the CLivt values, it was still less than Qaqueous humour
(0.18 ml/h) suggesting that the lens is only one of the factors that
limit molecular exchange between the vitreous and the anterior
chamber.
The CLivt of small molecular compounds can be deﬁned with the
following equation (Fig. 10):
CLivt ¼ Q choroid  Echoroid þ Q retina  Eretina þ Q ciliary body  Eciliary body
þ Q iris  Eiris þ Q aqueous humour  Eaqueous humour ð4Þ
where the blood ﬂows and the extraction ratios in choroid, retina,
ciliary body and iris are represented by Q and E, respectively, with
the corresponding subscripts. The values of the blood ﬂows in the
rabbit eye are: Qchoroid = 62 ml/h, Qretina = 0.66 ml/h, Qciliary body =
4.91 ml/h, Qiris = 3.72 ml/h [69] and Qaqueous humour = 0.18 ml/h
[70]. Qchoroid contributes about 87% of the total ocular ﬂow
(71.47 ml/h) (Fig. 3). If all Eocular values in the equation would be
equal to 1.0, the CLivt would be 71.4 ml/h. The highest CLivt was
1.53 ml/h (1-pentanol), indicating that the Eocular values are 1.0,
particularly in the case of drug elimination to the choroid. There-
fore, CLivt is limited by blood-ocular barrier permeability, not
blood ﬂow rate. Since choroid is the main contributor in the ocular
ﬂows (Fig. 3), the Eocular value must be highly dependent on the
permeability in the RPE, the barrier that separates choroidal
blood ﬂow from the vitreous humour. Unlike the changes in the
ocular blood ﬂow, the changes in the RPE permeability (e.g.
disease state, drug structure) should have a signiﬁcant impact on
the CLivt.
4.2. Intravitreal volume of distribution
No QSPR model for Vss, ivt of small compounds was constructed,
because the Vss, ivt values represented so narrow range. In principle,
the Vss, ivt is deﬁned by the equation (Fig. 10):
V ss; ivt ¼ Vvitreous þ VT1  Kp1 þ VT2  Kp2 . . . ð5Þ
where Vvitreous is the volume of the vitreous cavity and VT terms are
the anatomical volumes of the ocular tissues (lens, ciliary body,
choroid, retina. . .) (Table A.1, Supplementary material) and Kp val-
ues are the distribution coefﬁcients between the tissue and vitre-
ous. Thus, Vss, ivt depends on the tissue volumes, and the
distribution coefﬁcients for each tissue. The volume of vitreous is
much higher than the tissue volumes (Table A.1), and the impact
of Kp values on the Vss, ivt is only moderate. Therefore, the Vss, ivt val-
ues showed only a narrow range (Fig. 3B), and two-compartmental
intravitreal pharmacokinetics was not common (Supplementary
data, Table A.2). Likewise, we did not see signiﬁcant effects in the
Vss, ivt values in albino and pigmented rabbits.
The physiological factors affecting Vss, ivt and CLivt were summa-
rized in Fig. 10. The anatomical volume of the vitreous is the most
relevant factor for Vss, ivt, whereas the permeability and surface
area of RPE and choroidal blood ﬂow are the key parameters for
CLivt of small molecules.
Fig. 6. The simulations of intravitreal injection of 100 lg dose of high and low CLivt compounds. The drug concentrations in the vitreous were simulated. The dashed lines
correspond to simulations using the predicted CLivt values with the low Vss, ivt of 1.18 ml (blue, 1) and the high Vss, ivt of 2.28 ml (red, 2) and the solid lines are simulations with
the experimental CLivt and Vss, ivt values (green, 3) (see Table 3). The simulation length for high CLivt compound was of 10 h and DT was 0.0005. For low CLivt compound the
duration was 180 h and DT = 0.01. (For the interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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4.3. Pharmacokinetic simulations
Even though Vss, ivt could not be predicted from the molecular
structure, its lower and upper limiting values were deﬁned reli-
ably, since 80% of the compounds had Vss, ivt of 1.18–2.29 ml. Due
to the narrow scale of the Vss, ivt values and predictability of QSPR
model for CLivt, the estimates of Vss, ivt and CLivt were used in the
pharmacokinetic simulations. Such simulations can be done early
in drug discovery and development, even before the drug synthe-
sis. For drug solutions, the simulated proﬁles were close to the
observed values (Fig. 6). This was excellent level of prediction tak-
ing into account that these simulations were solely based on com-
putational parameters.
The in silico tools were also used for dosage form design to esti-
mate the required release rates that are needed to reach the target
product proﬁle. For example, the dose required in ﬁrst-order
release DDS for achieving a target concentration was simulated
(Fig. 7B). The required doses were 4-fold bigger for the high CLivt
compound than for the low CLivt drug. In addition, we calculated
the expected Cmax values (Fig. 7C); in this case 3.5-fold smaller val-
ue was seen for the high CLivt compound compared to the low CLivt
one. In the case of zero-order release, required dosing for a target
Css, ivt was 20 times higher for high CLivt than low CLivt compounds
(Fig. 8B). These dosing predictions are relevant for drug formula-
tors, because only small doses can be loaded in small intravitreal
formulations (maximum volume is about 100 ll) and it is often dif-
ﬁcult to formulate drug at high concentrations.
This approach can be used for any controlled release system or
release proﬁle, but it is important to note that the simulated input
rate is in vivo release rate that may differ from the in vitro rate.
Pharmacokinetics of the free drug is governed by CLivt and Vss, ivt.
In general, the CLivt and Vss, ivt values are not modiﬁed by the
clinically used DDS or other controlled release systems (implants,
inserts, microspheres, gels). However, CLivt and Vss, ivt might be
affected in the case of experimental intracellular targeting systems
(e.g. liposomes, nanoparticles).
4.4. Importance of the data and models
This study presented for the ﬁrst time a universal view on the
Vss, ivt and CLivt values that could be related to the physiology
and anatomy of the eye to yield mechanistic understanding of drug
distribution and elimination. Furthermore, the presented CLivt and
Vss, ivt values of individual compounds (Tables 1 and A.2) may be
used for the predictions of intravitreal drug concentrations in the
context of DDS design (e.g. dosing levels, release rate effects). Like-
wise, predicted CLivt and Vss, ivt values can be used to guide delivery
of the new drug candidates to the vitreous.
These in silico tools do not replace in vivo studies, but they may
reduce and reﬁne rabbit experiments, accelerate preclinical ocular
drug development, and augment clinical study design. Even though
our model is based on rabbit data, it can be further scaled up to the
human eye, since both species are similar, but not identical, in
terms of drug binding to tissues, ocular ﬂows and barriers affecting
the intravitreal pharmacokinetic (Fig. 10). For example, beva-
cizumab has a similar CLivt in human and in rabbit, 0.025 ml/h
[72] and 0.019 ml/h (Table 1), respectively. The Vss, ivt value in
human is 3.17 ml [72] and 2.02 ml in rabbit (Table 1), both of them
being close to the anatomical volumes of vitreous (i.e. 4 ml in
humans [73] and 1.15 ml in rabbits (Supplementary data,
Table A.1a). However, the disease state might render blood-ocular
barriers more leaky and, thereby, the CLivt values might change.
The liquefaction of vitreous in the elderly patients is another
factor that might affect ocular pharmacokinetics [74]. However,
diffusion coefﬁcients of small compounds are very similar in vitre-
ous and water and therefore, this factor may not be important.
Bevacizumab is a large molecule with established pharmacokinet-
ics in rabbit (Table 1) and human [72] vitreous. In this case, only
moderate difference is seen between the CLivt values of healthy
rabbits and human patients with exudative macular degeneration.
Based on these arguments, we propose that our in silico models
can be further developed for intravitreal pharmacokinetics in
humans.
Fig. 7. The simulations of intravitreal drug delivery with ﬁrst-order release DDS.
The high and low CLivt compounds were released at the rate of 0.0016 h1. (A) The
simulations of the observed and predicted intravitreal pharmacokinetic proﬁles of
the DDS loaded with 10 mg of the compounds. (B) The doses required to achieve the
drug concentrations on the x-axis after three months. (C) The doses required to
achieve different Cmax values in the vitreous. The dashed lines show the simulations
with predicted CLivt values with low Vss, ivt value (blue, 1) and high Vss, ivt value (red,
2) and solid lines are the simulations with the observed values (3). The solid and
dotted arrows show the concentrations achieved at the dose of 10 mg of the high
and low CLivt molecules respectively. (For the interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 8. The simulations of intravitreal zero-order drug delivery. (A) The relationship between the release rate and steady-state concentrations in the vitreous for low and high
CLivt compounds. (B) The relationship between the dose delivered in three months and the steady-state concentrations in the vitreous for low and high CLivt compounds. The
dashed red lines correspond to simulations using the predicted CLivt value (1 and 2) and the solid green lines correspond to simulations using the experimental CLivt (3) (see
Table 3). (For the interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 9. The routes of drug elimination after intravitreal injection. (A) Anterior elimination of the drug by aqueous humour ﬂow (1). (B) Drug elimination through blood-ocular
barriers. The drug permeates through the posterior iris epithelium into iris vein and is drained by vortex veins (2), through the non-pigmented ciliary epithelium to ciliary
muscles and from the ciliary plexus to the episcleral veins (3), to the retinal capillaries and through the RPE into the choroid and systemic circulation (4).
Fig. 10. Physiological factors affecting the intravitreal pharmacokinetics. The most important factors have been underlined.
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5. Conclusions
The Vss, ivt and CLivt predictions are needed for the ocular
pharmaceutical research and development. In our study, CLivt
was highly dependent on molecular structure, but it could be
predicted reliably with two to three molecular descriptors. On
the contrary, the Vss, ivt was almost constant regardless of the
molecular structure. These models were linked to pharmacokinetic
models to estimate drug delivery system properties in pharma-
cokinetic context. These data and computational tools will improve
the ocular pharmacokinetic understanding and give valuable
guidance in the design of compounds and drug delivery systems.
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a b s t r a c t
Intravitreal administration is the method of choice in drug delivery to the retina and/or choroid. Rabbit is
the most commonly used animal species in intravitreal pharmacokinetics, but it has been criticized as
being a poor model of human eye. The critique is based on some anatomical differences, properties of the
vitreous humor, and observed differences in drug concentrations in the anterior chamber after intra-
vitreal injections. We have systematically analyzed all published information on intravitreal pharma-
cokinetics in the rabbit and human eye. The analysis revealed major problems in the design of the
pharmacokinetic studies. In this review we provide advice for study design. Overall, the pharmacokinetic
parameters (clearance, volume of distribution, half-life) in the human and rabbit eye have good corre-
lation and comparable absolute values. Therefore, reliable rabbit-to-man translation of intravitreal
pharmacokinetics should be feasible. The relevant anatomical and physiological parameters in rabbit and
man show only small differences. Furthermore, the claimed discrepancy between drug concentrations in
the human and rabbit aqueous humor is not supported by the data analysis. Based on the available and
properly conducted pharmacokinetic studies, the differences in the vitreous structure in rabbits and
human patients do not lead to signiﬁcant pharmacokinetic differences. This review is the ﬁrst step to-
wards inter-species translation of intravitreal pharmacokinetics. More information is still needed to
dissect the roles of drug delivery systems, disease states, age and ocular manipulation on the intravitreal
pharmacokinetics in rabbit and man. Anyway, the published data and the derived pharmacokinetic
parameters indicate that the rabbit is a useful animal model in intravitreal pharmacokinetics.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Age-related macular degeneration, glaucoma, diabetes, and
various rare ocular diseases may impair the functionality of the
retina leading to visual impairment and blindness. Even though this
is a growing problem in the aging populations, effective treatments
are not available to most patients with retinal diseases.
New mechanisms of action and drug candidates are being
discovered for the retinal diseases (Zhang et al., 2012), but drug
delivery to the retina is very difﬁcult (and often impossible) from
topical eye drops or systemic medications (such as tablets).
Therefore, the intravitreal injections have emerged as the primary
method of drug administration to the retina and choroid (del Amo
and Urtti, 2008; Urtti, 2006). The number of annual intravitreal
injections has increased rapidly being nearly 400,000 in the United
Kingdom (Severn and Hamilton, 2015) and probably an order of
magnitude higher numbers in Europe and U.S.A. For example,
bevacizumab (Avastin®), ranibizumab (Lucentis®), pegaptanib so-
dium (Macugen®), aﬂibercept (Eylea®) and triamcinolone aceto-
nide (Kenalog®) are widely used as intravitreal injections to treat
neo-vascular macular degeneration and other retinal diseases.
ABBREVIATIONS: AIC, Akaike's information criterion; AUC, area under the curve;
C0, drug concentration at time zero; Ccalc, calculated concentration; CLivt, intra-
vitreal clearance; CLRPE, intravitreal clearance across the RPE; Cobs, observed con-
centration; CV%, coefﬁcient of variation; Divt, intravitreal dose; E, extraction ratio;
kelimination, ﬁrst-order elimination rate constant; fu, vitreous, fraction of unbound drug
in vitreous; fu, tissue, fraction of unbound drug in the tissue; Kp, distribution coef-
ﬁcient between the tissue and vitreous; MW, molecular weight; P, permeability in
the membrane; r, Spearman's rank correlation coefﬁcient; R2, coefﬁcient of
determination; Q, ﬂow; RPE, retinal pigment epithelium; S, membrane surface area;
t1/2, ivt, intravitreal half-life; TEER, trans-epithelial electrical resistance; V,
anatomical tissue volume; Vss, ivt, intravitreal volume of distribution; Y, actual
concentration; Y hat, predicted concentration.
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Intravitreal injection is an invasive procedure and, therefore, the
dosing intervals should be long. The dosing intervals of intravitreal
injections of antibodies, aptamers, soluble receptors and suspen-
sions are often four to six weeks and sometimes even twelve weeks
(Bashshur et al., 2008; Cheung and Eaton, 2013). This is based on
the slow clearance, long half-life (about two to six days) and
extremely high potency the macromolecules (anti-VEGF antibodies
and soluble receptors) or slow dissolution and long residence time
of suspension particles (corticosteroid suspensions). However, in
the case of intravitreal solutions of small molecular drugs, the fast
elimination rates (half-lives of 1e27 h) would lead to frequently
repeated injections that are not possible in the clinical setting.
Moreover, injections of the drug solutions intravitreally lead to high
ﬂuctuations in intravitreal drug concentrations. This is feasible only
for the drugs with wide therapeutic index, otherwise the adverse
effects would prohibit the clinical use. Controlled release formu-
lations canmaintain the intravitreal drug concentrations within the
therapeutic index for prolonged periods, thereby allowing long
dosing intervals of several months. Some controlled release im-
plants are already in the clinical use for instance, ﬂuocinolone
acetonide intravitreal implant (Iluvien®) and dexamethasone
intravitreal implant (Ozurdex®) (del Amo and Urtti, 2008; Sanford,
2013; Totan et al., 2015). Estimation of the time course of drug ef-
fects in the posterior eye segment is possible with pharmacokinetic
modeling tools (Kontturi et al., 2014; Stewart and Rosenfeld, 2008).
After intravitreal administration, drugs distribute to the ocular
tissues (lens, iris, ciliary body, retina). Distribution depends on the
ability of drug to partition into the tissues and it is described as
volume of drug distribution. Drug elimination may take place
posteriorly through the blood-retina barrier (Duvvuri et al., 2003;
Gupta et al., 2000; Maurice and Mishima, 1984; Shen et al., 2007)
to the choroidal blood circulation that constitutes most of the
ocular blood ﬂow (del Amo et al., 2015; Roh et al., 2006). Intra-
vitreal drug is eliminated also anteriorly via aqueous humor turn-
over and uveal blood ﬂow. The importance of anterior and posterior
routes depends on the drug properties (Maurice and Mishima,
1984): lipophilic drugs with high permeability in the blood-retina
barrier are mostly eliminated posteriorly (e.g. ﬂuconazole; vitreal
clearance 0.753 ml/h (Gupta et al., 2000)), whereas elimination of
large and hydrophilic compounds is restricted to the anterior route
(e.g. bevacizumab; vitreal clearance 0.019 ml/h (Bakri et al., 2007;
Christoforidis et al., 2011; del Amo et al., 2015)). These processes
determine drug elimination in rabbit and human eyes and it is
described as intravitreal clearance. Ocular pharmacokinetic pa-
rameters (i.e. volume of distribution and clearance) are the most
informative, reliable and quantitative basis for the pharmacokinetic
comparisons in terms of species, disease states, age, drug com-
pounds and delivery systems.
Ocular pharmacokinetics has only rarely been studied in the
human eye, because the invasive sampling from the human eye is
ethically restricted andmay inﬂuence pharmacokinetics. Therefore,
ocular pharmacokinetics relies on animal models, mostly rabbits.
Recently, the rabbit eye has been criticized for being a poor model
of the human eye (Laude et al., 2010; Rowe-Rendleman et al., 2014).
Therefore, we investigated all available intravitreal pharmacoki-
netic data in rabbits (del Amo et al., 2015) and humans (this review)
and derived the pharmacokinetic parameters (clearance, volume of
distribution) to compare systematically intravitreal pharmacoki-
netics in man and rabbit. We did not ﬁnd any convincing evidence
to justify the criticism of the rabbit model. Moreover, during the
process of analyzing the intravitreal pharmacokinetic parameters
in the rabbit eyes (del Amo et al., 2015), we noticed another
remarkable problem: many published studies are based on sub-
optimal study designs, and actually 58% of the studies were dis-
carded from the pharmacokinetic data analysis.
In this review, we summarize the current knowledge of intra-
vitreal pharmacokinetics in rabbits and humans, and provide
advice in intravitreal pharmacokinetic study design.
2. Intravitreal pharmacokinetics in rabbit eye
2.1. Introduction of concepts
The intravitreal pharmacokinetics is deﬁned by the primary
parameters: volume of distribution (Vss, ivt) and clearance (CLivt)
that describe drug distribution and elimination, respectively.
Vss, ivt can be compared to the anatomical volumes of the ocular
tissues based on the principles from the drug distribution from
plasma to the tissues (Jusko, 2006; Mager, 2006):
Vss; ivt ¼ Vvitreous þ Vlens  Kp; lens þ Vciliary body  Kp; ciliary body
þ Vretina  Kp; retina…
(1)
where V values indicate the anatomical tissue volumes and Kp
distribution coefﬁcients of the drug between the tissue and vitre-
ous. High Kp values indicate effective drug partitioning to the tis-
sues, leading to Vss, ivt values bigger than the anatomical volumes.
Systemic volume of drug distribution at steady-state can be
related to the anatomical volumes using Gillette equation (Gillette,
1971; Mager, 2006). In this case, the equation for the intravitreal
drug delivery would be:
Vss; ivt ¼ Vvitreous þ Vlens 
fu; vitreous
fu; lens
þ Vciliary body 
fu; vitreous
fu; ciliary body
þ Vretina 
fu; vitreous
fu; retina
…
(2)
where V values indicate the anatomical tissue volumes and fu terms
indicate the fractions of unbound drug in the vitreous and sur-
rounding tissues. Thus, in the context of intravitreal administration,
Vss, ivt is related to the anatomical volumes (Vvitreous, Vtissues) and
either 1) drug distribution between the tissues and vitreous humor
(Kp) or 2) free fractions of the drug in the vitreous (fu, vitreous) and
tissues (fu, tissue). Anyway, in both cases, high drug concentrations in
the tissues increase the value of Vss, ivt.
CLivt can be related to the ocular ﬂows:
CLivt ¼ Q ocular  E ocular (3)
where Q is the ocular ﬂow and E is the extraction ratio in the tissue
(0 < E < 1). Theoretical maximum for CLivt is equal to the ocular
ﬂows (aqueous humor and blood ﬂows) representing completely
ﬂow-limited clearance without any membrane barrier limitations
(e.g. blood-retinal barrier). On the contrary, at low values of E the
clearance is limited by membrane permeation and deﬁned as
product of drug permeability in the membrane (P) and the mem-
brane surface area (S):
CLivt ¼ P ocular barriers  S ocular barriers (4)
After intravitreal injection, the drug is partitioning to some
extent to the surrounding tissues and eliminated from the vitreous
through aqueous humor turnover and blood-ocular barriers (Fig. 1).
Membrane permeable drugs can cross the blood-ocular barriers,
while poorly permeable drugs (e.g. macromolecules) will be
cleared via aqueous humor turnover (Maurice and Mishima, 1984).
All intravitreal drug will eventually end-up to the systemic
E.M. del Amo, A. Urtti / Experimental Eye Research 137 (2015) 111e124112
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circulation unless it is metabolized in the eye which is not habitual
fate. However, the systemic circulation can be handled as a sink
because the clearance in the human systemic circulation is much
higher (10e100,000 ml/h) than the clearance in the eye
(0.01e1.0 ml/h). Therefore, the concentrations in the systemic cir-
culation are orders of magnitude lower than in the eye, and drug
elimination from the eye is rate-limited by the ocular processes,
and not affected by the drug concentrations in the blood
circulation.
The primary pharmacokinetic parameters Vss, ivt and CLivt are
useful in pharmacokinetic simulations and clinical translation. They
allow estimation of average steady-state concentrations, concen-
tration proﬁles, half-life (t1/2, ivt) and amount of drug in the eye after
administration of different doses or dosage forms (del Amo et al.,
2015). Vss, ivt and CLivt can be linked to the fundamental factors,
anatomy, physiology, and drug interactions with tissues, thereby
providing understanding of ocular pharmacokinetics in the physi-
ological context and generating tools for bottom-up simulation
models (del Amo et al., 2015). Noteworthy, the most frequently
used intravitreal pharmacokinetic parameter, t1/2, ivt depends on
both drug distribution and elimination,
t1=2; ivt ¼
ln2  Vss; ivt
CL ivt
(5)
if the intravitreal concentration proﬁle showsmulti-exponential
decline, the t1/2, ivt correspond to effective t1/2, ivt. Even though
t1/2, ivt is useful in deﬁning the dosage intervals of the drug, it does
not allowmechanistic analyses and simulations. Half-life cannot be
linked to physiology and pathophysiological alterations in the eye.
2.2. Analysis of the literature
Recently, we developed a universal collection of Vss, ivt, CLivt and
t1/2, ivt values (del Amo et al., 2015). For that, we carried out a
comprehensive literature search on intravitreal pharmacokinetic
studies in healthy and normal rabbit eyes during 1947e2013. We
set criteria for the data quality: at least four time-points, at least
two replicates per point, and balanced sampling for at least a time-
span of two t1/2, ivt of the drug (the derived parameters values are
presented later in the Section 2.4). The criteria are needed for
reliable determination of Vss, ivt, CLivt and t1/2, ivt values. Surpris-
ingly, only 42% of the literature reports fulﬁlled these quality
criteria. The corresponding references and the data analysis are
presented in our previous paper (del Amo et al., 2015). The
remaining 58% (92 reports) had to be discarded due to inadequate
data points or other problems (e.g. analytical issues, poor match
between dose and initial concentration, solubility problems) that
prevent reliable data analysis. Commonly, the problems were
related to inadequate number of data points, poorly selected time
spans and narrow concentration ranges. Table 1 illustrates some
data quality problems that hamper the calculation of the pharma-
cokinetic parameters (Vss, ivt, CLivt and t1/2, ivt) or lead to unreliable
estimates. For the analysis Phoenix WinNonlin® software (version
6.3, Pharsight Inc., St. Louis, USA) was used and accurate description
of the workﬂow is described in Section 2.3.
Even though many intravitreal pharmacokinetic studies did not
meet the normal quality standards, they give rough estimates of
t1/2, ivt and range of drug concentrations after injection of a certain
dose. Such information is valuable and important, but unfortu-
nately not adequate for determination of pharmacokinetic param-
eters accurately.
2.3. Design of an intravitreal pharmacokinetic study
In a typical intravitreal pharmacokinetic study, drug is injected
into the vitreal cavity in rabbits and, thereafter, drug concentrations
are determined periodically. In most studies, the animals are
sacriﬁced at different time intervals: the eyes are removed and the
vitreous humor samples are assayed for drug concentrations.
Continuous sampling with a microdialysis probe in the rabbit eyes
has also been used (Atluri and Mitra, 2003). This approach reduces
the number of animals, but reliable recovery estimates are needed
in the determination of the drug yield (Duvvuri et al., 2003) and the
duration of the experiments is often limited. In some cases, a
radioactively labeled drug has been injected to the vitreous fol-
lowed by imaging with positron emission tomography
(Christoforidis et al., 2011, 2012). In all cases, the sampling times are
crucial for obtaining reliable pharmacokinetic proﬁles and param-
eter values.
In rabbit studies, the number of test animals should be mini-
mized based on 3R (Reduce, Reﬁne, Replace) principles, but this
should not lead to inadequate experimental design, unreliable
pharmacokinetic proﬁles and parameters (Section 2.2.). Good
practices of systemic pharmacokinetic data analyses should be
applied with some modiﬁcations in ocular pharmacokinetics. The
Fig. 1. Routes of drug elimination after intravitreal injection. (A) Anterior elimination of the drug in the aqueous humor ﬂow (1). (B) Drug elimination through blood-ocular barriers.
The drug permeates through the posterior iris epithelium into iris vein and is drained by vortex veins (2), through the non-pigmented ciliary epithelium to ciliary muscles and from
the ciliary plexus to the episcleral veins (3), to the retinal capillaries and through the retinal pigment epithelium (RPE) into the choroid and systemic circulation (4) (del Amo et al.,
2015).
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pharmacokinetic parameters are determined using curve ﬁtting
software (e.g. Kinetica®, Thermo Fisher Scientiﬁc Inc, Waltham, USA or
Phoenix WinNonlin® software) that are based on the method of least
squares to ﬁt the concentration curves. The objective is to minimize
the difference between the observed and calculated concentrations
(Cobs and Ccalc respectively), i.e. sum of squared residuals S(Cobs e
Ccalc)2. These methods pool all the data from the experiment for
maximal information gain. As illustrated in Table 1 inadequate data
may not allow reliable estimation of pharmacokinetic parameters.
Proper procedure in pharmacokinetic data analysis is presented in
Table 2.
Usually, the kinetic analysis is done for each individual sepa-
rately (e.g. plasma samples at different times), but this is not
possible in intravitreal studies, because multiple sampling from the
vitreous is not possible. All individual data points can be ﬁtted
simultaneously, and the ﬁtted curve can be compared to the
observed mean values or individual points. In any case, it is
important to have adequate number of data points with proper
time span and concentration range.
We propose that the following points should be taken into
account in the design of intravitreal pharmacokinetic studies.
Firstly, the drug dose should be soluble in the formulation and in
the vitreous. This is not the case in many studies (some examples
(Chin et al., 2005; Doft et al., 1985; Wingard et al., 1989)). Then,
the resulting data does not allow reliable determination of CLivt,
Vss, ivt and t1/2, ivt for the drug. Anyway, the obtained concentra-
tion proﬁles describe the properties of the formulation in drug
delivery. Secondly, the dose should be reported, and if the drug is
in salt form, the reporting should allow the estimation of dose as
free acid or free base. Thirdly, at least six time points must be
used at properly balanced intervals to describe drug distribution
and elimination. The ﬁrst data point should be shortly after in-
jection and, thereafter, the data points should span at least three
t1/2, ivt of the drug (i.e. at least 87% of the drug has been elimi-
nated at that point). Fourthly, at least four to six replicate eyes
should be used for each time point. Overall, this will results in
24e36 rabbit eyes (12e18 animals). Within the European Union
the use of animals in scientiﬁc experiments should be rationally
reduced (Directive 86/609/EEC). Properly conducted intravitreal
pharmacokinetic study uses many rabbits, but it will yield reliable
quantitation of pharmacokinetics (incl. Vss, ivt, CLivt, t1/2, ivt) that
allows estimation of drug concentrations at different dosing
regimens thereby reducing the need of animals in later experi-
ments and in the long run.
2.4. Intravitreal pharmacokinetic parameters in rabbits
The universal collection of the intravitreal pharmacokinetic data
in rabbits was followed by determination of the primary pharma-
cokinetic parameters (CLivt and Vss, ivt). Only the studies that ful-
ﬁlled the quality criteria were included in the analysis. The CLivt and
Vss, ivt data are plotted against the molecular weight (MW) of the
compounds in Fig. 2AeB.
The Vss, ivt values in rabbits are in the range 0.72e3.14 ml.
Interestingly, there are no systematic differences in the Vss, ivt
values of small molecules and macromolecules. Overall, the scope
of Vss, ivt values is narrow (only 4-fold range) and in general the
values are slightly greater than the anatomical volume of the vit-
reous humor (1.15 ml) (Fig. 2B). Volume of vitreous is bigger than
the volumes of the surrounding tissues, such as iris, ciliary body,
choroid, retina (0.050e0.059ml) (Wiederholt et al., 1986; Wu et al.,
1970) and lens (0.33e0.53 ml) (Zamudio and Candia, 2011). The
small volumes of the tissues explain the narrow range of Vss, ivt
values (see Eqs. (1) and (2)). The highest Vss, ivt value (3.14 ml)
would be achieved with Kp (or fu, vitreous/fu, tissue) value of 2.8e4 if
we use the average combined volume for the surrounding tissues
(0.49e0.69ml) in Eq. (1) or Eq. (2), proving that Kp values in the eye
are moderate and do not have major impact on Vss, ivt values. It is
therefore likely that the new drug candidates will have Vss, ivt in the
range reported in Fig. 2B and del Amo et al. (2015). Vss, ivt values are
similar or only moderately bigger than the anatomical volume of
vitreal cavity and eye tissues, thereby ruling out the possibility that
drug partitioning to the orbita would be signiﬁcant. This is under-
standable, because the ocular blood ﬂow removes drug effectively
thereby minimizing its access to the orbita.
Drug elimination from the vitreous shows substantial differ-
ences among the compounds in the literature: CLivt values range
from 0.011 to 1.530 ml/h (139-fold difference) and the values
decrease clearly with increasing MW (Fig. 2A). Also, the t1/2, ivt
values have a broad range (del Amo et al., 2015; Kidron et al., 2012),
because the t1/2, ivt is dependent on CLivt and Vss, ivt.
The CLivt of macromolecules are low (0.011e0.027 ml/h, Fig. 2A
and D) because they are mainly eliminated via anterior route
(Fig. 1A). Interestingly, CLivt of macromolecules are clearly less than
Table 2
Pharmacokinetic data analysis with curve ﬁtting software.
Compartmental model
Select one- or two- compartmental model.
The experimental data are plotted in semi-logarithmic plot: logarithm of intravitreal concentration vs time.
Based on the shape of the plotted data one-compartmental (single slope) or two-compartmental (two distinct slopes) model may be feasible.
Weighting factor
Weighting is used to improve the curve ﬁtting by giving more weight to the last data points with low concentrations.
The sum of squared residuals can be weighted by
 one (uniform weighting)
 1/Cobs or 1/Ccalc (1/Y or 1/Yhat respectively)
 1/(Cobs)2 or 1/(Ccalc)2 (1/Y2 or 1/Yhat2 respectively)
The relative weight of small concentrations is increased with the use of the concentration or squared concentration in the denominator.
Y is the actual concentration and Yhat is the predicted concentration.
Goodness of ﬁt
Goodness of ﬁt describes how close the calculated curve is to the data points. The following criteria is used to evaluate the goodness of ﬁt:
1) Calculated concentration curve should lie between the observed concentration points.
2) Signs of the residuals (i.e., Cobs e Ccalc, shows either over-estimation or under-estimation) must change randomly. This indicates lack of systematic deviations.
3) Relative residuals (residual/Cobs) are not excessive at low concentrations.
4) Conﬁdence intervals of the parameters are positive. This depends on the number of animals and data points, and the complexity of the pharmacokinetic model.
5) Coefﬁcient of variation (CV%) should be less than 30%, preferably below 10%.
6) Correlation between various pharmacokinetic parameters should be < 0.95. This informs us that the parameters are independent from each other.
7) Sum of weighted squared residuals should be small enough.
8) Akaike's information criterion (AIC) is used to discriminate between models (for example, one- and two-compartment models) with the same weighting. The best
model has the lowest AIC value.
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the rate of aqueous humor turnover (0.18 ml/h) (Barany and Kinsey,
1949) suggesting that the access of drug from the vitreous to the
anterior chamber is restricted. Presumably, CLivt of macromolecules
via posterior route through blood-retina barrier is low, due to their
low permeability in the RPE (Pitkanen et al., 2005). Intravitreal
clearance across the RPE (CLRPE) was calculated using the bovine
RPE permeability for FITC-dextrans (Pitkanen et al., 2005) and
surface area of the rabbit RPE (5.2 cm2) (Reichenbach et al., 1994)
according to Eq. (4) (P  S). These CLRPE values are 5e30 times
lower than the CLivt values for the macromolecules in the sameMW
range (Fig. 2D). This suggests that only a small fraction (3e20%) of
the macromolecule dose is eliminated through the RPE.
The wide range of CLivt of small drugs (0.031e1.530 ml/h) is
probably determined by their ability to cross the blood-ocular
barriers. High permeability across the barriers should lead to high
CLivt values. Owing to the large surface area of the RPE and high
blood ﬂow in the choroid, it is probable that the compounds with
high CLivt values are eliminated via posterior route (Fig. 1B). In our
previous studies, the t1/2, ivt and CLivt of small drugs were
determined by H-bond capacity and LogD7.4 (del Amo et al., 2015;
Kidron et al., 2012). These descriptors typically deﬁne membrane
permeability, e.g. in the cornea (Kidron et al., 2010), intestinal wall
(Linnankoski et al., 2006) and bloodebrain barrier (Lanevskij et al.,
2009; Liu et al., 2004). Accordingly, the calculated CLRPE values for
betaxolol and carboxyﬂuorescein, using permeability values of
Pitkanen et al. (2005) and Mannermaa et al. (2010), are in the same
range with CLivt values of lipophilic and hydrophilic small mole-
cules, respectively, suggesting signiﬁcant elimination through the
RPE (Fig. 2C). Despite their ability to cross blood-retina barrier, the
CLivt values of the small molecules are far below the value of
choroidal blood ﬂow showing that clearance is permeability-
limited and not controlled by blood ﬂow (Fig. 2A).
Some clinical biologics (e.g. ranibizumab, bevacizumab) are
delivered intravitreally to the retinal and choroidal tissues. We
should note that the effects of these drugs are dependent on their
target concentrations and not on the quantity of drug that is
eliminated through the blood-retina barrier. Therefore, thera-
peutic effects in the retina and/or choroid do not mean that the
Fig. 2. The relationships between (A) MW and CLivt and (B) MW and Vss, ivt are presented for 40 small molecular compounds and 11 macromolecules after intravitreal injections in
rabbits. The relationships between MW and CLivt of the small molecular compounds (C) and macromolecules (D) are presented. The diamonds represent the small MW compounds
with Log D7.4 below 0 (blue symbols) and Log D7.4 above 0 (red symbols). The triangles represent the macromolecules. The circles represents intravitreal clearance via permeation
across the RPE. These values were calculated based on permeability in bovine RPE-choroid membrane (Mannermaa et al., 2010; Pitkanen et al., 2005) and RPE surface area in rabbit
(Reichenbach et al., 1994) using Eq. (4). In (A) the long dashed black line represents the sum of the ocular ﬂow factors (choroidal, retinal, iridial and ciliary body blood ﬂows, and
aqueous humor ﬂow), the short dashed lines correspond to the choroidal blood ﬂow (red) and aqueous humor ﬂow (blue). In (B) the dotted line represents the anatomical volume of
the vitreous 1.15 ml. The r represent Spearman's rank correlation coefﬁcient for small drugs and macromolecules. In the original publication (del Amo et al., 2015), the phar-
macokinetic parameters of PF-04523655 were extracted from an abstract (Johnson, 2010). The original concentration curve became recently available and it was analyzed. However,
the initial concentrations were too low for the administered dose. Therefore, the parameters of this drug were omitted from the ﬁgures.
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posterior elimination pathway would be signiﬁcant route for
macromolecules. Therapeutic concentrations can be reached in
the retina and/or choroid even though the posterior clearance
would be an order of magnitude less than the anterior
elimination.
3. Intravitreal pharmacokinetics in human eye
Intravitreal pharmacokinetic studies in humans are sparse,
because the vitreous sampling is invasive and potentially risky
procedure. There are, however, some studies that were carried out
in patients whowere selected for vitrectomy surgery or undergoing
treatments for endophthalmitis, cytomegalovirus retinitis or
choroidal neovascularization (Table 3). Typically, these studies re-
ported only a few drug concentrations, usually from one individual
and during the terminal elimination phase of the drug. For such
data it is not possible to calculate the CLivt as it has been presented
in Section 2.3. However, we did the following exercise to get rough
estimates of CLivt (apparent CLivt), assuming one-compartment
pharmacokinetics:
apparent CL ivt ¼
Divt
AUC
(6)
where Divt is the given intravitreal dose and AUC is area under the
curve. The AUC values were calculated using equation (7):
AUC ¼ C0
k elimination
(7)
where C0 is the drug concentration in vitreous at time zero and
kelimination is the ﬁrst-order elimination rate constant. C0 was
calculated with equation (8):
C 0 ¼
Divt
V ss; ivt
(8)
where Vss, ivt was assumed to be equal to the human vitreous vol-
ume of 4 ml (Ruby et al., 2006). This is probably a reliable estimate,
because the rabbit Vss, ivt values are limited in a narrow range (80%
of the values in the dataset of 51 compoundswere between 1.18 and
2.28 ml) (del Amo et al., 2015) and close to the anatomical volume
of the vitreous. The kelimination was the slope of the curve deﬁned by
the calculated C0 and the experimental concentration values. The
apparent CLivt values are presented in Table 3. The same calcula-
tions for 2-fold higher Vss, ivt value (8 ml) were carried out and
presented in Fig. A1 (versus rabbit CLivt) and A.2 (versus MW) in
appendices. Estimation of CLivt and apparent CLivt values in human
eyes enables universal rabbit-to-human comparison of intravitreal
drug elimination (Fig. 3). Drug clearance in rabbit and human vit-
reous correlated well (r ¼ 0.91; Rabbit CLivt ¼ 1.41  Human
apparent CLivt þ 0.04, units are ml/h; R2 ¼ 0.82) and absolute dif-
ferences of the clearance values are in within 3-fold range (13/15
Table 3
Intravitreal drug concentrations in vitreous after intravitreal injection of drugs in humans. In the ﬁrst panel, pharmacokinetic parameters are calculated by compartmental
model (section 2.3, Doc. A) and in the second panel, the apparent CLivt is calculated according to the description given in section 3.
Drugs Dose (mg) Subjects Time (h) C (mg/ml) Vss, ivt (ml) CLivt (ml/h) t1/2, ivt (h) References
Bevacizumab 1250 Patients with choroidal
neovascularization
24 92.70 3.17 0.025 160.8 (Zhu et al. 2008)
48 165.00 9.39 0.042 154.4 Own calculations
72 84.80
96 48.70
264 22.90
408 0.33
1032 1.39
1296 0.39
1776 0.022
2280 0.005
2424 0.003
Drugs Dose (mg) Subjects Time (h) C (mg/ml) Apparent CLivt
(ml/h)
References
Bevacizumab 1250 Patients with choroidal neovascularization 48 166.0a 0.036 (Beer et al. 2006)
696 0.5b
Bevacizumab 1250 Patients with diabetic retinopathy 672 0.107 0.028 (Moisseiev et al. 2014)
1344 0.019
Cidofovir 20 AIDS patient with cytomegalovirus retinitis 24 0.673 0.336 (Taskintuna et al. 1998)
Dexamethasone 383d Patients with postoperative endophthalmitis 66 0.023 0.472 (Gan et al. 2005)
phosphate with and without core vitrectomy 69 0.027
70 0.040
71 0.018
71 0.014
72 0.036
Fomivirsen 165 Patients with cytomegalovirus retinitis 1 39.24c 0.068 (Bejanian et al. 1999)
72 10.61
168 0.39
168 0.78
336 0.26
Foscarnet 504d AIDS patient with cytomegalovirus retinitis 23.25 51.53 0.152 (Diaz-Llopis et al. 1992)
Ganciclovir 200 AIDS patient with cytomegalovirus retinitis 51.4 1.17 0.292 (Henry et al. 1987)
Ganciclovir 2000 Patients with cytomegalovirus retinitis 24 212.0 0.172 (Morlet et al. 1996)
24 165.4
24 138.2
24 102.2
24 152.8
(continued on next page)
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Table 3 (continued )
Drugs Dose (mg) Subjects Time (h) C (mg/ml) Apparent CLivt
(ml/h)
References
24 92.2
72 59.8
72 10.0
72 20.8
72 19.4
72 6.8
72 23.4
Gentamicin 50 Patients with postoperative endophthalmitis 63 0.90 0.092 (Gan et al. 2001)
with and without core vitrectomy 66 1.41
69 3.30
69 1.21
69 1.01
71 1.91
71 1.40
71 1.80
72 1.40
72 2.41
72 1.01
90 1.21
92 2.61
Vancomycin 975d Patients with postoperative endophthalmitis 44 58.11 0.068 (Ferencz et al. 1999)
with core or entire vitrectomy 48 137.85
72 182.36
72 25.05
Vancomycin 200 Patients with postoperative endophthalmitis 63 2.59 0.084 (Gan et al. 2001)
with and without core vitrectomy 66 12.07
68 10.75
69 18.03
69 8.23
69 11.97
71 15.54
71 6.30
71 9.02
71 13.28
72 8.89
72 10.10
72 6.85
90 5.80
90 3.05
92 16.59
93 4.59
Vancomycin 1000 Patients with postoperative endophthalmitis 48 125 0.100 (Haider et al. 2001)
48 164
72 21
72 83
Vancomycin 2000 Patients with postoperative endophthalmitis 48 161 0.100 (Haider et al. 2001)
72 56
72 220
72 105
72 39
Vancomycin 975d Patients with exogenous endophthalmitis 24 133.7 0.132 (Raju et al. 2004)
with core vitrectomy 24 179.0
24 171.1
48 72.5
48 43.9
Vancomycin 200 Patients with postoperative endophthalmitis 62 2.6 0.092 (Gan et al. 2005)
with and without core vitrectomy 66 12.0
68 10.8
69 12.0
69 8.2
71 15.5
71 9.0
71 8.9
71 6.3
71 16.6
72 6.8
93 4.6
Footnote.
a The patient developed endophthalmitis 2 days after the drug injection, complete drug washout of previous treatment is assumed.
b The patient suffered retinal detachment 8 days before vitreous sampling.
c Average concentration of ﬁve patients. All other reported concentrations correspond to individual patient samples and only in Morlet's study (Morlet et al. 1996) two
vitreous samples were taken from the same patient, for four patients.
d Equivalent dose.
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studies). The relationship of the apparent CLivt in human eye and
MW was negative (Fig. B in appendices), like in rabbits (Fig. 2A). If
higher value is used for human Vss, ivt (8 ml), the trends remain the
same, and the CLivt difference is within 4-fold range (12/15 studies)
(Fig. A1 and A2 in appendices). It is important to note that the in-
dividual values of apparent CLivt in human vitreous may not be
accurate descriptors for the elimination of individual drugs. How-
ever, Fig. 3 shows good correlation and only moderate inter-species
CLivt differences in the large pooled data from 15 studies. This
supports the use of rabbit as a model in intravitreal pharmacoki-
netic studies. It is important to note that the human patients had
different disease conditions (Table 3), but still no striking outliers
were seen in the rabbit-to-man correlation in Fig. 3.
The experiment of Zhu et al. (2008) is the only human study that
allows calculation of CLivt values with curve ﬁtting (Table 3) though
only one samplewas available for each time point. It is important to
note that bevacizumab has similar CLivt values (1.5- and 2.1-fold
differences) in rabbit and humans (Fig. 3, Doc. A).
Intravitreal pharmacokinetics in human eyes is evaluated also
by monitoring drug concentrations in the aqueous humor. Major
concentration differences of bevacizumab in aqueous humor were
seen after intravitreal injections in human (Krohne et al., 2008) and
rabbit eyes (Nomoto et al., 2009). Based on this argument, the
rabbit was considered not to be a good animalmodel for human eye
(Rowe-Rendleman et al., 2014). However, that particular rabbit
study (Nomoto et al., 2009) has some quality concerns: the ﬁrst
sample was taken only one week after the intravitreal injection and
the assayed samples had exceptionally low concentrations. The
authors compared their results with the rabbit study of Bakri et al.
(Bakri et al., 2007) and justiﬁed the concentration differences based
on the analytical method used. Nomoto et al. (2009) measured all
variants of bevacizumab (free, in complex, fragments), but this kind
of non-speciﬁc assay should lead to higher concentration values,
not lower, than in Bakri's study. Then, it is interesting to plot
together the existing rabbit and human data. The human bev-
acizumab data (Krohne et al., 2008; Meyer et al., 2011) is in line
with Bakri's levels of bevacizumab in aqueous humor (Fig. 4).
Similar conclusion is reached when AUC values of bevacizumab
(normalized to 1 mg intravitreal dose) in aqueous humor are
compared (Table 4): Nomoto's study (Nomoto et al., 2009) is clearly
an outlier. Unfortunately, much criticism against rabbit model has
been based on the comparisons of human data with Nomoto's
rabbit data.
We carried out pharmacokinetic simulations of intravitreal
bevacizumab using the measured pharmacokinetic parameters
from the literature. We assumed that bevacizumab distributes in
the vitreous as indicated by the Vss, ivt values (human 9.39ml, rabbit
2.02 ml), its elimination takes place only via anterior route
(CLivt ¼ human 0.042 ml/h, rabbit 0.019 ml/h), and the elimination
from the aqueous humor (volume 0.3 ml) takes place at the rate of
aqueous humor outﬂow (human 0.14 ml/h, rabbit 0.18 ml/h) (Fig. 5,
Table 5). Since blood-aqueous barrier does not allow permeation of
proteins, the aqueous humor ﬂow remains as the only route of
bevacizumab elimination (Maurice and Mishima, 1984). The results
Fig. 4. Concentration of bevacizumab in aqueous humor versus time after intravitreal
injection in rabbit (Bakri et al., 2007; Nomoto et al., 2009) and in human eyes (Krohne
et al., 2008; Meyer et al., 2011) in arithmetic and semi-logarithmic scale.
Fig. 3. Correlation between CLivt in rabbit versus human apparent CLivt (and CLivt). The dotted and dashed lines represent 2- and 3-fold deviation and the solid line represents the
slope of 1.0. The open diamond correspond to bevacizumab CLivt calculated by Zhu et al. and the dotted one correspond to our calculations.
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and structure of the simulation model are shown in Fig. 5. The
simulated bevacizumab concentrations are in line with the real
values, except the data of Nomoto et al. (Nomoto et al., 2009) that
deviates substantially from the simulations (Figs. 4 and 5). The
same conclusion is reached when AUC values of the simulations are
compared to the experimental values (Table 4).
It is important to note that the drug concentrations in the
aqueous humor are different from the concentrations in the vitre-
ous. Moreover, the ratio of the concentrations (aqueous humor/
vitreous) may not be constant for all compounds. Based on simu-
lation, AUCaqueous humor/AUCvitreous for small lipophilic compound
(CLivt ¼ 0.5 ml/h, CLaqueous humor ¼ 1.2 ml/h (Schoenwald, 2003)) is
0.016. This means that the drug concentrations in the vitreous are
approximately 50 times greater than in the aqueous humor. In the
case of bevacizumab, the AUC-ratio is 0.095 meaning that
approximately 10-fold higher concentrations are seen in the vit-
reous than in the aqueous humor.
4. Role of the vitreous in intravitreal pharmacokinetics
Many studies suggest that the vitreous plays a role in ocular
pharmacokinetics, because the clearance of small MW drugs is
faster in vitrectomized and lensectomized rabbit eyes than in either
lensectomized or control rabbit eyes (Doft et al., 1985; Ficker et al.,
1990; Jarus et al., 1985; Mandell et al., 1993; Pearson et al., 1993;
Pﬂugfelder et al., 1987; Wingard et al., 1989). However, there are
many changing variables in such studies (Doft et al., 1985; Ficker
et al., 1990; Mandell et al., 1993; Wingard et al., 1989), and it is
impossible to distinguish the speciﬁc effects of vitreous from the
experiments with vitrectomized and lensectomized eyes (Jarus
et al., 1985; Pearson et al., 1993; Pﬂugfelder et al., 1987). There
are a few studies with vitrectomized rabbit eyes without lensec-
tomy (Ahn et al., 2013, 2014; Christoforidis et al., 2013; Lee et al.,
2010). In vitrectomized rabbit eyes, pharmacokinetics of bev-
acizumab and ranibizumab did not differ from the control rabbits
(Ahn et al., 2013, 2014), while in another study small (1.8- and 1.3-
fold) differences were seen for bevacizumab and ranibizumab,
respectively (Christoforidis et al., 2013). Likewise, small increase in
the elimination of FITC-dextrans was shown in the rabbit eyes after
hyaluronidase treatment (Tan et al., 2011). We must be cautious in
the interpretations because vitrectomy or enzyme treatment may
endanger the integrity of the blood-ocular barriers (Knudsen et al.,
2001; Mochizuki et al., 1992, 1993).
Lee et al. (Lee et al., 2010) claimed a 10 times shorter t1/2, ivt for
the vitrectomized rabbit as compared to the control rabbit. How-
ever, this study is misleading and data analysis is not reliable. In the
operated eye, the half-life was calculated based on two experi-
mental early data points, while additional later time point was
included in the data analysis of the control eye. Moreover, the
calculated t1/2, ivt in the control group was abnormally short
considering that VEGF is a macromolecule. This problem has also
been pointed out in other publications (Ahn et al., 2013, 2014). In
conclusion, the study of Lee et al. (Lee et al., 2010) is an outlier
among the studies on the vitreous effects on ocular pharmacoki-
netics. Most data does not support signiﬁcant role of vitreous in
drug elimination from the vitreous cavity.
Relatively minor effects of vitreous on ocular pharmacokinetics
is understandable, because the vitreous is relatively loose structure
that allows rapid diffusion of small molecular drugs and proteins
(Gajraj, 2012; Maurice and Mishima, 1984; Pitkanen et al., 2003; Xu
et al., 2000). Recently the mean pore size of the vitreous was
analyzed to be 550 ± 50 nm, value that is two orders of magnitude
greater than typical molecular diameter of a protein drug (Xu et al.,
2013). Therefore, changes in the vitreous viscosity are not expected
to have effects on drug diffusion and drug elimination from the eye.
For example, diffusivity in the porcine and rabbit vitreous was
similar (Gajraj, 2012) even though these species have difference in
the viscosity of the vitreous. Furthermore, CLivt values show 139-
fold range in vivo in rabbits (Fig. 2A). Compared to that range, the
differences in the drug diffusion in the vitreous are negligible
(Gajraj, 2012; Missel, 2012; Xu et al., 2000). Importantly, molecular
permeability in the isolated RPE-choroid had 618-fold range of
values depending on the lipophilicity and size of the compound
(Pitkanen et al., 2005). Overall, permeability in the blood-retina
barrier deﬁnes the range of CLivt values of drugs after intravitreal
injections. In the case of small molecules, there is no correlation
between MW and CLivt (Fig. 2C), but QSPR model with hydrogen
bonding and LogD7.4 describes the CLivt reliably (del Amo et al.,
2015) showing clear dependence on blood-ocular barrier
permeation.
Formacromolecules the range of CLivt values is only about 3-fold,
even though the MW range is 7122e149,000 (Fig. 2D). The CLRPE
values are much smaller than CLivt values indicating dominating
role of the anterior elimination route, but yet CLivt values are clearly
smaller than the rate of aqueous humor turnover (Fig. 2D). This is
mainly due the restricted access of the drug from vitreous to the
Table 4
The AUC values (0 e inﬁnity) of bevacizumab in aqueous humor after intravitreal injection in rabbit and human. The AUC values were dose normalized to 1 mg dose.
AUC (mg*days)/ml AUCsimulated (mg*days)/ml
Rabbit Bakri et al., 2007 234.6 231.5
Nomoto et al., 2009 7.1
Human Krohne et al., 2008 325.2 297.3
Meyer et al., 2011 131.8
Fig. 5. The model structure and simulated bevacizumab concentrations in the human
(in red) and rabbit (in black) aqueous humor are presented. The doses are as described
in Fig. 3. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
E.M. del Amo, A. Urtti / Experimental Eye Research 137 (2015) 111e124120
87
aqueous humor (i.e. bottleneck of the lens, ciliary body and lens)
and partly due to the diffusion in the vitreous. Even though CLivt
values of macromolecules may partly depend on their diffusivity in
the vitreous, the values are spanning only a narrow range despite
the large differences in the MWs. This is not surprising, because the
pore size of non-liqueﬁed vitreous (550 nm) is far greater than the
size of protein drugs (about 5e10 nm) (Xu et al., 2013). Interestingly,
CLivt values do not correlate with MW (Fig. 2D). This suggests that
the role of vitreous may be related to the vitreouseproteins in-
teractions, and not size related sieving effects.
Vitreous may have more signiﬁcant effects on intravitreal
pharmacokinetics in special cases. For example, highly cationic
macromolecules, cationic nanoparticles and larger suspension
particles show limited mobility and possible aggregation in the
vitreous (Chin et al., 2005; Doft et al., 1985; Pitkanen et al., 2003;
Wingard et al., 1989; Xu et al., 2013). These formulation aspects
are, however, beyond the scope of this article.
5. Rabbit as an animal model in intravitreal
pharmacokinetics
Successful translation of intravitreal pharmacokinetics from
rabbit to man requires quantitative understanding of intravitreal
pharmacokinetics in both. Unfortunately, there are only sparse data
on human intravitreal pharmacokinetics. As presented in Sections 2
and 3, we have pooled all available data to calculate the primary
pharmacokinetic parameters for the rabbit and human eye. The
outcome does not support the criticism of rabbit as an animal
model. Rather, it indicates that in general rabbit is a decent model
in the vitreal pharmacokinetics.
Vss, ivt values depend on the anatomical volumes of the vitreous
and surrounding tissues, and drug partitioning to the tissues
(Section 2.1). Like in the rabbits, the human Vss, ivt values are ex-
pected to be close to human vitreous volume (4 ml), since the
adjacent tissues are very small compared to the vitreous volume.
Indeed, for bevacizumab (Zhu et al., 2008) the Vss, ivt in humanwas
calculated as 3.2 ml and 9.4 ml (Table 3). These values were 1.6-fold
and 4.5-fold higher than the Vss, ivt in rabbit (2.0 ml) (Bakri et al.,
2007; Christoforidis et al., 2013; del Amo et al., 2015), while the
difference in the vitreous volumes is between 2- and 3-fold
(Table 5). Recently, Krohne et al. (2015) did not ﬁnd signiﬁcant
impact of axial length and lens status on the pharmacokinetics of
intravitreal ranibizumab and bevacizumab. This supports the
notion that the Vss, ivt is relatively constant, mostly governed by the
volume of the vitreous. On the contrary, systemic volumes of drug
distribution span approximately 200,000-fold range (Obach et al.,
2008). In conclusion, Vss, ivt in humans can be estimated with
good accuracy based on the rabbit data and size difference of hu-
man and rabbit eye.
CLivt for small lipophilic molecules takes place mostly via RPE
and choroid (Maurice andMishima,1984). The choroidal blood ﬂow
values in the rabbit and human are quite similar being about 85% of
the total ocular blood ﬂow (Table 5). It is known that both CLivt and
RPE permeability are strongly affected by lipophilicity indicator
(LogD7.4) of the drug (del Amo et al., 2015; Pitkanen et al., 2005).
Indeed, CLivt via RPE should be the product of drug permeability in
the RPE and surface area of the RPE (Section 2.1, Eq. (4)). The RPE
permeability in rabbit and human should be similar due to their
similar trans-epithelial electrical resistance (TEER) values (Table 5),
while the area of RPE is two to three times higher than in the rabbit.
Therefore, CLivt of small lipophilic compounds is expected to be two
or three times higher in man than in rabbit. This trend was
Table 5
Comparison between the pharmacokinetically relevant anatomical and physiological parameters in the rabbit and human (or monkey) eye. The factors affecting the CLivt of
macromolecules are marked by a dotted box. All parameters may affect the CLivt of small molecular drugs.
Rabbit Human  References 
Physiological 
values 
affecting  
CLivt 
B
lo
od
 fl
ow
 
m
ed
ia
te
d 
C
L i
vt
Barrier surface area Surface area of RPE 520a mm2 1204 ± 184b mm2 (Reichenbach et al. 1994) (Panda-Jonas et al. 1994) 
Barrier permeability TEER of RPE layer 179.2 ± 6 ohm.cm2 79 ± 48 ohm.cm2 (Koyano et al. 1993) (Quinn and Miller. 1992) 
Choroidal blood flow 62 ml/h 43 ml/h (Nilsson and Alm. 2012) (Sebag et al. 1994) 
Blood flows: Retinal blood flow 0.66 ml/h 0.26 ml/h (Nilsson and Alm. 2012) (Feke et al. 1989)  
Ciliary body blood flow 4.91 ml/h 5.34c ml/h (Nilsson and Alm. 2012) (Alm and Bill. 1973) 
Iridial blood flow 3.72 ml/h 1.02c ml/h (Nilsson and Alm. 2012) (Alm and Bill. 1973) 
A
qu
eo
us
 
hu
m
or
 fl
ow
 
m
ed
ia
te
d 
C
L i
vt
Aqueous humor flow 0.18 ml/h 0.14 ml/h (Barany and Kinsey. 1949) (Brubaker. 1982) 
Barrier between vitreous and anterior chamber undefined  undefined 
Physiological values 
affecting Vss, ivt of all 
drugs 
Ocular volumes: Vitreous volume 1.15 ml 4 ml (del Amo et al. 2015) (Ruby et al. 2006) 
Lens weight 0.33 - 0.53 g 0.15 - 0.26 g 
(Zamudio and Candia. 2011) 
(Hemenger et al. 1995) 
Uveal tract & retina weight 0.16 g (Wiederholt et al. 1986) 
Choroid weight 0.059 g (Wu et al. 1970) 
Iris weight 0.057 g (Wu et al. 1970) 
Ciliary body weight 0.050 g (Wu et al. 1970) 
Tissue affinities: Kp, ocular tissues No data No data 
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observed in Fig. 3. Apparent CLivt in humans was on average 1.4
times greater than the CLivt in rabbits. Anyway, the values are
relatively similar and the correlation is good (r ¼ 0.91, R2 ¼ 0.82).
One criticism has been based on the differences between the
vasculature of the rabbit retina and the human retina. Nevertheless,
in rabbit and human the retinal and choroidal blood ﬂows are
similar (Table 5) and the vascular walls as well (tight junctions in
the retina; leaky vessels in the choroid). However, some issues of
concern are related to the potential impact of the disease state on
leakiness of the bloodeocular barriers, especially the RPE. Since
CLivt is clearly permeability limited, changes in the rateelimiting
membranes are expected to modify pharmacokinetics. This factor
did not become evident in the data analysis based on the patients in
Fig. 3, but we cannot exclude the possibility that some disease
states might have signiﬁcant impact on the intravitreal
pharmacokinetics.
For macromolecules, anterior elimination via aqueous humor
turnover is the main route of elimination. The rates of the aqueous
humor turnover are similar in human and rabbit (Table 5), but these
values are higher than the CLivt of macromolecules (Dejneka et al.,
2008; del Amo et al., 2015; Eyetech Study Group, 2002; Leeds et al.,
1997). Therefore, the access of the drug to the aqueous humor may
limit its elimination in both rabbit and human eye. The CLivt values
of bevacizumab in humans are 0.025 ml/h and 0.042 ml/h (Table 4),
while in rabbit it is 0.019 ml/h (Bakri et al., 2007; Christoforidis
et al., 2013; del Amo et al., 2015). The role of the barrier between
vitreous and anterior chamber (lens, vitreous, zonules) remains
unknown, but the data do not support major differences between
man and rabbit.
In humans, the vitreous becomes more liqueﬁed and less ho-
mogenous with the age, and this is associated with increased
convective ﬂow in the vitreal cavity (Maurice, 2001; Missel, 2012).
Liquefaction and convection has been stated to be major pharma-
cokinetic differences between the rabbit and elderly patients
(Laude et al., 2010). However, no signiﬁcant difference in the
intravitreal concentrations in patients with and without vitrectomy
was observed in Gan's study (Gan et al., 2005) and the apparent
CLivt value of vancomycin was not higher in vitrectomized patients
(Ferencz et al., 1999) compared to non-vitrectomized patients
(Haider et al., 2001) (Fig. 3, Table 2). Moreover, apparent CLivt values
in elderly patients with and without vitrectomy were only
moderately different from the CLivt values in healthy rabbits (Fig. 3,
Table 2). Furthermore, Los (2008) showed that aging rabbit eyemay
be a good model for human vitreous liquefaction based on
anatomical and histological analysis. Such a model may be a better
approach than enzyme treatments to investigate the effect of the
liquefyingmatrix or vitrectomy on vitreal drug elimination. Overall,
even though vitreous humor may play a partial role in the elimi-
nation of macromolecules from the vitreal cavity, there is no evi-
dence that the differences in the vitreal liquefaction or convection
would cause signiﬁcant changes in intravitreal pharmacokinetics
(Fig. 3).
Drug metabolism in the liver is different in various species and,
therefore, test methods based on human cells are being developed
(Vellonen et al., 2014). The metabolic activity in the eye is relatively
small if any. In general, intravitreal drugs are eliminated from the
eye via elimination across the blood-ocular barriers and aqueous
humor outﬂow, and not via metabolism (del Amo et al., 2015).
Comparison between the rabbit and human data has not revealed
metabolism derived species differences in vitreal drug elimination.
Even though the eye is partly immune protected site, there is a
possibility that intravitreal injection of human protein or human-
ized antibody could cause immune response in the eye. Impact of
immune response on intravitreal pharmacokinetics has not been
demonstrated, even though Gaudreault et al. (2007) discussed this
possibility. Formation of anti-drug antibodies can have substantial
inﬂuence on systemic clearance of some protein-based drugs (Chen
et al., 2013). The neutralizing antibodies are formed in a fewweeks.
Therefore, the immunological inﬂuence on intravitreal pharmaco-
kinetics is expected to be minimal after a single injection, but may
become evident during multiple dosing therapy.
Sometimes binding of drug to target proteins determines the
drug clearance from the systemic circulation (Levy, 1994). For
example, FcRN receptors mediate clearance of monoclonal anti-
bodies from the systemic circulation so that the receptor turnover
processes bring drug back to the blood circulation thereby pro-
longing the retention in the circulation (Ezan, 2013; Mager and
Jusko, 2001). This leads sometimes also to receptor saturation
and dose-dependent clearance, i.e. increasing clearance at higher
doses. In principle, such mechanisms might operate within the eye,
but so far they have not been shown to exist.
This review has concentrated on intravitreal pharmacokinetics
of drugs in solution form. There is an increasing interest on ocular
drug delivery systems for prolonged and controlled drug delivery to
the posterior eye segment (del Amo and Urtti, 2008). The func-
tionality of the dosage forms in the rabbit and human eye is beyond
the scope of this review. Anyway, CLivt values are useful in the
design of drug delivery systems, because the required release rate
in vivo depends on the target concentration and CLivt (del Amo
et al., 2015). Furthermore, the required drug payload in the
dosage form is release rate multiplied by the dosing interval. As
only small volumes can be injected intravitreally (maximum
100 ml), computational estimation of drug payload is very impor-
tant aid in the design of prolonged action dosage forms for the
retinal treatment. Overall, CLivt should be taken into account in the
design of new intravitreal drug delivery systems.
6. Conclusions
In this review we have analyzed the data on intravitreal phar-
macokinetics in rabbits and humans. Overall, based on the current
data the rabbit is clinically predictable animal model for intravitreal
pharmacokinetics, since both intravitreal volume of distribution
and clearance values differ only moderately between rabbit and
human. Intravitreal pharmacokinetic studies should be designed so
that accurate values for clearance and volume of distribution are
obtained. Further studies are needed in special cases, such as dis-
ease state effects, to complement the understanding of intravitreal
pharmacokinetics.
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9. Synopsis of the main results 
The main results of the computational models and the comprehensive collation of the ocular 
data are summarized below: 
 
1. Systemic pharmacokinetics 
 
QSPR models for parallel prediction of systemic Vss and fu in humans were obtained based 
on a data set of 541 compounds (I): 
 
LogVss= 0.2464 + 0.0909LgS3 - 0.0269LgS10 - 0.0099LogS + 0.3894L3LgS  
+ 0.0465LogD10 + 0.0514LogD5.5 + 0.0010%FU10 + 0.0004MV - 0.0005W1  
+ 0.0023D4 + 0.0174HD 
 
fu= 0.7052 + 0.0091LgS3 - 0.0024LgS10 + 0.0600LogS + 0.0277L3LgS - 0.0153 LogD10 
- 0.0583LogD5.5 + 0.0009%FU10 - 0.0007MV + 0.0001W1 - 0.0025D4 + 0.0026HD 
  
where L3LgS is solubility profiling coefficient, LogS is the logarithm of solubility, LgS3 
and LgS10 are the logarithms of solubility at pH 3 and pH 10, respectively, LogD10 and 
LogD5.5 are distribution coefficients at pH 10 and pH 5.5, respectively, %FU10 is % of 
fraction unionized at pH 10, MV is molar volume, W1 is hydrophilic volume, D4 is 
hydrophobic volume and HD is hydrogen bond donor. The cross-validation value of the 
model was Q2 (leave-1/7-out) = 0.55. The model predicted the external test set: Q2 = 0.50 
for LogVss and Q2 = 0.54 for fu. A foreign test set was also evaluated and the following 
predictions obtained: Q2= 0.70 for LogVss and Q2 = 0.54 for fu. In both cases, 101 drugs 
were used and the results were statistically significant in the Y-permutation test. The 
applicability domain of the model was successfully defined. Eleven descriptors were needed 
in the QSPR models for Vss and fu, these were related to lipophilicity, polarity and size of 
the molecule. 
QSPR classification models were able to classify the drugs with high or low values of 
Vss while classification of fu was successful only for drugs with high Vss. The predominant 
descriptors in the models were also related to molecular size, charge and lipophilicity. 
 
2. Intravitreal pharmacokinetics 
 
? Comprehensive collection of intravitreal values for Vss, ivt, CLivt and t1/2, ivt in rabbit 
(40 small molecular weight compounds and 11 macromolecules) was generated 
(III). The CLivt and t1/2, ivt values showed wide ranges (0.011 – 1.530 ml/h for CLivt 
and 1.44 – 143.58 h for t1/2, ivt). The range of Vss, ivt was narrow (0.72 – 3.14 ml). The 
wide range of CLivt values stemmed from the small molecular drug data (49-fold 
range). The CLivt range of macromolecules was narrow (2-fold).  
? QSPR model for intravitreal half-life was constructed based on 40 intravitreal 
compounds (II): 
Logt1/2= - 0.046 - 0.051LogD7.4 + 0.640LogHtot 
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where LogHtot is the logarithm of the sum of hydrogen bond donors and acceptors. 
The Q2 (leave-1/7-out) was 0.66. The model predicted the internal (Q2= 0.76) and 
external (Q2= 0.81) test sets and was statistically robust in the Y-permutation test. 
The applicability domain of the model was described by the value range of the 
molecular descriptors. 
 
? Similarly, a QSPR model for intravitreal clearance of small molecular weight 
compounds was successfully built using 34 intravitreal drugs (III): 
 
LogCLivt = -0.25269 - 0.53747LogHD + 0.05189LogD7.4  
 
where LogHD is the logarithm of the hydrogen bond donors. The Q2 (leave-1/7-out) 
yielded 0.62. The model predicted internal (Q2= 0.85) and external (Q2= 0.92) test 
sets and was statistically robust in the Y-permutation test.  
 
? Pharmacokinetic simulations of vitreal drug concentrations were carried out (III). 
Intravitreal injections of drugs and drug delivery systems were simulated based on 
QSPR-derived CLivt values and typical Vss, ivt values. The simulations were used to 
estimate the relationships between drug dose, release rate, target concentration and 
duration of action. 
 
? Most of the published pharmacokinetic studies involving intravitreal injection in the 
rabbits did not fulfill the quality criteria. Guidance was compiled on how to design 
an intravitreal pharmacokinetic study to be conducted in experimental animals (IV).  
A comprehensive rabbit-to-human comparison of intravitreal drug distribution and 
elimination revealed that intravitreal pharmacokinetics in rabbit and human eye were 
similar (IV). In the case of CLivt values, a good correlation was seen between rabbit 
and man. In both species, Vss, ivt values were in the range of the anatomical volume 
of vitreous humour.  
 
? A comparison of CLivt with the calculated RPE mediated CLivt indicated that small 
molecules are mostly eliminated through the RPE, whereas macromolecules are 
primarily eliminated via the anterior route (IV). The data and analyses did not 
support the proposal that vitreous plays a significant role in drug elimination from 
the vitreal cavity. 
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10. General discussion and future prospects 
In the present thesis, novel pharmacokinetic models have been investigated, developed and 
validated so that they can be exploited in the drug discovery and development process in 
the systemic and ocular routes of drug administration.  
10.1. Systemic Vss and fu in silico prediction in humans 
A QSPR was developed using linear PCA-PLS methods which allowed the parallel 
prediction of Vss and fu. Additionally, a non-linear Recursive Partitioning method was 
employed for classification models estimating either Vss alone or Vss together with fu. Those 
molecular descriptors related to lipophilicity, charge and size were relevant in both QSPR 
approaches. 
With the PCA-PLS method, a final equation for Vss and fu was obtained with Q2Y (leave-
1/7-out) of 0.55. The model predicted the external and foreign test sets reliably with Q2 
values ranging from 0.50 to 0.70 and both its statistical significance and applicability 
domains were defined. The QSPR model provided insights about which molecular 
determinants may govern systemic drug distribution. For example, the fraction of unionized 
drug at pH 10 (%FU10) and LogD10 exhibited positive relationships with the values of Vss. 
Higher values of %FU10 and LogD10 were mostly found for basic drugs, and this is in line 
with the fact that the basic drugs have higher Vss values than their acidic counterparts 
(Rodgers and Rowland, 2007). Charge was also relevant for the drug distribution as basic 
drugs bind to the acidic phospholipids present on the lipid membranes in the tissues 
(Rodgers and Rowland, 2007). Basic compounds may also be entrapped inside the acidic 
lysosomes within the cells (Ishizaki et al., 1998), whereas the lipophilic neutral forms tend 
to distribute into the adipose tissues. 
On the other hand, the same descriptors exert an influence on fu, but for most of them, 
the trend was opposite. The most influential descriptors on fu were LogS (positive impact) 
and LogD5.5 (negative impact). Highly soluble drugs tend to be free in plasma, whereas the 
lipophilic drugs prefer to bind to plasma proteins (Mayer and Van de Waterbeemd, 1985). 
Acidic drugs with high LogD5.5 values bind to albumin which is the most abundant protein 
in human plasma (Kwon, 2001, Hall and Guyton, 2011) and this property leads to smaller 
fu values.  
Eleven in silico descriptors were necessary for the success of the model. This is a 
reflection of the complexity of systemic drug distribution, since there are a large number of 
different cellular and tissue binding sites as well as binding sites in plasma and factors that 
affect membrane permeation from plasma to the tissues (Rowland and Tozer, 2011, Toutain 
and Bousquet-Melou, 2004, Kwon, 2001, Pandit and Soltis, 2012). Overall, lipophilicity 
and solubility related descriptors were found to affect both Vss and fu, but in opposite 
directions.  
The developed QSPR model that encompasses both Vss and fu is a useful tool for virtual 
screening of new compounds in silico. The model may help in the selection of drug 
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candidates and therefore it may well accelerate drug discovery. However, this is only one 
factor in the complicated world of drug discovery (van de Waterbeemd and Gifford, 2003). 
One must also note that in many cases the accuracy of predictions was only modest and a 
comparison with the PBPK models for Vss (Poulin and Theil, 2002, Rodgers and Rowland, 
2007) could prove to be illuminating. In the future, Vss and fu models may become integrated 
into pharmacokinetic and pharmacodynamic models (Xu and Mager, 2011, Theil et al., 
2003). Nevertheless, there is still work to be done to improve the drug discovery and 
development process and to implement this kind of integrative approach (van de 
Waterbeemd and Gifford, 2003, Lombardo et al., 2003). 
10.2. Intravitreal pharmacokinetics: assessment of the rabbit 
model  
The rabbit is the most commonly used animal species in ocular pharmacokinetics (Maurice 
and Mishima, 1984, Prince, 1964). One goal of this thesis project was to evaluate the value 
of the rabbit when modelling intravitreal pharmacokinetics. This is an important topic since 
many ocular retinal diseases can be only treated and controlled by intravitreal injections. 
Only rarely have the intravitreal pharmacokinetics been investigated in humans due to the 
ethical constraints; animals have to used and the rabbit has been the most popular animal 
species in these kinds of studies (Maurice and Mishima, 1984). Nevertheless, the use of 
rabbits has been criticized, based on the anatomical and physiological differences between 
the rabbit and human eye (Bakri et al., 2007a, Bakri et al., 2007b, Vaishya et al., 2011, 
Rittenhouse and Pollack, 2000). Furthermore, although some investigators have claimed 
that there are pharmacokinetic differences between rabbit and man, often these 
discrepancies are attributable to inadequate sampling and assay problems (Nomoto et al., 
2009, Lee et al., 2010). Nonetheless, based on these misleading studies, the rabbit model 
has even been criticized in a recent authoritative ‘consensus’ paper focusing on ocular drug 
delivery (Rowe-Rendleman et al., 2014).  
The intravitreal pharmacokinetics in rabbits and humans were compared in a systematic 
manner. Apparent intravitreal clearance (CLivt, app) values of eight drugs were calculated 
based on the human patient studies. Interestingly, the apparent CLivt in humans correlated 
well with the values of rabbit CLivt displaying a Spearman's rank correlation coefficient of 
ρ= 0.91, (Rabbit CLivt = 1.41 x Human CLivt, app + 0.04, units are ml/h; R2= 0.82). The value 
of apparent CLivt in humans was, on average, 1.4 times greater than the corresponding CLivt 
value in rabbits. On the other hand, the intravitreal volume of distribution (Vss, ivt) of 
bevacizumab in humans was larger than in rabbits (maximally 4.5-fold difference) (Zhu et 
al. 2008, Bakri et al. 2007, Christoforidis et al. 2013, III). These results demonstrated that 
the rabbit eye is a reasonable model for intravitreal pharmacokinetics: there is a good 
correlation in CLivt values and only modestly different absolute values. Therefore, 
translation from rabbit data to humans should be relatively easy and reliable. 
Pharmacokinetic similarity is based on the physiological and anatomical parameters: flows, 
blood-ocular barriers permeability and surface areas. These parameters are surprisingly 
similar in human and rabbit eye. 
95
 
 
 
 
It has been claimed that there are differences in the viscosity of the vitreous between the 
healthy rabbit and elderly human patient eye and that this constitutes a major problem 
(Laude et al., 2010, Tan et al., 2011, Thakur et al., 2014). However, the data analyses did 
not provide support for this proposal. In fact, in the correlation conducted here between 
human CLivt, app and rabbit CLivt values much of the human data included studies with elderly 
patients suffering from ocular diseases. Nevertheless, CLivt is clearly dependent on RPE 
permeability and diseases affecting the ocular epithelium may have an impact on the 
intravitreal pharmacokinetics. In this regard, further studies will be needed to dissect the 
role of retinal diseases in altering the intravitreal pharmacokinetics of small molecular 
weight drugs and macromolecules. 
In conclusion, the rabbit is a useful animal model for the human eye and it can be used 
for preclinical studies of intravitreal pharmacokinetics. 
10.3. Intravitreal clearance and half-life in silico predictions  
In this work, a QSPR model for intravitreal half-life for small molecular drugs was built 
based on data of 47 compounds in experiments conducted in albino or pigmented rabbits. 
The pharmacokinetic studies selected were those in which the intravitreal concentrations 
had been measured during a time-span of not less than two half-lives. The final QSPR 
equation for t1/2, ivt (including albino and pigmented rabbits) was physiologically 
interpretable. The relevant descriptors were LogD7.4 and the total hydrogen bonding 
capacity (the sum of donor and acceptor hydrogen bonds). LogD7.4 showed a negative 
correlation with t1/2, ivt, whereas hydrogen bonding showed a positive relationship with 
t1/2, ivt. The ability of the QSPR model to predict t1/2, ivt was verified with an internal test set 
and a randomly chosen external test set. It is remarkable that t1/2, ivt can be reliably predicted 
with two descriptors that are known to affect membrane permeability (Kidron et al., 2010, 
Lanevskij et al., 2009, Linnankoski et al., 2006, Liu et al., 2004). Thus, this result supports 
the role of blood-ocular barriers in determining the vitreal elimination of small molecules. 
Moreover, these descriptors are related to the passive diffusion across barriers and thus it 
seems that active transport is not a major factor, at least for the 47 compounds used in the 
modelling because known substrates for these transporters (e.g. carbenicillin, quinidine) 
were not outliers in the model. From this data set, only 60% of the compounds could be 
included in the next study: QSPR models for intravitreal clearance and volume of 
distribution. The studies which had to be rejected had missing dose values or inadequate 
concentration profiles and these are values that are necessary for calculation of the primary 
pharmacokinetic parameters.  
The quality of the published intravitreal pharmacokinetic data was unsatisfactory in 
many cases. The criteria applied for the inclusion in the CLivt and Vss, ivt analyses (at least 
four time-points and two replicates per point, balanced sampling during two t1/2, ivt or longer) 
were fulfilled in only 58% of the studies selected for inclusion in study III. Many reports 
displayed shortcomings such as inadequate data points, poor match between dose and initial 
concentration, solubility problems and thus it was not possible to make any reliable 
calculations of CLivt and Vss, ivt. Indeed, sampling vitreous is not as simple task as obtaining 
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a blood specimen, it is an invasive technique and many rabbits are needed (12 - 18 animals) 
before one obtains sufficient data for the reliable estimation of the primary pharmacokinetic 
parameters. One aim of this thesis was to provide guidance about how best to design an 
intravitreal pharmacokinetic study in experimental animals.  
It was possible to make reliable calculations of CLivt and Vss, ivt for the 42% of the cases 
and a final data set of 40 small molecules and 11 macromolecules was obtained. The 
chemical space of the intravitreal small molecules (molecular weight of 18 to1500 Da, LogP 
of -5 to 3, HD of 1 to 21, and hydrogen bond acceptor (HA) of 1 to 33) deviated from the 
“druggability'' space of per oral administered drugs (i.e. molecular weight < 500, LogP < 5 
and HD < 5, HA < 10) (Lipinski et al. 2001). This is not surprising because there are major 
differences in the physicochemical properties between oral drug administration and 
intravitreal injections. For example, hydrophilic and larger molecules can have a 
beneficially long residence time after injection into the vitreous, but these compounds may 
not have adequate per oral absorption or undergo good distribution to the tissues. Therefore, 
the “druggable” space for intravitreal compounds may differ from the rule-of-5 
classification commonly used for orally administered drugs. 
Prediction of the primary pharmacokinetic parameters (CLivt, Vss, ivt) is useful, because 
the resulting models can be integrated into pharmacokinetic simulation models to allow the 
prediction of drug concentrations in the vitreous after different dosing regimens. 
Furthermore, these parameters can be related to the anatomical volumes (for distribution), 
flow factors (blood flow, aqueous humour turnover) and blood-ocular barriers (for 
elimination) and they can help provide a mechanistic understanding of ocular 
pharmacokinetics. 
Since the values of Vss, ivt of the compounds showed rather low variance (0.72–3.14 ml, 
4-fold), it was not possible to build a QSPR model for Vss, ivt. However, the narrow range of 
Vss, ivt represents new and useful information. These values are close to the typical 
anatomical volumes in the posterior segment of the rabbit eye, and therefore this indicates 
that the drug distribution to the surrounding tissues does not increase the Vss, ivt value 
significantly. Based on Eq. 3 and Eq. 8, one can conclude that Vss, ivt can be defined based 
on the anatomical volumes and Kp, T or fu/fu,T values in the posterior eye segment. There are 
two main reasons for the moderate Vss, ivt values: 1) the anatomical sizes of the surrounding 
ocular tissues are relatively small in comparison to the vitreous volume; 2) drug binding and 
partitioning to the ocular tissues is not extensive. The narrow range of Vss, ivt values is useful 
information, because without further experiments, one can assume with confidence that the 
Vss, ivt falls within a narrow range. Accordingly, values of 1.2 and 2.3 ml were used in the 
pharmacokinetic simulations, because 80% of the compounds have Vss, ivt values in this 
range. 
Unlike the values of Vss, ivt, the values of CLivt displayed a broad, 49-fold, range allowing 
QSPR model building for the first time. The CLivt model for small molecules was able to 
predict the CLivt values of the internal and external test sets accurately (mean fold errors of 
1.50 and 1.33, respectively) simply based on two descriptors: LogD7.4 and hydrogen bond 
donor capacity. The model equations for CLivt and t1/2, ivt were based on similar descriptors 
(not identical). This indicates that the variance of t1/2, ivt values is attributable to the 
differences in the CLivt values. The values of Vss, ivt lie in such a narrow range that their 
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impact on the variance of t1/2, ivt is of low significance. The models were also physiologically 
interpretable as a higher LogD7.4 value leads to a higher CLivt value (shorter t1/2, ivt). This is 
likely due to the increased permeability in blood-ocular barriers, while increased hydrogen 
bonding results in a smaller CLivt value (longer t1/2, ivt) as more polar compounds penetrate 
more slowly through the membranes. The only previous QSPR model which attempted to 
predict t1/2, ivt was done with a few descriptors and a miscellaneous compound set 
(macromolecules and small molecules) (Durairaj et al., 2009) and its performance was not 
properly validated (Durairaj et al., 2009). 
The ocular pharmacokinetic data collection in this work is the most extensive conducted 
so far. It is anticipated that the data collection and the QSPR models for CLivt and t1/2, ivt will 
prove useful in ocular drug discovery and development, although one must be aware of the 
intravitreal chemical space of the QSPR models generated because some new drug 
candidates may fall outside of this chemical space (e.g. new analogs with LogP > 3). 
Even though macromolecules could not be included in the QSPR model for CLivt, useful 
information was obtained. From 31 intravitreal pharmacokinetic studies with 
macromolecules, 13 studies met the selection criteria (11 compounds with molecular 
weights ranging from 7.1 kDa to 149 kDa). Both Vss, ivt and CLivt values showed a narrow 
distribution: 1.10 – 2.76 ml for Vss, ivt and 0.011 - 0.027 ml/h for CLivt, respectively. When 
compared to the small molecules, it seems that the macromolecules have similar Vss, ivt 
values but smaller CLivt values. When the CLivt of both sets, macromolecules and small 
molecular drugs, were plotted against molecular weight (18 Da - 149 kDa), a correlation 
was detected. Previously, Maurice and Mishima reported that the molecular weight exerts 
an influence on the vitreal elimination of those compounds that are eliminated anteriorly 
(Maurice, 1976, Maurice and Mishima, 1984). However, molecular weight does not affect 
the CLivt either of small compounds alone (LogD7.4 and HD are the relevant descriptors) or 
macromolecules alone (no correlation between CLivt and molecular weight). Even though it 
was not feasible to create a QSPR model for CLivt of macromolecules (small set of drugs, 
only one descriptor available) physiochemical characterization of these macromolecules 
(e.g. charge, lipophilicity, molecular shape) could help clarifying the factors affecting their 
ocular clearance. Moreover, the comprehensive collection of intravitreal pharmacokinetic 
data compiled in this work could be useful in itself for the development of novel 
macromolecules for use in the treatment of ocular diseases. 
Intravitreal drug clearance may occur via the anterior or posterior routes (Figure 7B) 
depending on the capability of the drug to cross the blood-ocular barriers, and in particular, 
the BRB (Maurice, 1976). Intravitreal clearance across RPE has been calculated for two 
small compounds (betaxolol and carboxyfluorescein) and for four FITC-dextrans based on 
their bovine RPE permeability values (Pitkanen et al., 2005). While the values for the small 
molecules were in the range of in vivo CLivt showing that significant elimination occurred 
through the RPE, the FITC-dextrans (4 – 80 KDa) were found to have values which were 
one order of magnitude lower than the in vivo CLivt of macromolecules. This finding 
supports the proposal that macromolecules are basically eliminated via the anterior route. 
This is the first attempt to quantify the RPE mediated CLivt and the result suggests that only 
about 3 - 20 % of the macromolecule drug may be eliminated via RPE. In the case of 
betaxolol, the role of RPE mediated CLivt was clearly more important. 
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10.4. Pharmacokinetic simulation of vitreal concentration of 
drugs 
In the present thesis, the time-courses of drug concentrations in vitreous after intravitreal 
injection were simulated. In that part of the work, predicted values of CLivt and Vss, ivt were 
incorporated into the models. The value of CLivt was calculated based on the QSPR model 
using in silico values for LogD7.4 and HD, while a typical range of Vss, ivt was employed. 
The simulated intravitreal pharmacokinetic profiles based on the predicted and real values 
matched well.  
Moreover, the versatility of the simulation softwares made it possible to create different 
scenarios, e.g. drug release profiles from intravitreal drug delivery systems. A knowledge 
of the drug release rate from the delivery system, makes it possible to estimate the dose that 
is required to maintain the drug concentration within the therapeutic range for a certain time 
period. Such simulations can be undertaken based on the structure of the drug and the in 
vitro release rate from the delivery system. This can be advantageous in the evaluation of 
novel formulations and dosing regimens as well as in the design of pharmacokinetic studies 
conducted in experimental animals. The CLivt, potency and safety windows of the drug are 
relevant background information for this strategy. These simulations can be done early in 
the discovery phase (for the drug candidate) or later during drug development (for the drug 
in a novel delivery system). The same approach is applicable also for macromolecular drugs, 
even without a QSPR model, because the obtained values of Vss, ivt and CLivt fall within 
narrow ranges.  
In conclusion, it is anticipated that the in silico tools developed in the present thesis will 
be of benefit in drug discovery and development in many ways, for example, by reducing 
and refining animal experiments, reducing the clinical attrition of investigational new drugs, 
and facilitating rational development of drug delivery systems. The results emerging from 
this thesis project should also make it possible to build relevant and reliable pharmacokinetic 
models for the human eye based on the translational information compiled here. 
99
 
 
 
 
11. Summary and conclusions 
The main outcomes of the thesis are summarized in the figure below. 
 
 
In this thesis project, new computational tools were built to permit pharmacokinetic 
predictions of drug candidates and drug delivery systems. 
 
1. A QSPR model was built for the parallel prediction of volume of drug distribution and 
fraction of unbound drug in plasma in humans. Eleven descriptors were needed in the model.  
The model displayed adequate accuracy and predictability. 
 
2. Comprehensive collections were obtained of data related to volume of distribution, 
clearance and half-life of intravitreally injected drugs in rabbits and humans. The volume 
of distribution had a narrow range of values, whereas clearance and half-life had broad 
variance.  
 
3. Accurate QSPR models were built for intravitreal clearance and for prediction of the 
half-life of small compounds. LogD7.4 and hydrogen bonding parameters adequately 
predicted the clearance and half-life.  
 
4. Hybrid in silico tools integrating the CLivt QSPR model and Vss, ivt typical values in 
pharmacokinetic simulation models were built successfully. The concentration profiles of 
intravitreal compounds could be simulated reliably after administration of the drug either in 
solution or incorporated into delivery systems.  
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5. The translational value of the rabbit as an animal model for clinical intravitreal 
pharmacokinetics was assessed and demonstrated in a quantitative manner. No evidence 
was found to support crucial roles for vitreous viscosity or rabbit species differences in any 
of the critical parameters affecting ocular drug pharmacokinetics.  
 
6. An improved framework was generated for connecting together the molecular structures, 
physiological factors and intravitreal pharmacokinetics. 
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